uhs-8k_20210726.htm

0001564590-21-038066.txt : 20210727 0001564590-21-038066.hdr.sgml : 20210727 20210727080302 ACCESSION NUMBER: 0001564590-21-038066 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210726 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210727 DATE AS OF CHANGE: 20210727 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UNIVERSAL HEALTH SERVICES INC CENTRAL INDEX KEY: 0000352915 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 232077891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-10765 FILM NUMBER: 211115948 BUSINESS ADDRESS: STREET 1: 367 S GULPH RD CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 BUSINESS PHONE: 6107683300 MAIL ADDRESS: STREET 1: 367 S GULPH ROAD CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 8-K 1 uhs-8k_20210726.htm 8-K uhs-8k_20210726.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 26, 2021

UNIVERSAL HEALTH SERVICES, INC.

(Exact name of registrant as specified in its charter)

Delaware	1-10765	23-2077891
(State or other jurisdiction of	(Commission	(I.R.S. Employer
Incorporation or Organization)	File Number)	Identification No.)

UNIVERSAL CORPORATE CENTER

367 SOUTH GULPH ROAD

KING OF PRUSSIA, Pennsylvania 19406

(Address of principal executive office) (Zip Code)

Registrant’s telephone number, including area code (610) 768-3300

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class B Common Stock	UHS	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On July 26, 2021, Universal Health Services, Inc. issued the press release attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.


99.1		Universal Health Services, Inc., press release, dated July 26, 2021.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

Exhibit Index

Exhibit No.		Exhibit

99.1		Universal Health Services, Inc., press release, dated July 26, 2021.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Universal Health Services, Inc.

By:		/s/ Steve Filton
Name: Steve Filton
Title: Executive Vice President and Chief Financial Officer

Date: July 27, 2021

EX-99.1 2 uhs-ex991_6.htm EX-99.1 uhs-ex991_6.htm

Exhibit 99.1

FOR IMMEDIATE RELEASE

July 26, 2021


CONTACT:	Steve Filton
	Chief Financial Officer
	610-768-3300

UNIVERSAL HEALTH SERVICES, INC.

REPORTS 2021 SECOND QUARTER FINANCIAL RESULTS, INCREASES 2021 FULL YEAR EARNINGS GUIDANCE AND ANNOUNCES $1 BILLION INCREASE TO STOCK REPURCHASE PROGRAM AUTHORIZATION

Consolidated Results of Operations, As Reported and As Adjusted – Three-month periods ended June 30, 2021 and 2020:

KING OF PRUSSIA, PA – Universal Health Services, Inc. (NYSE: UHS) announced today that its reported net income attributable to UHS was $325.0 million, or $3.79 per diluted share, during the second quarter of 2021, as compared to $251.9 million, or $2.95 per diluted share, during the second quarter of 2020. Net revenues increased 17.1% to $3.198 billion during the second quarter of 2021 as compared to $2.730 billion during the second quarter of 2020.

As reflected on the Schedule of Non-GAAP Supplemental Information (“Supplemental Schedule”), our adjusted net income attributable to UHS during the second quarter of 2021 was $322.3 million, or $3.76 per diluted share, as compared to $250.2 million, or $2.93 per diluted share, during the second quarter of 2020.

During 2021, we received approximately $189 million of additional funds from the federal government in connection with the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), substantially all of which was received during the first quarter of 2021. During the second quarter of 2021, we returned the $189 million to the appropriate government agencies utilizing a portion of our cash and cash equivalents held on deposit. Therefore, our results of operations for the three and six-month periods ended June 30, 2021 include no impact from the receipt of those funds.

Also, and as previously announced earlier this year, in March of 2021 we made an early repayment of $695 million of funds received during 2020 pursuant to the Medicare Accelerated and Advance Payment Program. These funds were returned to the government utilizing a portion of our cash and cash equivalents held on deposit.

Included in our reported and adjusted net income attributable to UHS during the three and six-month periods ended June 30, 2021 was a net favorable after-tax impact of approximately $29.8 million, or $.35 per diluted share, resulting from:

•

a favorable after-tax impact of $42.3 million, or $.49 per diluted share, resulting from $55.3 million of revenues recorded during the second quarter of 2021 in connection with the Kentucky Medicaid Managed Care Hospital Rate Increase Program, covering the period of July 1, 2020 to June 30, 2021, as discussed below in Kentucky Hospital Rate Increase Program;

•

an unfavorable after-tax impact of approximately $27.2 million, or $.32 per diluted share, resulting from a $36.0 million increase to our reserves for self-insured professional and general liability claims, as discussed below in Increase to Self-Insured Professional and General Liability Reserves, and;

•

an aggregate favorable after-tax impact of $14.6 million, or $.17 per diluted share, resulting from aggregate commercial insurance proceeds of $19.3 million received during the second quarter of 2021 in connection with the previously incurred, unfavorable economic impact from the following: (i) the previously disclosed information technology incident that occurred during 2020 ($10.0 million of insurance proceeds received representing partial recovery of the loss sustained), and; (ii) the COVID-19 pandemic ($9.3 million of insurance proceeds received representing recovery of the policy maximum).

Included in our reported and adjusted net income attributable to UHS during the three-month period ended June 30, 2020 was approximately $161.9 million, or $1.90 per diluted share, resulting from the recognition of approximately $218 million of net revenues recorded in connection with various governmental stimulus programs, most notably the CARES Act. Approximately $157 million of the governmental stimulus program net revenues were attributable to our acute care services and approximately $61 million were attributable to our behavioral health care services.

As reflected on the Supplemental Schedule, included in our reported results during the second quarter of 2021, was a net aggregate favorable after-tax impact of $2.7 million, or $.03 per diluted share, consisting of the following: (i) an after-tax unrealized gain of $1.6 million, or $.02 per diluted share, ($2.1 million pre-tax which is included in “Other (income) expense, net”), resulting from an increase in the market value of shares of certain marketable securities held for investment and classified as available for sale, and; (ii) a favorable after-tax impact of $1.2 million, or $.01 per diluted share, resulting from our adoption of ASU 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”).

As reflected on the Supplemental Schedule, included in our reported results during the second quarter of 2020, was a net aggregate favorable after-tax impact of $1.7 million, or $.02 per diluted share, consisting of the following: (i) an after-tax unrealized gain of $2.2 million, or $.03 per diluted share, resulting from an increase in the market value of shares of certain marketable securities held for investment and classified as available for sale, and; (ii) an unfavorable after-tax impact of $0.5 million, or $.01 per diluted share, resulting from our adoption of ASU 2016-09.

As calculated on the attached Supplemental Schedule, our earnings before interest, taxes, depreciation & amortization (“EBITDA net of NCI”, NCI is net income attributable to noncontrolling interests), was $581.8 million during the second quarter of 2021, as compared to $482.8 million during the second quarter of 2020. Our adjusted earnings before interest, taxes, depreciation & amortization (“Adjusted EBITDA net of NCI”), which excludes the impact of other (income) expense, net, was $572.7 million during the second quarter of 2021 as compared to $479.7 million during the second quarter of 2020.

Consolidated Results of Operations, As Reported and As Adjusted – Six-month periods ended June 30, 2021 and 2020:

Reported net income attributable to UHS was $534.1 million, or $6.22 per diluted share, during the six-month period ended June 30, 2021, as compared to $394.0 million, or $4.58 per diluted share, during the first six months of 2020. Net revenues increased 11.7% to $6.211 billion during the first six months of 2021 as compared to $5.559 billion during the comparable period of 2020.

As reflected on the Supplemental Schedule, our adjusted net income attributable to UHS during the six-month period ended June 30, 2021 was $532.4 million, or $6.20 per diluted share, as compared to $400.4 million, or $4.65 per diluted share, during the first six months of 2020.

Included in our reported and adjusted net income attributable to UHS during the six-month period ended June 30, 2021, was the net favorable after-tax impact of approximately $29.8 million, or $.35 per diluted share, as discussed above.

Our reported and adjusted net income attributable to UHS during the six-month period ended June 30, 2020 included approximately $161.9 million, or $1.89 per diluted share, resulting from the above-mentioned recognition of approximately $218 million of net revenues recorded in connection with various governmental stimulus programs, most notably the CARES Act.

As reflected on the Supplemental Schedule, included in our reported results during the six-month period ended June 30, 2021, was a net aggregate favorable after-tax impact of $1.7 million, or $.02 per diluted share, consisting of the following: (i) an after-tax unrealized loss of $0.5 million, or $.01 per diluted share, resulting from a decrease in the market value of shares of certain marketable securities held for investment and classified as available for sale, and; (ii) a favorable after-tax impact of $2.2 million, or $.03 per diluted share, resulting from our adoption of ASU 2016-09.

As reflected on the Supplemental Schedule, included in our reported results during the six-month period ended June 30, 2020, was a net aggregate unfavorable after-tax impact of $6.4 million, or $.07 per diluted share, consisting of the following: (i) an after-tax unrealized loss of $5.1 million, or $.06 per diluted share, resulting from a decrease in the market value of shares of certain marketable securities held for investment and classified as available for sale, and; (ii) an unfavorable after-tax impact of $1.3 million, or $.01 per diluted share, resulting from our adoption of ASU 2016-09.

As calculated on the attached Supplemental Schedule, our EBITDA net of NCI, was $1.008 billion during the six-month period ended June 30, 2021, as compared to $831.9 million during the first six months of 2020. Our Adjusted EBITDA net of NCI, which excludes the impact of other (income) expense, net, was $999.8 million during the six-month period ended June 30, 2021, as compared to $838.3 million during the first six months of 2020.

Acute Care Services – Three and six-month periods ended June 30, 2021 and 2020:

During the second quarter of 2021, at our acute care hospitals owned during both periods (“same facility basis”), adjusted admissions (adjusted for outpatient activity) increased 26.4% and adjusted patient days increased 21.6%, as compared to the second quarter of 2020. During the second quarter of 2021, patient volumes at our acute care hospitals, as compared to the same period of 2020, reflect robust recoveries from the COVID-19 pandemic-related restrictions and policies that negatively affected patient volumes during the second quarter of 2020.

At these facilities, excluding the governmental stimulus revenues of approximately $157 million recorded during the second quarter of 2020, net revenue per adjusted admission increased 5.1% while net revenue per adjusted patient day increased 9.3% during the second quarter of 2021, as compared to the second quarter of 2020. During the second quarter of 2021, as compared to the second quarter of 2020, net revenues generated from our acute care services on a same facility basis increased 18.5% including the governmental stimulus revenues recorded during the second quarter of 2020, and increased 33.0% excluding the governmental stimulus revenues recorded during the second quarter of 2020.

During the six-month period ended June 30, 2021, at our acute care hospitals on a same facility basis, adjusted admissions increased 4.7% and adjusted patient days increased 9.3%, as compared to the first six months of 2020. At these facilities, excluding the governmental stimulus revenues of approximately $157 million recorded during the first six months of 2020, net revenue per adjusted admission increased 15.7% while net revenue per adjusted patient day increased 10.8% during the first six months of 2021, as compared to the

comparable period of 2020. During the first six months of 2021, as compared to the comparable period of 2020, net revenues generated from our acute care services on a same facility basis increased 15.0% including the governmental stimulus revenues recorded during the first six months of 2020, and increased 21.5% excluding the governmental stimulus revenues recorded during the first six months of 2020.

Behavioral Health Care Services – Three and six-month periods ended June 30, 2021 and 2020:

During the second quarter of 2021, at our behavioral health care facilities on a same facility basis, adjusted admissions increased 14.1% and adjusted patient days increased 7.4%, as compared to the second quarter of 2020. During the second quarter of 2021, patient volumes at our behavioral health care hospitals, as compared to the same period of 2020, reflect robust recoveries from the COVID-19 pandemic-related restrictions and policies that negatively affected patient volumes during the second quarter of 2020.

At these facilities, excluding the governmental stimulus revenues of approximately $61 million recorded during the second quarter of 2020, net revenue per adjusted admission increased 1.9% while net revenue per adjusted patient day increased 8.3% during the second quarter of 2021, as compared to the second quarter of 2020. During the second quarter of 2021, as compared to the second quarter of 2020, net revenues generated from our behavioral health care services on a same facility basis increased 13.7% including the governmental stimulus revenues recorded during the second quarter of 2020, and increased 19.5% excluding the governmental stimulus revenues recorded during the second quarter of 2020.

During the six-month period ended June 30, 2021, at our behavioral health care facilities on a same facility basis, adjusted admissions increased 3.8% and adjusted patient days increased 1.6%, as compared to the first six months of 2020. At these facilities, excluding the governmental stimulus revenues of approximately $61 million recorded during the first six months of 2020, net revenue per adjusted admission increased 4.9% while net revenue per adjusted patient day increased 7.2% during the first six months of 2021, as compared to the comparable period of 2020. During the first six months of 2021, as compared to the comparable period of 2020, net revenues generated from our behavioral health care services on a same facility basis increased 7.2% including the governmental stimulus revenues recorded during the first six months of 2020, and increased 9.8% excluding the governmental stimulus revenues recorded during the first six months of 2020.

COVID-19

The impact of the COVID-19 pandemic, which began during the second half of March, 2020, has had a material unfavorable effect on our operations and financial results since that time. The COVID-19 vaccination process commenced during the first quarter of 2021 and we have generally experienced a decline in COVID-19 patients since that time as well as a corresponding recovery in non-COVID-19 patient activity. Since the future volumes and severity of COVID-19 patients remain highly uncertain and subject to change, including potential increases in future COVID-19 patient volumes caused by new variants of the virus, we are not able to fully quantify the impact that these factors will have on our future financial results. However, developments related to the COVID-19 pandemic could materially affect our financial performance during the remainder of 2021.

Net Cash Provided by Operating Activities and Liquidity:

Net Cash Provided by Operating Activities:

For the six months ended June 30, 2021, our net cash provided by operating activities was $119 million as compared to $1.451 billion during the first six months of 2020. The $1.332 billion net decrease in our cash provided by operating activities during the first six months of 2021, as compared to the first six months of 2020, was due to: (i) an unfavorable change of $1.174 billion resulting primarily from the above-mentioned $695 million of Medicare accelerated payments repaid during the first quarter of 2021, as compared to a favorable change of $477 million experienced during the first six months of 2020 resulting from receipt of the Medicare

accelerated payments and other deferred governmental stimulus grants; (ii) an unfavorable change of $167 million in accounts receivable; (iii) a favorable change of $151 million resulting from an increase in net income plus depreciation and amortization expense, stock-based compensation expense, gain/loss on sales of assets and businesses and provision for asset impairment, and; (iv) an unfavorable change of $143 million in accrued and deferred income taxes due, in part, to COVID-19 related deferrals granted in 2020 by the Federal government and those of certain states, which deferred income tax payments into the third quarter of 2020, that were originally scheduled to be remitted during the second quarter of 2020.

Liquidity:

As of June 30, 2021, we had $996 million of aggregate available borrowing capacity pursuant to our $1 billion revolving credit facility, net of outstanding letters of credit. In addition, as of June 30, 2021, we had approximately $199 million of cash and cash equivalents.

Revised 2021 Operating Results Forecasts:

Based upon the operating trends and financial results experienced during the first six months of 2021, as indicated on the Revised Forecast table below, we are increasing our guidance range for consolidated net revenues; earnings before interest, taxes, depreciation & amortization, and the impacts of other income/expense and net income attributable to noncontrolling interests (“Adjusted EBITDA, net of NCI”), and adjusted net income attributable to UHS per diluted share (“Adjusted EPS-diluted”) for the year ended December 31, 2021. The tables below include our revised 2021 operating results forecasts for the year ended December 31, 2021, as well as our original 2021 operating results forecast which was previously disclosed on February 25, 2021.


	Revised Forecast		Original Forecast
	For the Year Ended		For the Year Ended
	December 31, 2021		December 31, 2021
	Low	High	Low	High
Net revenues	$12.351 billion	$12.501 billion	$12.125 billion	$12.361 billion
Adjusted EBITDA, net of NCI	$1.883 billion	$1.961 billion	$1.738 billion	$1.849 billion
Adjusted EPS – diluted	$11.46 per share	$12.16 per share	$10.05 per share	$11.05 per share

•

Our revised 2021 forecasted net revenues are estimated to be approximately $12.351 billion to $12.502 billion, representing increases of 1.1% to 1.9% over our original 2021 forecasted net revenues.

•

Our revised 2021 forecasted Adjusted EBITDA, net of NCI, is estimated to be approximately $1.883 billion to $1.961 billion, representing increases of 6.1% to 8.4% over our original 2021 forecasted Adjusted EBITDA, net of NCI.

•

Our revised 2021 forecasted Adjusted EPS-diluted is estimated to be $11.46 per share to $12.16 per share, representing increases of 10.0% to 14.0% over our original 2021 forecasted Adjusted EPS-diluted.

Adjusted EPS-diluted and Adjusted EBITDA net of NCI, are non-GAAP financial measures and should be examined in connection with net income determined in accordance with GAAP as presented in the consolidated financial statements and notes thereto in this report or in our filings with the Securities and Exchange Commission including our Report on Form 10-K for the year ended December 31, 2020 and our

Form 10-Q for the quarter ended March 31, 2021. Please see the schedule of Supplemental Non-GAAP Disclosures - 2021 Revised Operating Results Forecast, as included herein for additional information and a reconciliation to the financial forecasts as computed in accordance with GAAP.

In addition, the 2021 revised forecasted amounts exclude the impact of future items, if applicable, that are nonrecurring or non-operational in nature including items such as, pre-tax unrealized gains/losses resulting from increases/decreases in the market value of shares of certain marketable securities held for investment and classified as available for sale, our adoption of ASU 2016-09, and other potential material items including, but not limited to, reserves for various matters including settlements, legal judgments and lawsuits, potential impacts of non-ordinary course acquisitions, divestitures, joint ventures or other strategic transactions, costs related to extinguishment of debt, gains/losses on sales of assets and businesses, impairment of long-lived and intangible assets, other amounts that may be reflected in the current financial statements that relate to prior periods, and the impact of share repurchases that differ from included assumptions. It is also subject to certain conditions including those as set forth below in General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures, including the likelihood that our future operations and financial results may continue to be materially impacted by developments related to COVID-19, as discussed herein.

Stock Repurchase Program:

On July 26, 2021, our Board of Directors authorized a $1.0 billion increase to our stock repurchase program, which increased the aggregate authorization to $3.7 billion from the previous $2.7 billion authorization approved in various increments since 2014. Pursuant to this program, which including today’s increased authorization has a current aggregate available repurchase authorization of $1.210 billion, shares of our Class B Common Stock may be repurchased, from time to time as conditions allow, on the open market or in negotiated private transactions.

In April, 2021, our Board of Directors approved a resumption to our stock repurchase program which had been suspended in April, 2020, as part of various COVID-19 initiatives. In conjunction with our stock repurchase program, during the three-month period ended June 30, 2021, we have repurchased approximately 2.21 million shares at an aggregate cost of $350 million (approximately $158 per share). Since inception of the program in 2014 through June 30, 2021, we have repurchased approximately 20.23 million shares at an aggregate cost of approximately $2.49 billion (approximately $123 per share).

Kentucky Hospital Rate Increase Program:

In early 2021, the Centers for Medicare and Medicaid Services (“CMS”) approved the Kentucky Medicaid Managed Care Hospital Rate Increase Program (“HRIP”) for state fiscal year (”SFY”) 2021. The CMS approval increased the program’s statewide net benefit to eligible Kentucky hospitals to approximately $1.1 billion from the original approved pool size of $86 million. During the second quarter of 2021, Kentucky enacted legislation that authorizes increased HRIP payments to hospitals and CMS approved the applicable HRIP rate add-on amount for SFY 2021, which is retroactive to July 1, 2020.

This program change increased our reimbursement for SFY 2021, covering the period of July 1, 2020 through June 30, 2021, by an aggregate of approximately $55 million, which we recorded during the second quarter of 2021. Programs such as HRIP require an annual state submission and approval by CMS. In May, 2021, Kentucky submitted a request to CMS in order to continue the HRIP program for SFY 2022 with a similar payment methodology and payment level as the SFY 2021 program. However, we are unable predict if CMS will approve the HRIP for SFY 2022, and if approved, if the rates will be generally comparable to the SFY 2021 HRIP rates.

Increase to Self-Insured Professional and General Liability Reserves:

Our estimated liability for self-insured professional and general liability claims is based on a number of factors including, among other things, the number of asserted claims and reported incidents, estimates of losses for these claims based on recent and historical settlement amounts, estimates of incurred but not reported claims based on historical experience, and estimates of amounts recoverable under our commercial insurance policies. As a result of unfavorable trends recently experienced, during the second quarter of 2021, we recorded a $36.0 million increase to our reserves for self-insured professional and general liability claims.

Conference call information:

We will hold a conference call for investors and analysts at 9:00 a.m. eastern time on July 27, 2021. The dial-in number is 1-877-648-7971.

A live broadcast of the conference call will be available on our website at www.uhs.com. Also, a replay of the call will be available following the conclusion of the live call and will be available for one full year.

General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures:

One of the nation’s largest and most respected providers of hospital and healthcare services, Universal Health Services, Inc. has built an impressive record of achievement and performance. Growing steadily since our inception into an esteemed Fortune 500 corporation, our annual revenues were approximately $11.6 billion during 2020. In 2021, UHS was again recognized as one of the World’s Most Admired Companies by Fortune; ranked #270 on the Fortune 500; and ranked #307 on Forbes’ list of America’s Largest Public Companies.

Our operating philosophy is as effective today as it was upon the Company’s founding in 1979, enabling us to provide compassionate care to our patients and their loved ones. Our strategy includes building or acquiring high quality hospitals in rapidly growing markets, investing in the people and equipment needed to allow each facility to thrive, and becoming the leading healthcare provider in each community we serve.

Headquartered in King of Prussia, PA, UHS has approximately 89,000 employees and through its subsidiaries operates 26 acute care hospitals, 334 behavioral health facilities, 39 outpatient facilities and ambulatory care access points, an insurance offering, a physician network and various related services located in 38 U.S. states, Washington, D.C., Puerto Rico and the United Kingdom. It acts as the advisor to Universal Health Realty Income Trust, a real estate investment trust (NYSE:UHT). For additional information visit www.uhs.com.

This press release contains forward-looking statements based on current management expectations. Numerous factors, including those disclosed herein, those related to the anticipated impact of COVID-19 on our operations and financial results, those related to healthcare industry trends and those detailed in our filings with the Securities and Exchange Commission (as set forth in Item 1A-Risk Factors and in Item 7-Forward-Looking Statements and Risk Factors in our Form 10-K for the year ended December 31, 2020 and in Item 2-Forward Looking Statements and Risk Factors in our Form 10-Q for the quarterly period ended March 31, 2021), may cause the results to differ materially from those anticipated in the forward-looking statements. These statements are subject to risks and uncertainties and therefore actual results may differ materially. Readers should not place undue reliance on such forward-looking statements which reflect management’s view only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Many of the factors that could affect our future results are beyond our control or ability to predict, including the impact of the COVID-19 pandemic. Our future operations and financial results will likely be materially impacted by developments related to COVID-19 including, but not limited to, the potential impact on future COVID-19 patient volumes resulting from new variants of the virus, the length of time and severity of the spread of the pandemic; the volume of cancelled or rescheduled elective procedures and the volume of COVID-19 patients treated at our hospitals and other healthcare facilities; measures we are taking to respond to the COVID-19

pandemic; the impact of government and administrative regulation and stimulus on the hospital industry and potential retrospective adjustment in future periods of CARES Act and other grant income revenues recorded as revenues in prior periods; declining patient volumes and unfavorable changes in payer mix caused by deteriorating macroeconomic conditions (including increases in uninsured and underinsured patients as the result of business closings and layoffs); potential disruptions to our clinical staffing and shortages and disruptions related to supplies required for our employees and patients; and potential increases to expenses related to staffing, supply chain or other expenditures; the impact of our substantial indebtedness and the ability to refinance such indebtedness on acceptable terms, as well as risks associated with disruptions in the financial markets and the business of financial institutions as the result of the COVID-19 pandemic which could impact us from a financing perspective; and changes in general economic conditions nationally and regionally in our markets resulting from the COVID-19 pandemic. We are not able to fully quantify the impact that these factors will have on our future financial results, but developments related to the COVID-19 pandemic could materially affect our financial performance during the remainder of 2021.

We believe that adjusted net income attributable to UHS, adjusted net income attributable to UHS per diluted share, EBITDA net of NCI and Adjusted EBITDA net of NCI, which are non-GAAP financial measures (“GAAP” is Generally Accepted Accounting Principles in the United States of America), are helpful to our investors as measures of our operating performance. In addition, we believe that, when applicable, comparing and discussing our financial results based on these measures, as calculated, is helpful to our investors since it neutralizes the effect of material items impacting our net income attributable to UHS, such as, our adoption of ASU 2016-09, unrealized gains/losses resulting from changes in the market value of shares of certain marketable securities held for investment and classified as available for sale, and other potential material items that are nonrecurring or non-operational in nature including, but not limited to, impairments of long-lived and intangible assets, changes in the reserve established in connection with our discussions with the Department of Justice, reserves for various matters including settlements, legal judgments and lawsuits, costs related to extinguishment of debt, gains/losses on sales of assets and businesses, and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. To obtain a complete understanding of our financial performance these measures should be examined in connection with net income attributable to UHS, as determined in accordance with GAAP, and as presented in the condensed consolidated financial statements and notes thereto in this report or in our other filings with the Securities and Exchange Commission including our Report on Form 10-K for the year ended December 31, 2020, and our Report on Form 10-Q for the quarter ended March 31, 2021. Since the items included or excluded from these measures are significant components in understanding and assessing financial performance under GAAP, these measures should not be considered to be alternatives to net income as a measure of our operating performance or profitability. Since these measures, as presented, are not determined in accordance with GAAP and are thus susceptible to varying calculations, they may not be comparable to other similarly titled measures of other companies. Investors are encouraged to use GAAP measures when evaluating our financial performance.

(more)

Universal Health Services, Inc.
Consolidated Statements of Income
(in thousands, except per share amounts)
(unaudited)

	Three months						Six months
	ended June 30,						ended June 30,
	2021			2020			2021			2020
Net revenues	$	3,197,880			2,729,754		$	6,210,867			5,559,421

Operating charges:
Salaries, wages and benefits		1,487,935			1,308,010			2,985,708			2,740,679
Other operating expenses		769,810			625,747			1,479,518			1,315,537
Supplies expense		338,033			283,572			685,143			601,399
Depreciation and amortization		133,985			126,208			265,388			250,602
Lease and rental expense		29,149			28,186			60,473			56,479
		2,758,912			2,371,723			5,476,230			4,964,696

Income from operations		438,968			358,031			734,637			594,725
Interest expense, net		21,299			25,473			43,256			61,824
Other (income) expense, net		(9,129	)		(3,100	)		(8,294	)		6,460
Income before income taxes		426,798			335,658			699,675			526,441
Provision for income taxes		101,522			79,154			165,329			125,477
Net income		325,276			256,504			534,346			400,964
Less: Net income attributable to noncontrolling interests		252			4,575			231			6,998
Net income attributable to UHS	$	325,024		$	251,929		$	534,115		$	393,966

Basic earnings per share attributable to UHS (a)	$	3.85		$	2.97		$	6.31		$	4.60

Diluted earnings per share attributable to UHS (a)	$	3.79		$	2.95		$	6.22		$	4.58

Universal Health Services, Inc.
Footnotes to Consolidated Statements of Income
(in thousands, except per share amounts)
(unaudited)

	Three months						Six months
	ended June 30,						ended June 30,
	2021			2020			2021			2020
(a) Earnings per share calculation:

Basic and diluted:
Net income attributable to UHS	$	325,024		$	251,929		$	534,115		$	393,966
Less: Net income attributable to unvested restricted share grants		(661	)		(824	)		(1,213	)		(1,197	)
Net income attributable to UHS - basic and diluted	$	324,363		$	251,105		$	532,902		$	392,769

Weighted average number of common shares - basic		84,224			84,632			84,503			85,422

Basic earnings per share attributable to UHS:	$	3.85		$	2.97		$	6.31		$	4.60

Weighted average number of common shares		84,224			84,632			84,503			85,422
Add: Other share equivalents		1,400			427			1,207			335
Weighted average number of common shares and equiv. - diluted		85,624			85,059			85,710			85,757

Diluted earnings per share attributable to UHS:	$	3.79		$	2.95		$	6.22		$	4.58

Universal Health Services, Inc.
Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule")
For the Three Months ended June 30, 2021 and 2020
(in thousands, except per share amounts)
(unaudited)



Calculation of Earnings/Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA/Adjusted EBITDA net of NCI")

	Three months ended			% Net			Three months ended			% Net
	June 30, 2021			revenues			June 30, 2020			revenues
Net income attributable to UHS	$	325,024					$	251,929
Depreciation and amortization		133,985						126,208
Interest expense, net		21,299						25,473
Provision for income taxes		101,522						79,154
EBITDA net of NCI	$	581,830			18.2	%	$	482,764			17.7	%

Other (income) expense, net		(9,129	)					(3,100	)
Adjusted EBITDA net of NCI	$	572,701			17.9	%	$	479,664			17.6	%

Net revenues	$	3,197,880					$	2,729,754

Calculation of Adjusted Net Income Attributable to UHS

	Three months ended						Three months ended
	June 30, 2021						June 30, 2020
				Per						Per
	Amount			Diluted Share			Amount			Diluted Share
Net income attributable to UHS	$	325,024		$	3.79		$	251,929		$	2.95
Plus/minus after-tax adjustments:
Unrealized gain on available for sale marketable securities		(1,607	)		(0.02	)		(2,223	)		(0.03	)
Impact of ASU 2016-09		(1,120	)		(0.01	)		505			0.01
Subtotal adjustments		(2,727	)		(0.03	)		(1,718	)		(0.02	)
Adjusted net income attributable to UHS	$	322,297		$	3.76		$	250,211		$	2.93

Universal Health Services, Inc.
Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule")
For the Six Months ended June 30, 2021 and 2020
(in thousands, except per share amounts)
(unaudited)



Calculation of Earnings/Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA/Adjusted EBITDA net of NCI")

	Six months ended			% Net			Six months ended		% Net
	June 30, 2021			revenues			June 30, 2020		revenues
Net income attributable to UHS	$	534,115					$	393,966
Depreciation and amortization		265,388						250,602
Interest expense, net		43,256						61,824
Provision for income taxes		165,329						125,477
EBITDA net of NCI	$	1,008,088			16.2	%	$	831,869		15.0	%

Other (income) expense, net		(8,294	)					6,460
Adjusted EBITDA net of NCI	$	999,794			16.1	%	$	838,329		15.1	%

Net revenues	$	6,210,867					$	5,559,421

Calculation of Adjusted Net Income Attributable to UHS

	Six months ended						Six months ended
	June 30, 2021						June 30, 2020
				Per					Per
	Amount			Diluted Share			Amount		Diluted Share
Net income attributable to UHS	$	534,115		$	6.22		$	393,966	$	4.58
Plus/minus after-tax adjustments:
Unrealized loss on available for sale marketable securities		530			0.01			5,127		0.06
Impact of ASU 2016-09		(2,199	)		(0.03	)		1,275		0.01
Subtotal adjustments		(1,669	)		(0.02	)		6,402		0.07
Adjusted net income attributable to UHS	$	532,446		$	6.20		$	400,368	$	4.65

Universal Health Services, Inc.
Consolidated Statements of Comprehensive Income
(in thousands)
(unaudited)

	Three months					Six months
	ended June 30,					ended June 30,
	2021			2020		2021			2020
Net income	$	325,276		$	256,504	$	534,346		$	400,964
Other comprehensive income (loss):
Foreign currency translation adjustment		(3,717	)		6,676		(14,063	)		(32,525	)
Other comprehensive income (loss) before tax		(3,717	)		6,676		(14,063	)		(32,525	)
Income tax expense (benefit) related to items of other comprehensive income (loss)		(601	)		898		(2,067	)		(1,210	)
Total other comprehensive income (loss), net of tax		(3,116	)		5,778		(11,996	)		(31,315	)

Comprehensive income		322,160			262,282		522,350			369,649
Less: Comprehensive income attributable to noncontrolling interests		252			4,575		231			6,998
Comprehensive income attributable to UHS	$	321,908		$	257,707	$	522,119		$	362,651

Universal Health Services, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)

	June 30,			December 31,
	2021			2020
Assets
Current assets:
Cash and cash equivalents	$	199,017		$	1,224,490
Accounts receivable, net		1,787,931			1,728,928
Supplies		195,141			190,417
Other current assets		183,216			138,034
Total current assets		2,365,305			3,281,869

Property and equipment		10,361,669			9,885,888
Less: accumulated depreciation		(4,731,772	)		(4,512,764	)
		5,629,897			5,373,124
Other assets:
Goodwill		3,903,266			3,882,715
Deferred income taxes		34,945			22,689
Right of use assets-operating leases		317,231			336,513
Deferred charges		4,865			4,985
Other		557,126			574,984
Total Assets	$	12,812,635		$	13,476,879

Liabilities and Stockholders' Equity
Current liabilities:
Current maturities of long-term debt	$	107,370		$	331,998
Accounts payable and other liabilities		1,765,773			1,668,671
Medicare accelerated payments and deferred CARES Act and other grants		1,757			376,151
Operating lease liabilities		60,595			59,796
Federal and state taxes		33,315			44,423
Total current liabilities		1,968,810			2,481,039

Other noncurrent liabilities		522,007			458,549
Operating lease liabilities noncurrent		258,823			278,303
Medicare accelerated payments noncurrent		0			322,617
Long-term debt		3,486,222			3,524,253
Deferred income taxes		0			5,582

Redeemable noncontrolling interest		4,693			4,569

UHS common stockholders' equity		6,480,100			6,317,146
Noncontrolling interest		91,980			84,821
Total equity		6,572,080			6,401,967

Total Liabilities and Stockholders' Equity	$	12,812,635		$	13,476,879

Universal Health Services, Inc.
Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
	Six months
	ended June 30,
	2021			2020
Cash Flows from Operating Activities:
Net income	$	534,346		$	400,964
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation & amortization		265,388			250,602
(Gain) loss on sale of assets and businesses		(4,803	)		2,161
Stock-based compensation expense		37,031			33,954
Provision for asset impairment		7,195			0
Changes in assets & liabilities, net of effects from acquisitions and dispositions:
Accounts receivable		(35,903	)		131,294
Accrued interest		(1,459	)		(2,191	)
Accrued and deferred income taxes		(26,769	)		116,707
Other working capital accounts		3,560			26,361
Medicare accelerated payments and deferred CARES Act and other grants		(697,011	)		477,099
Other assets and deferred charges		(28,763	)		5,095
Other		5,052			(7,659	)
Accrued insurance expense, net of commercial premiums paid		104,079			81,016
Payments made in settlement of self-insurance claims		(42,495	)		(64,034	)
Net cash provided by operating activities		119,448			1,451,369
Cash Flows from Investing Activities:
Property and equipment additions		(482,211	)		(354,610	)
Proceeds received from sales of assets and businesses		21,143			6,440
Acquisition of businesses and property		0			(968	)
Inflows (outflows) from foreign exchange contracts that hedge our net U.K. investment		(21,487	)		57,029
Increase in capital reserves of commercial insurance subsidiary		100			0
Costs incurred for purchase and implementation of information technology applications		(1,246	)		(4,421	)
Investment in, and advances to, joint venture and other		0			(285	)
Net cash used in investing activities		(483,701	)		(296,815	)
Cash Flows from Financing Activities:
Reduction of long-term debt		(278,785	)		(459,332	)
Additional borrowings		6,578			5,453
Repurchase of common shares		(368,080	)		(200,054	)
Dividends paid		(33,844	)		(17,344	)
Issuance of common stock		6,442			5,852
Profit distributions to noncontrolling interests		(5,617	)		(8,885	)
Purchase of ownership interests by minority member		11,433			0
Net cash used in financing activities		(661,873	)		(674,310	)

Effect of exchange rate changes on cash, cash equivalents and restricted cash		660			(1,639	)
(Decrease) increase in cash, cash equivalents and restricted cash		(1,025,466	)		478,605
Cash, cash equivalents and restricted cash, beginning of period		1,279,154			105,667
Cash, cash equivalents and restricted cash, end of period	$	253,688		$	584,272
Supplemental Disclosures of Cash Flow Information:
Interest paid	$	43,641		$	61,082
Income taxes paid, net of refunds	$	189,979		$	14,394
Noncash purchases of property and equipment	$	95,979		$	80,031

Universal Health Services, Inc.
Supplemental Statistical Information
(unaudited)


				% Change
Same Facility:			% Change Quarter ended	6 months ended
			6/30/2021	6/30/2021
Acute Care Services
Revenues (a)			11.7%	11.7%
Revenues-excludes governmental stimulus revenues			-2.2%	-2.2%
Adjusted Admissions			-12.1%	-12.1%
Adjusted Patient Days			-0.7%	-0.7%
Revenue Per Adjusted Admission-excludes governmental stimulus revenues			26.3%	26.3%
Revenue Per Adjusted Patient Day-excludes governmental stimulus revenues			11.8%	11.8%

Behavioral Health Care Services
Revenues (b			0.9%	0.9%
Revenues-excludes governmental stimulus revenues			-1.3%	-1.3%
Adjusted Admissions			-4.9%	-4.9%
Adjusted Patient Days			-3.8%	-3.8%
Revenue Per Adjusted Admission-excludes governmental stimulus revenues			6.2%	6.2%
Revenue Per Adjusted Patient Day-excludes governmental stimulus revenues			4.9%	4.9%

(a) Includes governmental stimulus program revenues of $157 million recorded in the three and six-month periods ended June 30, 2020.
(b) Includes governmental stimulus program revenues of $61 million recorded in the three and six-month periods ended June 30, 2020.

UHS Consolidated	Second Quarter Ended		Six months ended
	6/30/2021	6/30/2020	6/30/2021	6/30/2020
Revenues	$3,197,880	$2,729,754	$6,210,867	$5,559,421
EBITDA net of NCI	$581,830	$482,764	$1,008,088	$831,869
EBITDA Margin net of NCI	18.2%	17.7%	16.2%	15.0%
Adjusted EBITDA net of NCI	$572,701	$479,664	$999,794	$838,329
Adjusted EBITDA Margin net of NCI	17.9%	17.6%	16.1%	15.1%

Cash Flow From Operations			$119,448	$1,451,369
Days Sales Outstanding			52	47
Capital Expenditures			$482,211	$354,610

Debt			$3,593,592	$3,532,025
UHS' Shareholders Equity			$6,480,100	$5,688,647
Debt / Total Capitalization			35.7%	38.3%
Debt / EBITDA net of NCI (1)			1.76	2.19
Debt / Adjusted EBITDA net of NCI (1)			1.78	2.07
Debt / Cash From Operations (1)			3.49	1.59
Net Debt / EBITDA net of NCI (1) (2)			1.72	1.83
Net Debt / Adjusted EBITDA net of NCI (1) (2)			1.73	1.73
Net Debt / Cash From Operations (1) (2)			3.40	1.33
(1) Latest 4 quarters
(2) Debt, net of approximately $97 million of short-term cash investments as of June 30, 2021 and $574 million as of June 30, 2020.

Universal Health Services, Inc.

Acute Care Hospital Services

For the Three and Six Months ended

June 30, 2021 and 2020

(in thousands)

Same Facility Basis - Acute Care Hospital Services

	Three months ended					Three months ended					Six months ended					Six months ended
	June 30, 2021					June 30, 2020					June 30, 2021					June 30, 2020
	Amount		% of Net Revenues			Amount		% of Net Revenues			Amount		% of Net Revenues			Amount		% of Net Revenues
Net revenues (a)	$	1,713,896		100.0	%	$	1,446,099		100.0	%	$	3,385,732		100.0	%		2,943,222		100.0	%
Operating charges:
Salaries, wages and benefits		691,019		40.3	%		589,677		40.8	%		1,397,830		41.3	%		1,248,606		42.4	%
Other operating expenses		412,111		24.0	%		344,384		23.8	%		805,318		23.8	%		719,915		24.5	%
Supplies expense		289,111		16.9	%		233,419		16.1	%		585,589		17.3	%		497,949		16.9	%
Depreciation and amortization		82,959		4.8	%		78,440		5.4	%		164,143		4.8	%		156,368		5.3	%
Lease and rental expense		18,046		1.1	%		16,563		1.1	%		38,158		1.1	%		32,583		1.1	%
Subtotal-operating expenses		1,493,246		87.1	%		1,262,483		87.3	%		2,991,038		88.3	%		2,655,421		90.2	%
Income from operations		220,650		12.9	%		183,616		12.7	%		394,694		11.7	%		287,801		9.8	%
Interest expense, net		248		0.0	%		516		0.0	%		494		0.0	%		1,134		0.0	%
Other (income) expense, net		-		-			-		-			-		-			-		-
Income before income taxes	$	220,402		12.9	%	$	183,100		12.7	%	$	394,200		11.6	%	$	286,667		9.7	%

All Acute Care Hospital Services

	Three months ended					Three months ended					Six months ended					Six months ended
	June 30, 2021					June 30, 2020					June 30, 2021					June 30, 2020
	Amount		% of Net Revenues			Amount		% of Net Revenues			Amount		% of Net Revenues			Amount		% of Net Revenues
Net revenues (a)	$	1,754,431		100.0	%	$	1,467,506		100.0	%	$	3,448,973		100.0	%		2,988,555		100.0	%
Operating charges:
Salaries, wages and benefits		691,880		39.4	%		589,762		40.2	%		1,399,098		40.6	%		1,248,721		41.8	%
Other operating expenses		453,063		25.8	%		365,810		24.9	%		869,070		25.2	%		765,267		25.6	%
Supplies expense		289,225		16.5	%		233,419		15.9	%		585,704		17.0	%		497,949		16.7	%
Depreciation and amortization		83,306		4.7	%		78,440		5.3	%		164,668		4.8	%		156,368		5.2	%
Lease and rental expense		18,046		1.0	%		16,563		1.1	%		38,158		1.1	%		32,583		1.1	%
Subtotal-operating expenses		1,535,520		87.5	%		1,283,994		87.5	%		3,056,698		88.6	%		2,700,888		90.4	%
Income from operations		218,911		12.5	%		183,512		12.5	%		392,275		11.4	%		287,667		9.6	%
Interest expense, net		248		0.0	%		516		0.0	%		494		0.0	%		1,134		0.0	%
Other (income) expense, net		-		-			-		-			-		-			-		-
Income before income taxes	$	218,663		12.5	%	$	182,996		12.5	%	$	391,781		11.4	%	$	286,533		9.6	%

(a) Includes $157 million of CARES Act and other grant revenues in each of the three and six-months periods ended June 30, 2020.

We believe that providing our results on a “Same Facility” basis (which is a non-GAAP measure), which includes the operating results for facilities and businesses operated in both the current year and prior year periods, is helpful to our investors as a measure of our operating performance. Our Same Facility results also neutralize (if applicable), the effect of material items that are nonrecurring or non-operational in nature including items such as, but not limited to, reserves for various matters, settlements, legal judgments and lawsuits, cost related to extinguishment of debt, gains/losses on sales of assets and businesses, impairments of long-lived and intangible assets and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. Our Same Facility basis results exclude from net revenues and other operating expenses, provider tax assessments incurred in each period. However, these provider tax assessments are included in net revenues and other operating expenses as reflected in the table under All Acute Care Hospital Services. The provider tax assessments had no impact on the income before income taxes as reflected on the above tables since the amounts offset between net revenues and other operating expenses. To obtain a complete understanding of our financial performance, the Same Facility results should be examined in connection with our net income as determined in accordance with GAAP and as presented herein and the condensed consolidated financial statements and notes thereto as contained in our Form 10-K for the year ended December 31, 2020 and Form 10-Q for the quarter ended March 31, 2021.

The All Acute Care Hospital Services table summarizes the results of operations for all our acute care operations during the periods presented. These amounts include: (i) our acute care results on a same facility basis, as indicated above; (ii) the impact of provider tax assessments which increased net revenues and other operating expenses but had no impact on income before income taxes, and; (iii) certain other amounts including the results of facilities acquired or opened during the last twelve months.

Universal Health Services, Inc.

Behavioral Health Care Services

For the Three and Six Months ended

June 30, 2021 and 2020

(in thousands)

Same Facility - Behavioral Health Care Services

	Three months ended						Three months ended					Six months ended					Six months ended
	June 30, 2021						June 30, 2020					June 30, 2021					June 30, 2020
	Amount			% of Net Revenues			Amount		% of Net Revenues			Amount		% of Net Revenues			Amount		% of Net Revenues
Net revenues (a)	$	1,409,556			100.0	%		1,239,959		100.0	%	$	2,701,598		100.0	%		2,521,011		100.0	%
Operating charges:
Salaries, wages and benefits		710,239			50.4	%		648,124		52.3	%		1,411,806		52.3	%		1,338,499		53.1	%
Other operating expenses		262,836			18.6	%		221,496		17.9	%		508,209		18.8	%		463,862		18.4	%
Supplies expense		49,352			3.5	%		50,394		4.1	%		100,098		3.7	%		101,955		4.0	%
Depreciation and amortization		45,826			3.3	%		43,243		3.5	%		91,128		3.4	%		85,958		3.4	%
Lease and rental expense		9,754			0.7	%		10,436		0.8	%		21,028		0.8	%		21,456		0.9	%
Subtotal-operating expenses		1,078,007			76.5	%		973,693		78.5	%		2,132,269		78.9	%		2,011,730		79.8	%
Income from operations		331,549			23.5	%		266,266		21.5	%		569,329		21.1	%		509,281		20.2	%
Interest expense, net		340			0.0	%		361		0.0	%		678		0.0	%		725		0.0	%
Other (income) expense, net		(5	)		(0.0	)%		922		0.1	%		408		0.0	%		1,811		0.1	%
Income before income taxes	$	331,214			23.5	%	$	264,983		21.4	%	$	568,243		21.0	%	$	506,745		20.1	%

All Behavioral Health Care Services

	Three months ended						Three months ended					Six months ended					Six months ended
	June 30, 2021						June 30, 2020					June 30, 2021					June 30, 2020
	Amount			% of Net Revenues			Amount		% of Net Revenues			Amount		% of Net Revenues			Amount		% of Net Revenues
Net revenues (a)	$	1,431,497			100.0	%		1,259,123		100.0	%	$	2,746,834		100.0	%		2,565,232		100.0	%
Operating charges:
Salaries, wages and benefits		713,623			49.9	%		649,376		51.6	%		1,417,598		51.6	%		1,342,648		52.3	%
Other operating expenses		285,689			20.0	%		245,045		19.5	%		554,986		20.2	%		511,227		19.9	%
Supplies expense		49,552			3.5	%		50,363		4.0	%		100,561		3.7	%		102,002		4.0	%
Depreciation and amortization		47,183			3.3	%		45,038		3.6	%		93,665		3.4	%		88,927		3.5	%
Lease and rental expense		9,685			0.7	%		11,259		0.9	%		21,368		0.8	%		23,417		0.9	%
Subtotal-operating expenses		1,105,732			77.2	%		1,001,081		79.5	%		2,188,178		79.7	%		2,068,221		80.6	%
Income from operations		325,765			22.8	%		258,042		20.5	%		558,656		20.3	%		497,011		19.4	%
Interest expense, net		1,193			0.1	%		354		0.0	%		2,346		0.1	%		751		0.0	%
Other (income) expense, net		(5	)		(0.0	)%		922		0.1	%		408		0.0	%		1,811		0.1	%
Income before income taxes	$	324,577			22.7	%	$	256,766		20.4	%	$	555,902		20.2	%	$	494,449		19.3	%

(a) Includes $61 million of CARES Act and other grant revenues in each of the three and six-months periods ended June 30, 2020.

We believe that providing our results on a “Same Facility” basis (which is a non-GAAP measure), which includes the operating results for facilities and businesses operated in both the current year and prior year periods, is helpful to our investors as a measure of our operating performance. Our Same Facility results also neutralize (if applicable), the effect of material items that are nonrecurring or non-operational in nature including items such as, but not limited to, reserves for various matters, settlements, legal judgments, lawsuits and reserves established in connection with the government's investigation of our behavioral health care facilities, cost related to extinguishment of debt, gains/losses on sales of assets and businesses, impairments of long-lived and intangible assets and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. Our Same Facility basis results exclude from net revenues and other operating expenses, provider tax assessments incurred in each period. However, these provider tax assessments are included in net revenues and other operating expenses as reflected in the table under All Behavioral Health Care Services. The provider tax assessments had no impact on the income before income taxes as reflected on the above tables since the amounts offset between net revenues and other operating expenses. To obtain a complete understanding of our financial performance, the Same Facility results should be examined in connection with our net income as determined in accordance with GAAP and as presented herein and in the condensed consolidated financial statements and notes thereto as contained in our Form 10-K for the year ended December 31, 2020 and Form 10-Q for the quarter ended March 31, 2021.

The All Behavioral Health Care Services table summarizes the results of operations for all our behavioral health care facilities during the periods presented. These amounts include: (i) our behavioral health results on a same facility basis, as indicated above; (ii) the impact of provider tax assessments which increased net revenues and other operating expenses but had no impact on income before income taxes, and; (iii) certain other amounts including the results of facilities acquired or opened during the last twelve months as well as the results of certain facilities that were closed or restructured during the past year.

Universal Health Services, Inc.
Selected Hospital Statistics
For the Three Months Ended
June 30, 2021 and 2020


AS REPORTED:
	ACUTE									BEHAVIORAL HEALTH
	06/30/21			06/30/20			% change			06/30/21			06/30/20			% change

Hospitals owned and leased		26			26			0.0	%		334			330			1.2	%
Average licensed beds		6,511			6,451			0.9	%		24,161			23,573			2.5	%
Average available beds		6,339			6,279			1.0	%		24,056			23,470			2.5	%
Patient days		362,325			317,359			14.2	%		1,564,902			1,464,601			6.8	%
Average daily census		3,981.6			3,487.4			14.2	%		17,009.8			16,094.5			5.7	%
Occupancy-licensed beds		61.2	%		54.1	%		13.1	%		70.4	%		68.3	%		3.1	%
Occupancy-available beds		62.8	%		55.5	%		13.1	%		70.7	%		68.6	%		3.1	%
Admissions		76,221			64,208			18.7	%		117,018			102,770			13.9	%
Length of stay		4.8			4.9			-3.8	%		13.4			14.3			-6.0	%

Inpatient revenue	$	8,662,335		$	6,736,777			28.6	%	$	2,527,776		$	2,285,359			10.6	%
Outpatient revenue		5,357,888			3,394,680			57.8	%		266,328			216,174			23.2	%
Total patient revenue		14,020,223			10,131,457			38.4	%		2,794,104			2,501,533			11.7	%
Other revenue		167,899			269,749			-37.8	%		70,929			113,717			-37.6	%
Gross hospital revenue		14,188,122			10,401,206			36.4	%		2,865,033			2,615,250			9.6	%
Total deductions		12,433,691			8,933,700			39.2	%		1,433,536			1,356,127			5.7	%
Net hospital revenue	$	1,754,431		$	1,467,506			19.6	%	$	1,431,497		$	1,259,123			13.7	%

SAME FACILITY:
	ACUTE									BEHAVIORAL HEALTH
	06/30/21			06/30/20			% change			06/30/21			06/30/20			% change

Hospitals owned and leased		26			26			0.0	%		330			330			0.0	%
Average licensed beds		6,511			6,451			0.9	%		23,731			23,410			1.4	%
Average available beds		6,339			6,279			1.0	%		23,626			23,307			1.4	%
Patient days		362,325			317,359			14.2	%		1,553,416			1,458,430			6.5	%
Average daily census		3,981.6			3,487.4			14.2	%		17,070.5			16,026.7			6.5	%
Occupancy-licensed beds		61.2	%		54.1	%		13.1	%		71.9	%		68.5	%		5.1	%
Occupancy-available beds		62.8	%		55.5	%		13.1	%		72.3	%		68.8	%		5.1	%
Admissions		76,221			64,208			18.7	%		115,694			102,226			13.2	%
Length of stay		4.8			4.9			-3.8	%		13.4			14.3			-5.9	%

Universal Health Services, Inc.
Selected Hospital Statistics
For the Six Months Ended
June 30, 2021 and 2020


AS REPORTED:
	ACUTE									BEHAVIORAL HEALTH
	06/30/21			06/30/20			% change			06/30/21			06/30/20			% change

Hospitals owned and leased		26			26			0.0	%		334			330			1.2	%
Average licensed beds		6,513			6,451			1.0	%		24,089			23,604			2.1	%
Average available beds		6,341			6,279			1.0	%		23,987			23,501			2.1	%
Patient days		754,719			687,872			9.7	%		3,099,064			3,057,212			1.4	%
Average daily census		4,169.7			3,779.5			10.3	%		17,121.9			16,797.9			1.9	%
Occupancy-licensed beds		64.0	%		58.6	%		9.3	%		71.1	%		71.2	%		-0.1	%
Occupancy-available beds		65.8	%		60.2	%		9.2	%		71.4	%		71.5	%		-0.1	%
Admissions		149,145			141,976			5.0	%		232,426			223,787			3.9	%
Length of stay		5.1			4.8			4.4	%		13.3			13.7			-2.4	%

Inpatient revenue	$	17,781,519		$	14,558,249			22.1	%	$	5,001,341		$	4,810,898			4.0	%
Outpatient revenue		9,938,608			8,076,421			23.1	%		513,092			475,913			7.8	%
Total patient revenue		27,720,127			22,634,670			22.5	%		5,514,433			5,286,811			4.3	%
Other revenue		311,164			386,027			-19.4	%		133,137			170,107			-21.7	%
Gross hospital revenue		28,031,291			23,020,697			21.8	%		5,647,570			5,456,918			3.5	%
Total deductions		24,582,318			20,032,142			22.7	%		2,900,736			2,891,686			0.3	%
Net hospital revenue	$	3,448,973		$	2,988,555			15.4	%	$	2,746,834		$	2,565,232			7.1	%

SAME FACILITY:
	ACUTE									BEHAVIORAL HEALTH
	06/30/21			06/30/20			% change			06/30/21			06/30/20			% change

Hospitals owned and leased		26			26			0.0	%		330			330			0.0	%
Average licensed beds		6,513			6,451			1.0	%		23,710			23,404			1.3	%
Average available beds		6,341			6,279			1.0	%		23,608			23,301			1.3	%
Patient days		754,719			687,872			9.7	%		3,079,136			3,040,874			1.3	%
Average daily census		4,169.7			3,779.5			10.3	%		17,011.8			16,708.1			1.8	%
Occupancy-licensed beds		64.0	%		58.6	%		9.3	%		71.7	%		71.4	%		0.5	%
Occupancy-available beds		65.8	%		60.2	%		9.2	%		72.1	%		71.7	%		0.5	%
Admissions		149,145			141,976			5.0	%		230,120			222,308			3.5	%
Length of stay		5.1			4.8			4.4	%		13.4			13.7			-2.2	%

Universal Health Services, Inc.
Supplemental Non-GAAP Disclosures
Revised 2021 Operating Results Forecast
(in thousands, except per share amounts)


	Forecast For The Year Ending December 31, 2021
				% Net						% Net
	Low			revenues			High			revenues
Net revenues	$	12,351,000					$	12,501,000

Adjusted net income attributable to UHS (a)	$	971,099					$	1,030,488
Depreciation and amortization		533,228						533,228
Interest expense		91,615						91,615
Other (income) expense, net		(12,952	)					(12,952	)
Provision for income taxes		300,254						318,865
Adjusted EBITDA net of NCI (b)	$	1,883,244			15.2	%	$	1,961,244			15.7	%

Adjusted net income attributable to UHS, per diluted share (a)	$	11.46					$	12.16

Shares used in computing diluted earnings per share		84,533						84,533

(a) Adjusted net income attributable to UHS/per diluted share are non-GAAP financial measures. The 2021 revised forecasted amounts exclude the impact of future items, if applicable, that are nonrecurring or non-operational in nature including items such as pre-tax unrealized gains/losses resulting from increases/decreases in the market value of shares of certain marketable securities held for investment and classified as available for sale, our adoption of ASU 2016-09, and other potential material items including, but not limited to, reserves for various matters including settlements, legal judgments and lawsuits, potential impacts of non-ordinary course acquisitions, divestitures, joint ventures or other strategic transactions, costs related to extinguishment of debt, gains/losses on sales of assets and businesses, impairment of long-lived and intangible assets, other amounts that may be reflected in the current financial statements that relate to prior periods, and the impact of share repurchases that differ from included assumptions. It is also subject to certain conditions including those as set forth below in General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures, including the liklihood that our future operations and financial results may continue to be materially impacted by developments related to COVID-19, as discussed herein.

(b) Adjusted EBITDA net of NCI is a non-GAAP financial measure. To obtain a complete understanding of our financial performance, Adjusted EBITDA net of NCI should be examined in connection with net income determined in accordance with GAAP as presented in the consolidated financial statements and notes thereto in this report or in our filings with the Securities and Exchange Commission including our Report on Form 10-K for the year ended December 31, 2020, and our Report on Form 10-Q for the quarter ended March 31, 2021.

EX-101.SCH 3 uhs-20210726.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 uhs-20210726_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of each class Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 5 uhs-20210726_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 uhs-8k_20210726_htm.xml IDEA: XBRL DOCUMENT 0000352915 2021-07-26 2021-07-26 false 0000352915 8-K 2021-07-26 UNIVERSAL HEALTH SERVICES, INC. DE 1-10765 23-2077891 UNIVERSAL CORPORATE CENTER 367 SOUTH GULPH ROAD KING OF PRUSSIA PA 19406 610 768-3300 false false false false Class B Common Stock UHS NYSE false XML 7 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Jul. 26, 2021
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jul. 26, 2021
Entity Registrant Name	UNIVERSAL HEALTH SERVICES, INC.
Entity Central Index Key	0000352915
Entity Emerging Growth Company	false
Entity File Number	1-10765
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	23-2077891
Entity Address, Address Line One	UNIVERSAL CORPORATE CENTER
Entity Address, Address Line Two	367 SOUTH GULPH ROAD
Entity Address, City or Town	KING OF PRUSSIA
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19406
City Area Code	610
Local Phone Number	768-3300
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of each class	Class B Common Stock
Trading Symbol	UHS
Security Exchange Name	NYSE

EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( &! ^U('04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !@0/M2_U?QZ>X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R''9 B;UI66G#08K;.QF;+4UC6-C:R1]^R59FS*V!]C1TN]/ MGT"-B=*$A"\I1$SD,-\-ONVR-''-CD11 F1S1*]S.2:ZL;D/R6L:G^D 49N3 M/B (SA_ (VFK2<,$+.)"9*JQ1IJ$FD*ZX*U9\/$SM3/,&L 6/7:4H2HK8&J: M&,]#V\ -,,$(D\_?!;0+<:[^B9T[P"[)(;LEU?=]V:_FW+A#!>_/3Z_SNH7K M,NG.X/@K.TGGB&MVG?RVVFQWCTP)+JJ"UX6H=Y607,C[^F-R_>%W$_;!NKW[ MQ\970=7 K[M07U!+ P04 " !@0/M2F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M &! ^U($3XVY6@0 /(0 8 >&PO=V]R:W-H965T&UL MC9A=<^HV$(:O3W^%ANLDM@7AXPQAAC@DH^D>D\WG&OR&4=)>M?8:+W];EEIL.$Q2V_DEB=P M9R55S#1TU=I*MXJS,#>*(XO:=MN*F4@:@WY^S5.#OLQT)!+N*9)F<(@9:@5'P?N# M(#TC^'L6W1#:OB+4ILY_S2U@*P!I 4ASO>89/5=^<$7^&BY3K6 )_T8DFX5D M,Y=LU?9!Q"H(F5"')2Q(4UDK1Y3>U.I]O#=JM3 MIFJ'7D(X#$/%T_3JJT%>81R9)M6^PR7+K>M.9]YT-IR/B#N:S$ MRU'B^4Y6$N.2S7:'^-,%9)FGQ:OW3&;3X0/&6A8,!\_XO[*ZI@?1.9>[ZCJ- MR[V,)T]D^DB\V<+WQT,,L:PE#EX"?D4L=I"GY(=(@NH(P#4]%*TL),;PRXU,\1<\5"TV8^?MX*:N##!=8//L82)G7*9Z# M?1YD*C])?@8;EJSYV8-XC=#D#[_R,&2=O,&:?P-^,'-@34G$5Z!CWW1 5AU> ML \=+;?Y2^U2:GA%SIL;SB"JS "XOY)2?W7,>W+Q-\?@7U!+ P04 " !@ M0/M2GZ ;\+$" #B# #0 'AL+W-T>6QEO%DN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M8SDK6W!2 M,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B M6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG- M@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3T MXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(? M]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I M^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE< MA!OZ%>Y7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=> MBD[E\ZI[J,NXZBQ_AOMHD\%G'!QR>(W?#$T

%^@2O&+(=/EB>N$_NG_A. M\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.( M[12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF M&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ; 4/2='@//GL?)=-[*CG_5U/\ M!%!+ P04 " !@0/M2EXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y M;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI M0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:W MO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%B MM/XU@LD/['X 4$L#!!0 ( &! ^U(<.&7J/P$ #P" / >&PO=V]R M:V)O;VLN>&ULC5'+;L) #/R5U7Y $U"+5$2XE#Z0JA:5BON2=8C%/B*O RU? M7R=15*1>>O)Z;(UG9A?G2,=]C$?UY5U(A:Z9FWF6I;(&;])-;"#(I(KD#4M+ MARPU!,:F&H"]RZ9Y/LN\P:"7BY%K0]EU$QE*QA@$[( =PCG]SKM6G3#A'AWR M=Z'[MP.M/ ;T> %;Z%RK5,?S2R2\Q,#&;4N*SA5Z,@QV0(SE'WC;B?PT^]0C M;/8?1H04>I8+8864N-_H^8UH/($L#UW+\0D= ZT,PS/%ML%PZ&C$179EH\]A MK$.(<_I/C+&JL(15+%L/@8<<"5PG,*0:FZ15,!X*/:XH$ZQZ#"PAJ748J&2W MEYIK=WDWM)J'7N M0;#W\!J-'[IFBG#S^0W1UW6E\./VR./ / M,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G M>1,)KM\,<'AT_@%02P,$% @ 8$#[4F60>9(9 0 SP, !, M !;0V]N=&5N=%]4>7!E&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 ! M8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB M'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T.EY&TWP39G M8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM 2D9# ML9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/ MN]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DW MY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4 " !@ M0/M2!T%-8H$ "Q $ @ $ 9&]C4')O<',O87!P M+GAM;%!+ 0(4 Q0 ( &! ^U+_5_'I[@ "L" 1 " M :\ !D;V-0&UL4$L! M A0#% @ 8$#[4@1/C;E:! \A !@ ("!#0@ 'AL M+W=O7!E&UL4$L%!@ ) D /@( /T3 $! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports uhs-8k_20210726.htm uhs-20210726.xsd uhs-20210726_lab.xml uhs-20210726_pre.xml uhs-ex991_6.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "uhs-8k_20210726.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "uhs-8k_20210726.htm" ] }, "labelLink": { "local": [ "uhs-20210726_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "uhs-20210726_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "uhs-20210726.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "uhs", "nsuri": "http://www.uhsinc.com/20210726", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "uhs-8k_20210726.htm", "contextRef": "C_0000352915_20210726_20210726", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "uhs-8k_20210726.htm", "contextRef": "C_0000352915_20210726_20210726", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "verboseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhsinc.com/20210726/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001564590-21-038066-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-038066-xbrl.zip M4$L#!!0 ( &! ^U(_K4%]' M4J8LV[1K*>G\$HKG]O'<>)CKCZN4@F?,!\8@(1#-1GX4]B_Z\>7O83@,PYJ"?\HS@-IO"*[\T(_\[F6_QO@%HN]P M@<%X5&.,^_'5(!ST+KO]WF6OU^OC[FS6BR(F\@ MJO,RABG%:W!/&&2(0 H>[4D_@#%#/KBC%$RUF !3+#!_QHF_T;H2R5"4GE/1 M8&+(E+XBO>G4G+>:<>IG?!$DD@=RG>- ,7F*"W.".ANY!)-*R @(C/Q%]APH M0J"0AEX8>1>193_#QJY^E0]Z6U1209%965UP/]R8;BCP6 0&&H%J.!<=:1CB#94!R2\0DNWD*;L M"$ I.9D5$M]G/!WA.2RH"F/!_BT@)7."$]44*=8=;8>A1I:0+[!\@"D6.43X M[,P2B3;%J7*Q']XV[TYB M.%5R;>'4:Z7Z:@S(57$M$=EK22^:XMB_TMKE1?TV?2@O.YT? YV?4?>L_'1? MR*^%\UHLS7 <1*9JD6;5-#8'#;:=-RCG >2(9Q2KVQ')3ZN<0@9E9LJHD6,T M^XXN#V^5W:OOUV T2AE>J,DU:06LKN -@,C7@&C?[K8C2+GTMM/(65ES.,*T M!&('/KUHFKK[P^+9P3!:#D:^ %,IS-CZ8QQ'Y\4WPZ!#+!HB*85^#AXSRC?% M$L\C1/'ROPT1(U3 MQ_E"K2&"C&72P#![=C?/"9MGFRVUJ0?1H3[:DU(&B!K?GW"J;A*))^;1HDE_ M3\<_>@"4W797M-E+JH)D025X3A@Q!PCU#WCU_\-84T#;N@[V)?:5%0(G?[%; ML\XY%DJ)\4U->L-R2A)!B@K:0G"+[+C<9M?&8B]$UD]3/ ?F/3GK4;!DN.Y>A4N3=J9*'ZC<.:KL%F. _V[L3,Q5R*83K;HK*PD M4@M/--D$27P D%:J=>[>=(2J&UH]@O[OTZI$:'K:_=QQ'_I+C:OQV:MB/+?T M)%QE+$O7)4);(_;O'4L^,85K/59USU.#J6,*?:K8OYW%?JHV(T=Q5DO($E"J M S5]S]'ZI)(-B5+,E4S M+U$4\IR/YSL?+_+EPZ?U H,G2!DB_D7+;ELM 'V/3) _NVBMF.$R#Z$68('K M3UQ,?'C1VD#6^O3QYY\^_&(8X.IF< S)%/B-X%7!VUO;(P@2&D4#W*73% M/\"5&T 0_O2 8SFV874,QQG9YSWKK&=WVK9U?G+NG/YF63W+2@'\%0T+I'YZ MX'W;:MOML]/S5,,'U_ONSB 87*4:.N?.^Z[5[9R>G7=..YW..3P;CSNV#1VG M:SO663I2LMQ0-)L'X%?O;1@B'Z_O0XSA!MP@W_4]Y&(P3$;Z#@Q\KPTN,0:/ MHAL#CY!!^@0G[1@5<]UZ.!&/Y\AGX9\7K91ZZS'%;4)GIF-9)V;2NA4W7^^T M?SX)6]O=;M<,__O2E"%90PYKFU\_WPZ].5RX!D\5=X$G"!CJL?#F+?'"')6( M"^2V$'\923-#W#)LQSBQVVLV:7$U (CTH 3#1S@%XO>7QT$N9]<4+4P?SKAQ M)K?N&&(>7"H=S!0 M&^TVH.J 'R!%9'+M*Q99#MM,\,/ I8I5SP-6/8 1G]^@VM!W(94'30(7*PYZ M!U)AT#6\$>S&>:@1IBX;AS1\29ZY[C*BP@+4=->(7<&IN\*!-,PPQ!T ODI9 M)L0!$W<$&C/$+<.RXYGWC00W/_ P%+':QRT%8L&B$(4?+4$I9+@.H#^!\:S_ M@DV\G7&Q9& ,>NT9>3(G$$5CXA?;(^&WOEW[ 0HV?;X%H2X><)+UGW"39<=B M,2,TN1D.Z:)5T-G,ABG:BQ657XG=$_2-+\.R8-_P>,L>%#*RHN%R6UK1X+5\ M/T8T(.8!(1'@3!_,UX!VX[^D7B8*EWI) /QR3PQQ"],C?)NP# R<-OV4DD6A MFC$MV:N2J=X=?<+WP)=CQLF\H*PKMCK5,EY M)H+K!KNSLF[C^^P .!?WQ#RH4FN5IH(RJNIJ?*&?+E$"8>OU2= M*K8DLKKNX$\ AG2.PQ_.#. M793VM;SO(?O_+%9CV_]7&B!XCN_IPBR0?0KIICBN+_9Q3XK9P"L<$M55XO4" MTAGR9W]0\AS,^V2Q=/V*)_((QJ\X:H3EY_@QV7:Z( $1BR[NENA.BG3126-< M75QUAAWX'J%+0L.7_H8!W[GUR8JO()L^F53<4NV!.D3R0NC&9O0,ZSL0\@)" M0G*\Y6N52I*Z>1NQY,^ X,35'T:GJ=Q2 7Y)!T MY( V5CR<#V0)-5LR]J6*E%9/V[3@0S.BKC N)Q,^ A;_ND4^M*L5A13@$.4E M@(T50TSR+KD0;Z:"X-[79ODH2@\II9J6J<"R+&228!_'_,ZAYG=4*^[\8/./ MGHF^YG?*FM]IPOR*4K'?_,X/-'^?7][3$7GV:UD_W5V!VJ]PS=M><(EC@V#3 MS/*2I,@,OZV6A@F0FSV4_GZ?],J]'IX][ND#)4_(]RH>H_,P%(B^A=F\]5^. MS FE9O[/2Y2L"*3BZ9H4>3E$Z;@ODP[E-?% 6.#B?]"R^H,E.8("Z3.(S5=# M1 !:73H.3=B&* %+I57)_M4_.]B"D,]*DP])!AY*$#^[#/?CE/DXK*.EO6LI^PNDGHOOW* A.3X1BX0 MGQ1+HY?0N(;&*LS[0*&H%^GT_);B2*$>AKG(ZHW->Y=(#RDGFIZIP"]9 /WJ66B@ :,K2 ]O PD.$HRL(/[ THBXM2[ M,O+S)J^/'!UUSE%>K51*CY(-#_16?)^UL9WQ" 6X]'.0W7XUU^ M'/4E$,(" M,@70]>; PR[38,^>*SLIDD4GB9--SBLX"-&;M>N(NN([[%86,&(N8N&*Z[L"IUG&Y[E0L!U=+5??J5XSK&.\8^&L]++3SJ:-K M"UN.5;ZJ[@AV/?_9&Q/4OMT1=*ON=0W7*E?E:N6J4JE427DXK#@.<=V:X^+R M+E(Q74DZGD3HO?\AA@CCY9PP1E;HGG*/^]1CJ)^,]#?4YKZ%FHRAGE93J$<4 MD7,26!NK#'BKLX0\N$=2"_*,723JU6 ML^.K6U%%LP3!K&-_>>CT_0D)/1-N%42!KQTH6E?QR8[PXWMT!BYT5$+_,Q,Q M4Y\R'=^T]G[.)HL"I#B'-/ZZX95O+V0,2 M3AD$4&<]WMC01)(11/=$F8FL=O4N2S1:32'D%84K,'#[#6@B;RFX"%=K6,GS MD!R;/+CC$8U6;3X2,HQ)/0&W!W:^7F+G^%BF$N*/1[&T'OV> EE&A L?FAML8F<3-^_@U-<^\6<2 MO-PM_8G'Q^31"\D^&4S'KY#)2>8-"6L8QW7M[P]R(#V=;?NK<"C8N>A>*.4 M*QF_XPX'-&(7\Y;JY0"N*TE+A!!)/M'AU%9J1N1 1ZE\&HV(/!?L:3OY@W\[ M[+P!0]VB/HT@WAX@.THH96<'0X9F#@#_AH"#'*4YF7&ZKDCJ7(Q'E'. J8LE MZTZ@B7JA7@[@6O#,-J'C:HG@[&=]7R<'4.LBT0P"J$^J*Z#_8/_0 MZ2407[.0-^ ^%%3R)+M2S.FZ;[H<\H&-O$'K>_HD!V+!OPGOKGK>4#<':%B( M^TU@]PW\0+C.6^$Z.<(=>,MV &6%CC;9\+)L=<)(;K!A2B7D5,C86_S8M,2, M1W)U>;HX82JW(=Q3=F%I.-3+#=Q=2.08*OEG*1;1!,KEU..KRW >,9$;Y!8$ MH/18&]JCY1_D0K 'RKG![)$Q5>"+1Y=,4+)UCWF7)1' ME'. V00W@79US[SQN?!>*.7(W@"07$K:6B>/9D_,B6P.=>#XT=G=WK[2/JS= M%82F]/=,>M)/S,'/@^6#_<6@C80]]238,_T)9=N5AY$482:6C3>119^0,#EJ M& [&#K8P-M 4(E'/4!L&%/V9 C!BJF'KR0D, V91D@2=];B/PHPQPI1&D5CR MOTS'BQA/^2@5DX\C*2GEY;J8O&07E)262I%I.>@&4EYJ1>;E2$NW9<7$["KEJ=!Y^.@$.N6GT DY6O+C5OH ME)RQ3IDR4]".^/45YY2>0B?D['<(*3D%S<;[[X!2.@J:@ _?U6TI*14T[QYY MP9KR4M"LF_5R/"6EH+GVM:T-*3D%S;6GMZND%!4T_QYN/]I2.4QE4M(-]O=20KH.W?WRRUABZ!I8WLDD83Y]7LDVV"# M(3AI&M+7^="-K?=YGZ,C^?QOSQ,7H4?"./6]BY*I&R5$/-MWJ/=P49J*D=8H M_>WR/_[]_#\U#5W?=&_1E2WH([FFW'9]/F7DJ/_E&'4]EWH$_?YK[S.Z]NWI MA'@":6@L1- JEY^>GG1G1#WNNU,!XW#=]B=EI&EQQVU&L"Q UU@0I/Y:R#(L M4S/JFF4-S$;+J+7,NFX:C4K#JOZW8;0,(]'!;^$"4.*OA4YU0S?U6K61J'B/ M[6_X@:#N=:*BU;!.FT:S7JTUZM5ZO=X@M>&P;IK$LIJF9=22,_6#&:,/8X&. M[&,U15BOYQ'7)3-T0SWLV12[J!^O] 1 8^OHRG513S;CJ$QP(P M %CP>.MYR%QZ44I 3;[1??90M@RC4@8("AB E!+UG46#9.5:.2R,JT['/-4Q M/%.8F,2#7(11MVKSJEP3LX LZH\P'ZI^XQ+9Q- ,4ZN8B48/& >9;61!1A,N M I:>.R>V_N _EF4)-# ;2PV86#>S>5'6.$QD-LBJ2NTU,Z)V1G4/4YMG-U!% M<@WU=!/R;(^S6\B2K#&FDVR*< 0KRR67H09AU)XW ')\N8WO:4OM'$(U+ISL MR46%&?.3)<#LFYM&%;*;KVV64=V>,@;B:9;=)B[-:NA//<'6M0L+,YH]@UC[ MEH+E4T5!TFPVFV55.N< P=:R;K,,I7'%E2[33"Z+AYC/F9QROVJ9]4UB(:PQ MGS.G63.&JF;Y]R^?^_:83+"V+$OH\[H13"EXI'B7TGV.-\&6>#&;T&*06@L. M +JSLF2690 /".)Q.G2)1A1Y*JW -4NJI7B>(GO(Q1S+@F&/CWPV4:XUO?\2R6H._01<3%SR47)H3QP\4P*#B+G_&_G M]+DENR-,/H6/U'&(IQ[5,]2]#<4'HL#W-W\8\@_@XN&)[)+0UA78 (ZT VY< M_!"M\%GTR C6KJI73D&[GLZ7-/]1NAQAEY/S "861L&9]CM M>@YY_D1F^>:P*,V:B'J7 (J<%R,C(L4/X=%<)2>WN&(W&!(I:=&27'%1XG02 MN)+WU+LQDS.2*)[C]YD[<2EF-O,EHK86&3FDUK;"Z/*\G%[. @Q+ZPY!P?TI M6T!"&3:M"/P*:R^!7[6+&Q*%SNA=_)(Z\O6( HFK29%,;FYW/Z5QN=PX'JF< M,50T4@!H]YVEX4%Z,B'-UD)Y,<.'X7 3$)_@2L M0[J,>?>\#&PN_P]B7I]@]D ];>@+X4]:1B#.HC?"#]2C[!MT@P1/R_BOLQ&, MIHWPA+JSUH!."$>WY GU_ GVPC)._T5:IFQ9NOS++V;-.#LO!R\,.?09S"]^ M<^U/0=XC2[=.H2S CG0]XD)SNQFJ650W3$(UPBY]\%HV-"3L;",DJFO&>2+2 MAF\-?==)+K\!U5^&E)P)R!'0)F[8^5R]*-$;UGK$C&(8$4452Y=?;[N#SC7J M#ZX&G3YZX\+6 7 ?"^MWVE][W4$75G5U>XTZO[<_7MU^Z*#VW9W?[ M@U=K[7*U?\=\#(0M?.\$7>MM'7S'TVHS]PJM%?X!5Y,Z"!@%_:(4H;',0QE MB1Y=,A*M*D E>E:.K7JQELFV U($X&CQ;X+;=^%G->M#H?N;N]X7M-Z0,9*& M3!Q+25B)6]HO#>W3LN%2$-M!$MM.Q0Z(V%[G=H!ZG?N[WN!G$JCW4\:G\ H) M'_6)+3VT$'UF!=WUD'EZY!S_3.OU1V@P)G*I4T8%A8X[S_88>P]$AF01%)O- M2O6M*ZX=T(I5,!C6U2.!SP0ZBI\)!D.8<('(HPPS,U5,G./6!JEJ94G5>V5? M=T+;.Y=X16%4X*)$GT7+@=83:#MV\&P&DR->Z?)_INX,6;43%2)>%L0[HLIW M+#/SD9U5W279K2>BRFJ,H4<>*)?]BELHR:>BP;+_K=/K7WU&'SM7GPVK;]9?;]-F!F[A/%1YQF#T)+0E!S-YE!$F",>$%OZY@ZB'J*" M(Q!S,I257YP7!LSKO?X#6$ 4O1!8!@A"/%Z4P#ZVB>OR -MJCS)ZCM"HGE/+ M;N&I\&,JL'W7Q0$GK?C'&7JBCA@#N<.Z5<16J,B)<-"C(BP@,C^8=QE6KEA1 MW;>P8I*JY',:"?+%6[AS">33("#,QIQD8">W&*ROBL&N9_L,U+ *E/<%*,1V MN*?2]IW7:U89HY?!-$$"YC_*,:5JO28N?@(MFZ55S\O"64)?B($E#*X@\'NA M*X?LW G79 #@7=+OCC1X;95T;ZA+H.:0L'S:V]3@1VUE=Z"@PH(*7Z+"QBH5 M#O!S-]J3L)40?0U)6A7-,NKU1C/3XXB14HXTW'O02LH_)D9>;=DTO8G$\IE?EE!$@5)*)+HZCV]KZ/.)'#] M&6&%>,T 4LHGD%+VCCU@C_Y+/1\7K%2PDMH- _,;A<9.01,%3822(V4)HUM? M/\Z0L&45%[I<37+9\7[=GIR&YJK3<.4XC' >_?>9>L1\;02Z?=>[O^M=#3JH MW;D=='H_<_!Y+8Q-8QL86_E@7*G54?_NZ^ C^O#U\_U'U+N[NOYS0M=<"]TV M_+QC __)RP?;3]W;#^CN!MWWOO;[W:MEL)Z@MO,<[ M=L_\1ZH2J;]KE/.>>!Z?N8]@,>%5;UXNZW+]=J>9L5,5S?K>AZ'<_Z-![LCL MI=FL&K7]DNYNK?H(1')'*F" 4QI@%Y%G8D_ED2=X#2J)'*,C@!Z2X'MS?L%! MJ9[%5N9??FE89OV,(T%<$HRA#?*4A7:" "KN5&ZT(,P(!O)Q"#I:3X>IK&S) MY5?0*C_EU4QCF>Z.-U#_:7+4S[Z-W7NYB->$U.JUAE:I&"O#_U28O_4%N@H" M%PPNN=/V$W'T#?PB+-IG9DKJPB,.^1RH>83"%!H'R>-P!+F8QPDE.TL>VL*E M4#!: M*K-G>;&S=W?_0&07M,[&](C G" >@ZD+$R_CKTG]&0N/Z31(T3&E%72AK*0>P( BMP9+(7IY.I*[!'_"EW9XB#D\!',]4R:N / 4E1V"'L M,I%@,(5^@ 2\65PV\ET87+:3^I?*.!]'1YP0](%XA($*Z'K0=JKBPAQ=Z98> MSEKFZ?(^=^[0PPD)H#0 M)1,WZ]7JV9;;AC\8"[L6 !%X 9Y)^*(@DF774 MONDAJV+H4#&4TP4Y1^2<2LZ0V4XV0,Y[^ *2%CIQ"UK^7BA8P!9-(N"N$K)9 MQ9II)6@YE;,[I^2JH8$2F7Y4E#=21"&@3L;C3*:=(71+TI MJ9X1S4X ^45);58=S3H:'F]'XF'=@LA31-[<0.1=SJ>$%:1^$*1>(5I5WOJR M#:E'=3-)?>W&Q8NN7"H363^MI%./-7A5W?;,[O8N96T[MW9/6GAA&X8^'F'@ M)0:K9X.0J<14Y/,!OEH+WRU>=^C;2^A&+M8K_;F7DXU-O69M].,J=;VVR8^S M ->-314J3;U:S73TXGKC$ MF16\&\8*S-QTC$"CT;='>-[)'B/;Q9QOL4%.%%.16'^#?G@:4WBS4")Y<[H*=.X#G6O- M:BNUEQ^9"3/3&BJQFF\3J"UE+_H52Z>C\HZ'J.=++!L9HA6^T(PE2_@?XEZA3&TG8=Y0A["#QTN9H'],#\)S&6 MOGH@M_ P1PX942\\*QSN'1BGL9>WM'$07I%004?2ZZV?R2P'PSQ3VPAQ&ZH. M&P?JL+'/(K_?&FI61I>9UR\L]2U# 8OFB=[U=[R-V\E&1A1+2&9<;0JP;[!<*&'D MD7)H-YK?M(QM=7NKK"PO-'4P^L"P15CO \$)1D8OT%"O[K$N3_*FEX MI7(VTE;:)N@MHJ]-9#9/&5H5$WE33-;>V#>>1X8"_$"T(2/XFX9'(*U:V'W" M,QY=27I8EPD>YI![XEQ!)B!B#$M>,CYUA5M'SA9<42N M)1^6,7'G(7G53HBZ^+Z=$_35H_).>UCE1X)=D"%]PAZI3>+[V*G<5W&4! A4 MRB<#285!.F$A,$@U!X$I0D!H8*GGQW1(!6HV=5//!RMUD=SA $O11U,WS.1- M]3+Q6.Y_A.01+9:_9YJ0%W_%Z\AG9ZU;QZLDR&'<7C*ACB/C':G- =7I;HY/ MO0BJVA*D$FXR+$LJP8L2^&(;Y]\T=W7ZZ]73W_[8IP+^TY@*HDDRD!3^Q'#P M4UT%(65EGM-\.\/G/F_"R'FH;X=,N:=8"T:+F\W)<[-I_J$NKE^RFE6/#K&C MD\(MM;TN[^"7EQ]OUN,G:>U]@N15? Y*7;ZGSRUKG&&M1Z!H U:&C":A92I& M3YOE!:]GH-DTJ@6K_\E9O>T#FZ)[]64E&3/&ZB-1\G-.&*D3WD=D,B2.=,FE M2T\]97HGOQKE1'=R'NOYF10EN'2G =,?Z$GFR>4YP%&_TUF9/2FN;=53[!JJ M3XR@K2*%N19>W+Z8K4/VH%9_](T0>6DP1-VMKV?(POVJY/W!K[#2JDMQF*R$(162CXO8@LO.4;>]_;S2\2 M!78ZI+F#0,N>CK\E,F/"Q)U_3BF+=H*W2W8[RM!&=0=";>PS ).3<__]L*,K MZ6-G*D%WM^?.JBM1EO21L4WGR0R]NO% 6J6F*'K]Q2)S/ZQ2>O%(Z5MT52+R MJ$[R[9''7C T-WEZ6="*O-;]N*B+"ZM2IR1?Y[-N2FU7H WD5[3$]S=D#H@X M?IVUMC-N"V#EN!]WFT,3FP"5\<'A=P6H,B^COB!@(8-Q+-(WUA<269W^:Q4 M>N'0<0O,O?C2R]] 7Z%[1KCZ9+K,$=QL@;UW!DIZW6_YMSVF9)3(L[Q3EX=F M?2G@=8[DV@LD]P,V^07-5C)&5H\_??D^$[@/#DY,5\V M+FAT;>R];7/;RK$M_#U5^0]SM>T?5_7G\\__*_ MG]ZP=U_^?,\^??W]_<4Y.SI^\>*?[?,7+UY_>9W]H=,R+?8E/'C]:/=BN,OKWX\OG%))GZG1=^&,:\Y2;NT>E?__)* M_D[]+W=<^;^)E_A<_".=Q,?\YW!H_;]>2WQ&_.5%\:=7+XH/_Y_C8_;A#W8> M!M<\2GC$KKLMLV6WNB8[/I8?&(7NC?C?O[R:L3BY\?G?CZ9.],T+CD=ADH33 M$W.6O,Q_DX0S]6/"?R;'7N#R(#DQG[Z\"H/D^,J9>O[-R1=ORF/V@?]@G\.I M$V1_B[W_\!-+?O/H]&_!*)Z]?/5B=EJZH[J@XWO?@I/(^S:9WW"[1_C!Y7=/ M1J'OOAR'?AB=_&:J_ZP^Q?T/+!_K) BCJ>-GMTHD?E?B%^*W <\^=>U$GB/N MS_(/'IV^DK\O7NIW9_S]6Q2F@7NO9!?.EV1 MR(,$D+VA7>4->?;UY?G'UYPSZ_>?_F[/+-HP!HBIN-XU4_+[^Y'/KY(C\:O$&?F[_,<7V17RRUSG+R!D<\2VDF+^HWQS]?.R6.4O:M2/ M\X\?OIR=?SF10"V$TM"7O4SX-6=O/3\)@](+[QGH[2VH\<"<3SQ^)8 )G&#L M.3[[>'7EC7D$C AAU+/,XWYO<-QNF^8M8%XH?RY^)UQ]+113_8ZUB;#\JKU6 MK_^T0D Y%A_FT:]'E-N^]$YB2/4]EX_#R)&YPXD()GGD>^+;1Z=?/US\SYO/ MEV?OV;LW9^^_O&.7;S[_S\7YFTN#77PX;ZV/*W40C(A!/WW\_.52!6Q"*H*@ M7[/_^_7L\Y7C^7_+A_CZ^?R=_-VGSQ__^'SV)SO[^N7=Q\\7_]_9%_D5?0$J3'9WB8]Z M8B\1V^V96QKU-=%"(OCT/?/;IV&!GL?C++(SD1YS E3^?N?]*8_%S)LG\OW\;V);UDGV9 M1)P?3\4#3)BXBA>Z,>/BEB[[1QIPUC:S3$9=2OS#/-D!$)DSKI%:_UO8*?OX M5IC:U\O+BS.#?3ICA4"^!MXUCV(1%+WCCB^D!.,6>_;A?R_? MG+"O[RZ?"Z$$(F,?"V$EH>O-1'XF[L-9 M+%1$8/+OU%$+-4(+)$X&$U<4MYN)C\NG8D_LKM4:+E_=;@V[#[FZV1*8).+E MKGF0"H#$BT7JINUVY9PP$;9;>[_WEO/VZKWS8K?U\\T8X4\7%C M(%+:?R;U\\KG8PF]$+*4[N5XPMU4**:0ZX.Y%1B+I^[/VL$(T(1^*G+A<:Q3QAX@*DN2HHF<\2 M>:-D$L8\4Q4:/+%QD?^PS/?,C\/,8(2.ST0XX(5I+/5_'@YQ1X2L7&+KQ>Q& M_&1(>_S3B81AS/TY9U/'E:BKC]_(H,FY4>HJ/O*D)V*4DNUG!K]J4-(7LUD: MQ:EXPL(&_N2N-Q9^7)CJF/M2UXI0V+UVQ..Q3_EM/D7AM\B9"I6=\$)1Q&-% M93O++EDRI<>WH+_]9O7,EW?_]VZC<(VHYR+S'*[4Q\POE7*E!P0KVWHN20N. MNOZ5/$^5DX,\EURTQH#UN#Y=BEU5X;PV=^5CZ=](@G;'<% MH:H5(*G?5M]ZMXNV%VLAXLU?V^>O5IZ%6QO M,_7=GOA)YU;*V>JL79U9]KWL2;>[^**\TGSA))(/ZB[G!1NRW@UIS'\+,DW' MWV_R8,=S17 5B"C?9>0UQ2Q#/%G3.ZDG=4 MS0N6D855@NN6J$MEU*X7C]-8+OF,N!_^$(^W6;W+RZRK0E^\P-V/6@7 EVS5 M,E21;+5&!@XD82&C7W'F\8;.(P]C,0N2@]X*9_G(G^>3ZO/\T?^/._GS_,Y M?YDJ$*BUEHHLMYJ62]56.G1;^7?3"B);C:/BIC,1@AR/A%"^'RM%.7'\'\Y- M_'*%%0^S(Q+D3X;\]?+]"&OI@X2P%F$MPMI?#&O[_8$(;?<5UCK?OD7\FUQU MN&BL!K=6O$M#.;S .IU,>J59K%;.J,I2(6L>*69Q&B>.%W#W>1XP/_/R%SC_^#\7KX^MH?B^""7E6S][ M,EQ>FZO\"*NWGH4B-;AA4T8N)_SPH4D?5KG+SY%#\IS/(_,2C%/26 M"GEKZGAF5L=;Z5;IW>JT$[\P*SB*O&\A_!9X1V!F5M#//5Y#6^ M0(I26&ZI@"VL)TZ$JOJIK-VK15:1%D_#.!'BED*YR4RF:'9IL;.5U^SVRX^R M7!Y?<_7EAU7E]54(5*/8.)6.4JY>QWG'90;A\MU[UOSF&R\UXA-'."R9<$^R M'LZERZ)YZY=L<6W[X+I&0*-HT[EMFT4W4(5^UD7!O#)?VZW^"EV;:]O\Q UC M+U9FF"OR"OG)(&%^@S2(A#()D;OLF^,%&6O?"@S,M2M=S\0S+117L(FZ8M8H MYL5+Q.)*0A"+]K/5>*.T9N9EP A%^BY$)T+) M5/5VJN=1$<>81Y(M\T\H8<99UYOL$U,]*7*=S0NN>9QD362R><5WXMB[\KCJ M_7&N'<]77U5+%*T=E\FX?@[6_K3LR_A3(0#?6OP_(1=3(6KN59J'$M?\F8Z\\,; M+M1;/L?Q[ZK5N6@>.AN/13PJGRK'8]XG6'J> JH6W QE-V,^R,U8M]W,6N/_ M=3=CWS:4M0Z-N#^XOY+PQ&QU=^P2:'1^'ISMC1U_G/I.R?A$I.5(D]MDA1(# M[D2! "46(9AL_17:(C 6^F(P@;/<0N/*5$KDP9E?=J:SE\R9RD;)_RSO+'CS M^\67UV?*'N6.A/.+W),:\M^2,N\(Z,6;"9-+(F%D4D&*9XB?9U;^I#NP%LUT M#]E2TQG86US ;+&/Y8T0.Y-1L:V+;1*6?&$58O"?RD'&ZB$7UA9NCC$*4?5+ ML=0#=O-T^L,MOF_^$DWN9S6M/>\:O*S4Z]JH/8.?M]G2UVUW%O%^ M1F2]EKTV.B@;Q8I4UPGUMC=J#SNKVP<[K>[@GGMEVU#$'9FZ8WS_%C\1[F1; M_,2;6-:Z+7H;KGG;+71;W>YPW16R3REQ+KK2L,_OT2/HA^[4JZ"PA4'8KU?C'FG+\M./MW]E MJ3_+&877'*Y_>^WXN!^-,!=++U5J(8,J7?,JU92X'TN6$M]6ZSA4:R-032KK M>I7]%[55/E6[_H6U+X>)O(_.(M_]Q9D'K65BA:\A5KAAK?W>E>'>:A+0,M?V MX/RZ'7974_>6N7; "&T[K+#8;MW:UX;%]@-:;+^U[)LOVEHMTUP_@NE!ZTN# M=BF4J[:$),//S:O3O[PJ/1P.-ZR_/_ %!Z5>L$HO>%C)*JG!=WV[T^[96PZ^ M.U/-06IK:S&.C2U-L-MB D.C5J4KC V2;9C+_563?,NM4.@?P:(Y4[SR0G)% MD2D6T(F0;ISM6AHY@EL7U:5Y5NFX4T_M=Q)?G/]2TE*8)C,!IV(PD7I=BXL\ M+RTJVX+5GRXGJ,7'7>>FO/QL6ZW>TUNV>U?1K8)HBGM=AWXJ<;I#5.MO+86S MO%!M%'$5B\*1>*.B7U3R^CR_O=6/>ASQS/W+0F#DC;/I2%(NJKW44TY2/%T@ M@R7O6J:]SM55%KVMO@2&ESTR7\O>9C4O*+,*3]9L,RXKY+Y^16&^*'%[":/< M4UEY.(!IE- MV%A>_LGV@2IG-(]_Y#D'>2Y4$>9M@)2FOKA9N]TRGVZG M4]5OMB1[Q.N_1+G5XLV["'B#YJWGUH6&=&0QM@IO2M-=:S^5"F1U^+I-#[:E MM[.Z4D0/6V1H\K5+87BM8U/=V8O-U[C8IIR4U/L?F;H@-]+F5GFZ\^N-Q M:%?2VB]SZ&8'L08/2_'OV@%8*5]HR@]A3RF\-=Q*L5, !7J&.[/_Q:+8MD]4J++MQ!7US MG:L&'[BC]+_S8"_8;]D/3_[)IFP[\(=*,'O+WH92K>M(W@Z^LKOQ-&LB"=P\ M*KXST2J&%]V]7I;QP2[?^)?8X=&)1K" MB+@Z_X*=WSDNJ7B+:V<\%M=+LC$&H? <<3;<2!W[<=\Q-^IY?HALR[GFQ8Q. M00FRQ4,D3NH2JHM**HILHBH)3WGJ6X\NG>0/[ONJ'TH\2"1><2:DN#2H1UQ( M8':\>K%Y0;K%+O.KRC- DE2XQ7G2*%OU M/./-[CN_H= 0-6]* E52LTS\;ODDI1V>%(FUMQ77+?<&GLOS:SY%X;7G9HJ8 M[R,5B)QE%N7EEO/>^W?JN<)T'KJD5ILGOTTQAP]R9>Q.#CI!>YL?*5:*^=;F M9=*]R*!9'<.4GA*D35N6I%_=%'+=>M+P_H?3O70 7>DT,M2%41?>S7.L-0A)N%GKM,NON!JZN3Y?_A;)B''+T;6/_4HO M[QC!7\L#K=M$4?9SO86_D-%^-@RLF!DJ/TWOC8@]CT?M>03@Q!YI UE9W?(2 MZETCOTJ[?6?2]I=&"ZDUX_)@H?E6BU@.RCL>J76X<7EL;DH MY=GVYKG+RU]635*2(8LZ=U1.#38D^<^3SR(IS;XG&_&45\PVN2E2'V4Y\MO; M!PO+^V4GRY8V9R%H_:"/-Y*)EZTIBZD\G$UVS2,/,%\*B>. M\YT_*H89J;S72Y)*M1]J2KW2?HID?4OYE;/J \[3SN+LQ+GE_=E<+7,^&0Y[ MY51@L4UTL>EQ%$:1VM4ILB(Y?CZY63H(6*9+3ZQ2)G(=^M?JT\(NO61>Y3"* MC6EAFLBCO-7:7#;6/MNIJ3[>8NPBF)\_KI**C0^_VNXZ7#K#?.,QP#OKUM#- M'BHO7GWF@H*XFZU$+Q8^BHEH;T-!C4Z>V9ZOF[T6*<#E,QLH7>%BET59E;I7D:YPJ.*6WE,=-_E\TCLQ_()]8OC M*P3>;_DH$K'2#;.[^8L=G\PM_M5G^PP\N_R%YBOG@ZR=C9ZK0Z M2NI+AS1EV"Z.4KM]MM>6*ZME"VC!S]KZ<"I M,9?4=?>14UL\?1[PC$+?W=S$858)G1X^UG4U%EEW!!=-B4$#=J$!'XN(8HT* M/*H+.#0ER1E$/8R*N)G9ZG=G"2L0H_'"]6A147;^7QG,OI'!K)Z>!$KR4"7Y M)5]3B#T7TI+DU;/) GB0$)'^[M5MW7M#XXY.;R74U;P2U GJM*TZP7]M./X9 M2K9E@2O\ 4'N0I#OQ /HZ^^A-3 _2N:WB1][+;-+8CWQUZ2TP]IE^02BW631 M39+.$\MNM1>]YA#0.@%U37H"^B76T@U R^Z2 Y"4@-J]=1H.DJGU.MFI.ZI[$1):&R13E!!(IS*"IO"2!!$D)"%KDX0RXGFA6AO%[USO>D>] MC_^+]^293K]I%7LIG2MA9U MP]^=\?=O49@&[G'Y1>IZJ>UV&=ZZO5 ;N0FA5QZ?O5Y]&FHU2Y+;@.U:/5@O M^UL3O%:W9A0[)59VS:A=-UQ."RC&-HWXK3UM2RO0V?P3N>8ZGUXBIR//(A[+ MX1YJOTLQX2J\8I:<"BV^HN;4RFVU:_9U;'BVE3URRWJB* &,0%*WP0A@!##" M 3'"':OC!O/B>PFBO%R10^]G!X&\F3 ^^GAC@==&@4(BB"N[* ( M4 0HXB I8K&/?!TUK"[E%NE">?'RSGS!E*=&R82A(_^Q#24L'FS[S.$P=PS7 M-,MEG2K(:05W'0*>32@.CO\X._M4&D4Q%<"G43%[>:*& PLMXC_%JP39@*9Q M& 1$B3J@AT=*VHF-)YY?EJZ(2ZI;SZ)1^GT6(L[IN? M^5"K\W!:.K@@GPLMK_ YOV0@]R1.A04<_W>5:0EF-@107 "S)G=B9#6:%)5I M784"_M^Y A;SQ3(=_%..J2^-!OGDJ]ES,<_FJ1=SRZ35;R9[]6SS\3"7Z6SF M\WQLY8?"0[S.1G=(UU#U0I7O>+SS*]IFY4]:.[]YL:>]ZND M9LVX3/IA+Q\HF$_F4M/TU9SXQ81#=1! (*=]9;^<3SLNO/QB(DT^*SA--M/' MID#BUPZPJ%&F2W/-I&!4.%4$?:6PRIEF(TZS,UEX^0@!8=SY"0$B'YO&!O/4 MJ3]"NV1(E8\TS/D^DF2H)DL)W"3_SX^K4."QP,DN-"=$=4D6I\+-..+2@KN/ MY3S%5%Q)Z.]_Y)Q;QPMB-8U2G0*S-!!S'DJ^*(9IQP7I"V"^B\A!9 FI\D\J M$HW+4QVS3ZC%@'C!X1/N*\&(ZUR+8'<^%'+L.X+,KSPIJ[@TJ4Y^5([(S&:. M.VXX2_)A<&>77X6XK=ZQ.31* WP71T/,3_O(A# 7BL%&::+.=_"]J9?%VC*& MEL?Y\&RRDD0Z3&-Y"37+;B'06.0A_'RN1%"F<5SB^M/E*S%([A\E!C+N-\[A]0H M#1R5'_+#X-NQ+Y[4S4\>2D10YDG LJ\;^6,6>J^4>.K<9.,WU=F/I0!2Z+2\ M[MK847TS>Q_Y.C,!3%0<1;HZ8FRNB#*N3 6W*HU55W"]JROQ/(5:9TY0/&LZ M50H5M]A%(A,PQX_#I;-'> QC% M9+CE4Z=\[SOWO4D8NIE@2B>4W'OVC010CF+S C7/7H)9.GHDPR";K;_I%)-B MB*PB(SE0+(WC.1O=*[(6)IYN'PL[@A6FXIG_WSO_>[]OFM:@WY4+&,Z:/[7M M0?ZG,A1WS86\E-..92S/E4*^*RNF:G-\S$]3%@_TB% M"=B]\@D9OX?"E*5/>NT)XLYL-A4^(U+$Z\AU?7.^SC^?/)W/7U5CI$M^3$Z! MEH(MQB0O#GM3YT$LAKSF=YC':T_:K?[\+O,#)(JY?NR)7?KS\I=57>(Z\],% M(ZK;3DO'20D*[BS%=9]*@V15CG_[P0MW%+K.C>KF[+\LGY6W_!23['BJG"/6 M3;,M"6GYJ]FA&K9E+FHGBSA%"OE<1AWL=[68(#Z?*?.MR*S$VZV__6;US$,=MT?& M0D4X?B;$Z]]GA(5>.XK9L@C@/KO+M5<.*1YQ 6^ MA=7,9Z=[@2?50(9X2T9SH2*,?Z5!:67N;B]0FC";R,/:*YRF6AP>5]+LE=JC M+8QE/G Y-Q69?00ENY,1IK*L=M>@VS-6P_);>4P)U(J;)4>77_>"Y[+(X@;:83WS^Y^5\'/']6^;S MR[_[?/%I:=RQ2M1$IA"/Q7?5ZOJS_.^7;_]W_LG%X&/Q?/ESE?EK+J-9&(JT M4R"O7-M@/D&_Q2HR*H*\^:I0]M5(A4&N>RQC-95H*TR$Y N_F05<,@-+HE"=!O;SJ2JT%JA6491G44:Z&#B[.KRRAN M8DZ1BB]1X&WVZ\[/C2OTY0=?>QKT>N5O%3YBOLJ8ZZ8\G4&Y*_%_05JLZ':6:3E",L70A#>*[=&-N7"7ET1UWZ[R8[@R7_ORW4-^9*J-)DC M5%RYQ>:GN.8#^-,@.V]]]7<_M6JL#JS M51Z5DUUA5#X&N'2Z>;Y&/W^ZN:_ ,1F/'L1 M2]81X!;+?^\]9Y0=&?\Y7X&^.\)!'?I!=>AZU.:0^U)NKP[:/3-?[A*$M>A4 M\N<:K")"J?5>KO6S5:W/'5;I.V/?\61U)F;9D6F2&%B0JM8,61K+%[M+U1L1 MZL@"F*HO)!/9+9*%RXLOR1I$)!\MO[B\<]9IDATKYKE9_:9XAS@K::A22%ZI M%R:A>9%56G^9.LWJ!TU<59 M,AD5+%VQ**KDA[0KIY]FYWC+O MRX?+6_<'PD8[ Z-*<<4#GO2[K7,TG%TRRN?2Y6XAZG3$M%M M:.BAY*,.D.G.P^"*1U(YF%#8I=:!DW6=#YNO5=Y3V^Z5I%C]OYMPZ-0_>1;6 M34)?VLAX1;Z+FGE1^Q/YNW^C.B\2-CPQ3>:T1 C*9<-!%&2+U&%1E^B73Q]R MA6\XEHO2F<,4KMADLC#.1B+C=M5I2OEBYRJB M11"_*&2$60_D#SZ*/9G:)ZRR.?[X\:.53N*6\/ZY,2RA>.;'H:$<_\QW;N9/ MM/XQKD)9S2B\O>S_\=.XM&JK7D]]5ZKANN\+4A!IZ%7J9XM"AW2*XL2 %-9=U 2&.6=:VHXWC= M_(C+8LDN"PNYXR<3M4P;YRNS!OL:"'.)8O&1=^K/\T5;0ZZSME1]%/97AU[UT6\I.*]\<3CUWS>*R6B,@6W\"0M]D=^D*?P^H[KR=-N5:E%^I%% MN44=FRLN+]Z(B^NH$WL2N5+4%;0A;C/+E2OOLLH6;.:;FM5YNJO+JE:K-U]7 MS6/#[,3
O((.4>V&JG7^19DE>]8N8=<\/\,(]^=R_U/*>LS=^K) M>.]<+FH$LFUL='-_0TW^3KG*OI2G''X7%_G-[IM%8;;TVB^SK"#_3-OLR\]4 MN<>(Q_G3%@TVOI?BP,+9 MQ!/I6CB;W*B>K9CQJRM>+&^[@N!DJVNBM&]^BF'@"B\H[Z@N)//.-)!7^I&Y/PX]WU[/!4>X>6*=M1;\M]*/*_8I M2H4..@;[=):Y5M47L^24!T/#%/Z<3V=^>,-YH9998<"3'3NI""Q%]!])EYI9 MD_B'W1/*EQ:J/5^(,.,FN[(S%J07LYGL:%6MFZ7UB5!V9V:K.\*X;V)/A"&R:R;Y$4;?U=6* M5HJBF; @6&%QV0&Z0E;M ?O:NFRQXD#Y?SJQ7!]*)+&];IVWA/!2'@E%_^R- MPWGOJ"!H^7TI:#>E @]MF*S- &[; M8B.L>F5ES&X/^L.\TS(O#4K+$*JMUL%DZ4IV9\M$2D7R?A[)E]JBYXN&16/< M5)7SE9[)=;MQXN2=924=^Y"*"$4:4;ZJ:MSJ95Z<\9NUY!KY[TLMO,HF@D18 MZ"RSNWGK];S+*<]C[^LG7G/Q$L$([(2Y".=1.G0[?T@NQ.-G)O_0/8//EKJV MJ_1K7PC1,^LLMZCC^S<2E?*L(E+,>N4KWJM_O$4FMVCV5B)YP-;'RL]E%\_% MJC_7'0:P^LBW-LL)9EOJ:EO>-?? J+;] ML@YG4=-F>ULRHR^J/%#>WQKQ\IZ!2+Q_)HDTR/(^LT)]OQ"BYCGEP?.T) M7Q@&OHJD\T1-;O!5;B&\6GJN?^;5A\3Y+CI>_I2E M=\BBP^O03Z>W]YA)F'+"G&O:M28#)N8KBE6NMJ@7QXLOBF=;V@'X4KBQL8C^U*+0BJ/)"'A1WLZ"P.P:SHWD M6>]G%C?D_E"ZR3!?89HZXRB4=>Y0X%+>Z?&LM+DV*&V*38.B2IW=UY7Y;%ZV MGB\3Q:4(14JUV&#)9- M8UAB>\;S':TW(CV/G[\L*8_($Z(TVSE9+(8I&,99 MH]_5E91//H1$! ;?2VC$.3+%55> *$V MO,YXD&UF7MP@?R0CN]6-U 75+)AKJ?J.F^VY735"M0TC'8E+%#>3&VBYJW K MB*+$\"*J4HS,LRALZ>.AVA?/9]FV:#EM)5;[17YP7W45YI%C'(?C;+.02FG* M4BLBU<7(EVP- M>)^\"U+6'V]D%B& N[HIPZKBN:S+IPCQLMJ[W&629Z^Y#UR3M%E[3]%SBV4=$LLZ_Y0!OR]K71M4/JIU'Q4BH?-;7K6%0]\Z*RNSXOHE1Q18/^?=\XX:L MK?PQ[S ^4XY+C@@;CV7_F53/3Y'LIIOYB[D0^6*J6A&(2T6QY]G,J@GW9\(L M"\XH-;3$BT?)G6ZIW%,N>"[-W/BQC(!*!H.E\1E98W1!1_F6\V)6U.W<:;ZN MEGF'XIF4EQ;D-DZ5I:LQGAO?):O >K+@D@I%\M6V#RDN9ZY'A=$=OS("97WRNIAF$5<;9[$BIKQ'42WRCWPO MGJP?KB8!*E1.;1Y( O8MIKQ(4-W%<"K M]YP*04T5&V[8NP/0NW983FYM6RS<2Z;-?;#\E;[\_C"L/S,IEM MF*#GRIC5W>TLO7SIK+:)>L9\I-[M*U0=B99M'%:A6VF*3[:*DP]3;K,$ZPW&]#DD?,\K&(ZDO91DDRJS0U5R]C'A%7F>PH M92 7HR:I+!3'JG4HUW'AB6[D Q4$F(T:$K>^4?8^?_'R%J1\3%&VKTJ$#R+] MD*MM2R2O/C)>M,5<+,(!N5 ;R/E(:H^JN)YF!WK-%\ MLAG-6\_ISP>"9T\['RF_]=1^\0%Q%W$AJW=T^Z"VW_\X__C^X^>_'_WV5OWG M:*&UZDD61Z\5O_B<;_KN=TN__")%MORKWQ=RS9YL.%Q1] = 4MZ[(G_><*)? M[D=&H>]NGI;3J>*1=E)_N*M[Z)YVY3MGQ=>!HK7N)(/'.9>Q?A1OG?-0'"&K MI6F1F3NUS::Y17I7ZIH1P7#60ZBI>9%!$@9&\BS39VJ-(TQCD:7*_=4_979: M.A4C7X)Z#KNI"2#8#4E8GJ6!D[IRU1NF0=0TZD2BTVU9 UI)4"5T=@9%W9;0 MZO6V76R!L.%V#E+\9LNT[X>@V7Q,#A38!#'_#_V'_NLC?G "05!@$\0X >*& MMC=5_& @J# )H@Q /0?^J^/^,$)!$'1W"90M$$=8;_T3%C\\W)^S=5\N]/J MVUJ%2E_D47],'?47$S()SI29)KO*2ED MJQJ>6?;![-#CF2.W NOML/8&2D8.P.3P2.0NS!9CLK0AFL61UMDAS&W3J,ND M-*<7N"^X+[BO0W9?5>U):S>'*)J\RP,-T<-D3D-VO31D6:J,6& F9;N6@\!3 M2Y#*L4L@)DJ($')\#S*B_7I&TK#!-QXTI'*H'7PC)40(^<;Z71^"0C@^!(5P M? @*#PHV^,:#AA1!(35$'KZ2>_[VK?GV?,_-NTT2_0>>S ]KJFP4CRYU[*G< MK[CUJH\_(23YK;?.1/)6C>+CMF$-^\9@4)V481 -]T=P_]!V?<0/#CBUC;X] M-/K=#B%88!7@ 'W$K9>V(P4@!4?/L"W3&/3ZARR#(^2.X?VB[/N('!YQV MC6YW:'2VJ%O#*JB486J9H=)HT=>](1OTB_WO^HB_&OT" EA 4\4/?P]MUT?\ M\/>U0P#QP]_K(VYH._R]WA! _/#W^H@;V@Y_KS<$FHN_\:63DKB\1+S>>*=@ M;"'ZCS,>.8EX=3:>B*?F\0DA*WB\\X(IB!Y.AY;3J5O\H-W:(8#XF^?O(6YH M.TGQP]_7#@'$#W^OC[BA[?#W>D, \W97Y&75I_?#)AIN$V M:+L^X@<#R!ZM_M#H6M5K,["*AEL%. #:KH_XP0&R1\OJ&MTV\@ R5H'],WN4 M_F4ZF_F>N$5>E"%4H@07HR*LC_C!Q:?M]L PVVU"H, FP #ZB!O:#@:HN5-N MT#:Z?9L0*+ ),( ^XH:V@P%JKLH/NH;500X FP #0-NU$S\8X+1G6D9[B+TR M9&P">V7V*/W7?!;QL>R>86\QR 8VT7"; - V_41/QC@U.YUC?8 # "; M - V[43/QC@U.Z:1L^LWJ %FZ!2G-E5F6RI$L-&8>3RJ)!M'/J>R[(/,O5" M,R<20FQTQ>8]=V*N2C7R51V_MITT94Y^?& .S5#J+R+?A4DA,:U]6=T09?R^ M"YB:'0,,#:NS__Z,2G94]FVP)5".!AB <@X8(E!.Q7U!AC7H@7(H80+*T18# M4,X!0P3*J=B&;G3Z^]^'!,JA9TN@G/HQ .4<,$2@G$JX=7MR("DHAQ(F]>^& MVG/![=#PV"<(" %H-F8L,)'27$LLB!&(8[@<(SPJCHT.(FRCWQT80VO_/3J( M(^C9&WBK?@S 6TW&$+RU*]YJ]RVC;U=?<@5O-=?>P%OU8P#>:C*&X*T=+=H: MG7[/L-O[/TH6O$7/WL!;]6, WFHRAN"MW0#;,8:]CM$;5N^J!&]I46_<:'J_ M/'WQT$1?MZO#[GIJT8'6GJAN?"HR/S#";GQ=Q0_& &, 'S#& 6$$Q@!CZ"-N M>"/:^( QZ&,$Q@!CZ"-N>"/:^( QZ&.D.6/L?4:DMB6DBV <3CF[BL(I"V<\ M4J=VQ81VXH*\<7*@/N+'P.;33GM@#'O51_;#)AIN$V :+L^X@<#G+:[ \-L M6X1 @4V ?01-[0=#% O)OUVQ^BU^X1 @4V ?01-[0=#%#S)M5AQ^C;U0]O MATU0*Y8QL#N$,-'<)/:^009G.I7Q^)A,>,2>>6KSS/.'%6IPUF/]W(&S M'@$1SGJLAMNSH6'9..N1%";/P39P96";0X((;%.-;=J&958_H0)L [8!VX!M M !'8YB%L,S#L8?7E3; -V 9L [8!1&";AQ33C$X/J0TI2+#=J3;1YQ/H1EQ\ MDK.LI,82YR>O/H4.#2\-Z[C0O+I?M_C1\'+:L7M&?UA]"AULHN$V 0: MNLC M?C# :;O=-7I=, !L @P ;==._&" T]YP:/3ZU6<0P28:;A-@ &B[/N(' YQV M[9[1Z52?1 V;H%*6P;ZGQ\#C4Q1>>[$7!DQ\]&&U&C1KU,\=:-8 1&C6J(:; M95I&U[;1KD$)E)J,"9Q3/P;@G .&")Q3[?B+H6%UT8Y."A-0CK88@'(.&")0 M3K4TI]^P"3 M%T[ M\8,!3KOMCM'N( > 38 !H.W:B1\,<-HQ36/80PY QB;VOO-)VS+,>Q[')YG\ ML_]>U&68DR21-TH39^1SEH3B2^+W01*%OB]D)3Z5\(C'R?ZW0X&ZB8A;KCBF /#;<'>']HNS[BA_<_[1G#+0XM@$50*=KLJGQVU[@Z-TQEU<)N:;-W M\X["S==WEWNO;=ZQKU8_;,@5_1>82&FNW:UY%V@Z;KQ]0@B^Y3VWCPIAHR,( MN?W'M/??^+%I4^Y&SZB3H=7D+$%8]6, P@)A@;#N;'>PC.$6DXM 6,UUEB"L M^C$ 88&P0%CW;*ZRK/T?*P7"HN^\;O,:>^8\1[<**>NIN]WA;DQTY!>ZS2CH-=G4:](:H#.2%"+H MC-06 W -N*;!7&.WAM4/'P;7--?/@6OJQP!< ZYI,-?T6EO,9037--?/@6OJ MQP!< ZYI,-=T6CT37$,)D?HK;=BL1<6)H2VFQCW7_8K%7&X[7GIPEW'V.[UFX!0ZL)U;VF:#5Y:*O)OG=KH]5D V3M5K_ZR2L[ M]FMH-2'DY\ U]6, K@'7-)AK[-:P^M9@<$US_1RXIGX,P#7@F@9S3:]EV^ : M2HB :[3% %P#KFDPUW1:W0&XYBY$ZG9S6:GMA2KHB-^YWO56;[[THD]75:U\ MO]U==9_R>C6*V(O3]<\OG]:R9^LL=MT+W/7$ZT7VU[^\FD0+<_C&CT<1=[X? M.U<)CTX<_X=S$\\=DKEMC\MNGK&..V9*FM4@,Q/_^Y%YQ,;<]Z41"WUY-'0NN*1L4:/0=S>[LDX5VWRP(&)RDXGDCWQ/?/CK] M&GC7/(H=G[WCCI],V"6/KKTQCPUV$8Q;KU[("YWJUNM!!,5[.CTT,ZV-&-C[ M9KFJQO4V#),@3,3#)"$[#P-UZ*PC>T4N$_$_4_%J,0NOI*6%4ZZIK9&!%=9& M,BEZY@4LF81I[ 2N8"7^<\Q%0E+JL9J&J;"C_<_ IFHWM:\%P6XHP/(L#9S4 M%6KHPC2(FD:MTUZ&K;Y6]D"N:[V%83MP/)J(?]#J=X #$!?\X]4RV'IRG8NU7O,LL]MWJ.JF[_:XS&/MT"]X+WNN O5=5>]+:RR&$IN[Q0$+D()F3 MD%WSCBM5*RR?G;"6@$!2R],M3=L"*U%"A([;>Y -[=T81G MI(0('<]8O^-#0 BWAX 0;@\!X0&A!L]XR(@B(*2&2/V'$V[3K=NWVD#66'M]<9 =T-@/2@E$9+ MONY]U^!9['+71?S@V;H1@ ' V^LC;2@[O+W.", X.WUD3:4'=Y>9P1@ /#V M^D@;R@YOKS,"NAL *B9[DGSE[2J_.[$W9D[@,M?STX2[6^]. 4?#14'\X.BF M( #@+?71]I0=GA[G1& <#;ZR-M*#N\O<.4D2>:,T<48^9TG(OKZ[)+1A"_R+[7&/)?XG="1?C7I+ MHSLC>:=&3>YLVUW#M#MT,-',&L@Y([A^*#MTL%$,VL@YXS@ M^J'LJXN;W7JS>'"?K!1;"!IL!$2G,M^]P%FHYQ M!+DNG+T@V.@8HVUWC':O>D*[8]=8W3'J9&T0@*Y 5Z"KN_>;6>;^ M-QV KNCY2M!5[1" KD!7H*N[]LC9QM"T05>40 %=Z0H!Z IT!;JZ:U^?;?1[ M^Y_F ;HBO=EOH]TU?-0BM;8)[+"OJ8](2E-[OJ>&SVW2!T3$(-)]6W[=X@=? M@"^ #_CB4" "7X O])$VG!%I?, 7Y"$"7X O])$VG!%I?, 7Y"'2G2\H;5C3 M;Z/T/]6EN,N<:QXYWS@+TNF(1RR\8N-P.@V#;"9D7&Q=(]2AHA]8A#M4L*N= M)D38U5X)MD''L&LX+ R[VNF9$@BG=@A .(<+$0BG*N'TVG1Z\$$X(!R-(0#A M'"Y$()RJA-,UZ8S4 .& <#2& (1SN!"!<*H13M?HV,AP2&&";5MD)%]WU1EM M,O6UR8#2B>%3<:\V($*;C*[B!U^ +X /^.)0( )?@"_TD3:<$6E\P!?D(0)? M@"_TD3:<$6E\P!?D(=*=+RAMV])O5NWOZA@Q[D2!D%+,9CS*]FFM.W7LA%"# MB7Y(4>M>N&>@J8[40G9H\*\ U.C>DG9K@.-62"%"KI413%.W+P/3@&D.'C&[ MM<5AUV":YKHY,$WM$(!IP#3-99I>JVV!:2@A J;1%0(P#9BFN4S3:?5,, TE M1+ OBXSDZRXKHP\&XXN!#\87'PI$NO?!U"U^\ 7X OB +PX%(O %^$(?:<,9 MD<8'?$$>(O %^$(?:<,9D<8'?$$>(MWY8N_[LG2M'%4].8M.>1Q$*W[/&HZU H60=,BX/ZA[-J('^Z_KB.F8!$T+0+N'\JNC?CA_NLZ\ D6 M0=,BX/ZA[-J('^Z_KN.78!%4=O3<,2]/OV/^SESWA'U,)O,Y>?S?J2= $$]: MO4"S6V1P_B+1\C'.7Z0-$7@T[N!!XT+,U4%;M$("R&HPA*&MGE&5VAZ L2IB MLG2% )358 Q!63NCK+Y%YT044!8H2V,(0%D-QA"4M3O*ZM(YF!B416++WT:S M:_@H1FH]%=AK7^/09' ^,7PJ*) G9UW>7)X2:5/3#BEJ#P^W:N/8G1#ZA@\[:S>X/ JC1 MW27M5I].!_]&GZ:3#9%KAP33U.W+P#1@FH-'S&X-J\]5 =,TU\V!:6J' $P# MIFDNT_1:-9R& Z:AY^; -+5# *8!TS27:3JM[@!,KJE:^W^VKRFM8]FR=QJ^[[%T26G_+O_[EU21:J-,W?CR*N//] MV+E*>'3B^#^0N?''9@D>A[VYV!9TJON"AAO]*_G[I15T^#B,G\<+@)!7/&_F>^/;1 MZ=? N^91[/CL'7?\9,(N>73MC7ELL(M@W'KU0E[H5+?^""(HWM,=H9EI;<3 MWC.K5C:NR_&$NZEPN^$5^Q &QW^"UA=!>!O)OZ)GMVM/2G MXLM'SS4U0C)XPPQ)PE+9#-^&$4LFG'V91)RS/\6W)C'CX@,N^T<:\+_]9O7, MEVW38+9I6VI,M_B'":N#U1V U>T[QW_F!<*8PC06=B*"1/YSS$5^7>H3G(9I MD,3/83=45C9A-Q1@>98&3NH*-71A&D1-H]8Y1>:M.47-M@=LO(#XR^*W6VW[ M?@A@$[ );<1OM_HV. 'ZKZOX^TK_00F4,(%)U"K^;JNW.M ^@_]UT?\2!,( M@@*;0)J@,0#0?Z0)P 0FH75AH2S2NUOF*H$#0VB&(=0M?N0+!$&!32!?T!@ MZ#_R!6 "DZ C?I05H/]:BQ]I D%08!-($S0& /J/- &8P"2PE0<5AMIM@JKP MM;8(,HZJ\E;L<\G+G_2F-Y\D3Q&_8[%W?E[$+*BL>) MP;XX/^54DM=\%O&QEUU"[M4^FX91XOVGF*'PYO>++Z_/2A=4/[. )VH*P_D% MYBG4K2VHEI-UIS $K<-K+(,1! 4V@64PC0& _F,9#)C ).B(']5RZ+_6XD>: M0! 4V 32!(T!@/XC30 F,(E#*2LT6O+E4JQ=;R76:JM@52,WE(VYGH:+,==P M280, U$J/%-QJ)A>8#P5UT[H& -\$;55U*:+FXKG04R$F(B482 F@F="3$3 M&'3W15@R@A/2,#RJW+]_^[PT--/3,R2$4_!D>H93E1U9Q*]YD/(8[HN>]6!5 M2DMGA;"K>MB%TVD)&A+"+G@RA%T(NPX L(7E0WBT6'0S"">$)+\UMLK(GFK1A%*V^X:IMTA M!(I>YK!E>/OHXE\3WD+2/$^M!V?<2/6+]N!'0W /2\[E7RV7_?GF/LE.88HRY&Q3CJ%C_R M@U.KW3:&@RXA4& 3Q%I=(&YH>T/%C_R@;@1@ .C(UD?_7'>]WC4Z_30@3F 3B M?6W$#6U'O*\U KH;P-[W!937_-DHC%P>%:*-0]]S6?8YIMYGYD1"ADV'(Z\- M?(K":R^6.P7$]XKQ08GS4P[2(E0UNPNT0J1:FU3=$&5)Q2Y@:G3B89F6T;7M MO0-7R9#*W@_&M"=,LMP#I$3-H8%SJ$/4O]=R@!((1GM,LNH&"(:8]P+!T(<( M24TEW/I#P^I6GZ@*RFFN+2&GJ1\#4,[A0H2SM0U"G!\>;WBR^O MS^3&#A9>L0_G%Z2JG04\4K!KO1D\'O5!LGN!L-%I4G=@&8.VN7=D06/T6D.0 M)]6/ 0BKP1@N)U(@K0LT1V53\&(*P&8XCL:D?9E1 D&(L2(D_KW*:TT=ZTF%9&IPI? MA:)T,@IR^%1,FH 11EUJ*GZ,- !C )]M$Q9 !,+05/P8@@;" #Y(,0X)(S & M4@QMQ W&H(T/4@SR$.E.&)B[5B<<'Y,)C]BS;,;:\X<=QH(]H@3,J&Z(,):@ M$F[/AH9E5S_4!;M&]X#)8A &)BTIH^X01C$\4&*01\C, 92#&W$#<:@ MC0]2#/(0Z4X8E/;JN&$Z\CFS6]H4XC_PA$7\F@0T=%MT6T/ M^Q6$&EU(;QO6L&\,!M4G$3QV-7VC?]/)DNCU?^E'.[5B +N@A\G:80. I6Y8 M8"KT,%F[YP444GM4C)P%.,%.DL95',L58>W3%'+XW&[S D;4,-*\:H\V+YW$#6TGT,4%!& MFHH?^T"0( ?) B'A!$8 PF"-N*&MB-!T!H!W0U@N9@@GE/(04!A=8]JA64X M7"&!4O/&6(B51XWJWG@E?[_TJBX?AY&3>&%PDHHGCGQ/?/OH]-SQQZFO?B^/ M9IF?V"*W@UP$XW#*V5F21-XH31P95R8A^_KN\M4+>?U36!U-JR-6PGL44RN+ M=!3Z[B^" _IIAB'4+?XL(=^B<["!Y$,.%-@$L0P<^@_]UT;\U7)RF 1,0AOQ MKRGC0?^A__J('VD"05!@$T@3- 8 ^H\T 9C )%!6H%E6F-=2>_664NUN2Z_D M[/B"5UX*"H>"@L9]0, QP3'!,=4=^ATQS3;:L?*(IZJTVU5 M.8U4(]?VCS3@?_O-ZIDOVZ;!;-.V]N[:X,?V+>NU ^UJ=%ZD48'[(@S8+?=5 M??3SSMT7#E*F&*YAI8MF1H^#;(CCLZ.CSYK-/^100Q1=?VW]7IO1W$#F$;5= M;T0] %HK:'WB$1UC@B]#R45G ! A$\<'$?(AH@96081,'2%$R%310H1,R%)0 M^Z>^PDS%D5GM=:<1Z>[,SJ9A&B0H^#[SZ+HK/S3M;O6UW#=/> M_\GJ*-@\*"A^=/'CC!)HNQ;LL/6,HP;Z_E9_2 <0S4R!FB?"<8;(&\ ,R!LJ MXF5W+6-H@S[@SY W0-LU8@?D#:=V:]BE XAFIE!_AZ^N)8E/?AJ_F'I!&C/G M*I&1H?.3.>J4PJEXVO@$7>]4;*)N\5<[4P$0P (:*GZD ]!V?<2/H\[K1@ & M0&T0!L0-;6^J^!'>UPX!Q(_P7AMQ0]L1WFN-@.X&@&T'>Y+\UR#B0KK_X2[[ MYG@!"P/F7#N>K_8>B&^SV!'_$"_TG6?[$6(^3B,O\7B,BA@5:ZE;_%N?J-R\ M$O$SR^B9?4*8Z&42S^E('JD"%%T?\:,[Z/29V3)M.HAH9A"$/#^* E!TC<2/ MJ/_TF6W8=IL0)GJ9!"'?CZ@?BJZ/^!'UJZ@?GI^"YS^\B=]-0N)B*A0N8>$5 M.[O\RFS3ZAV;U7=)[J.05F52I$ZV0Z[6:5<>Z*DWXUB&A;.,:6%2/0,A,[R] M2>(GY\K -M0AZM]K.2";/+VQP#64(*F+:WYA2GZ3Q$_-D8%KZ$.$S*82;EVS M^G@-4$US#0FY3?T8@&\.%R+D-I5@0VI##9'Z]W^@IE."XS(=)6'B^.5A3Z1* MG?>.*@53T6X@J#IR%EQV?P=:W][_OA.P&:FV-"1.E'T=^.K@,5S.K$!7A]4U M![8BR%8H*Y'T=&"K!F"([&IG+7=]:P"^HH0)LBOX.O!5HS!$=G7(DPC 5@>X M4ZR M=Z&Y_I9__!1QY_NQ;\]R/SB(VY[TN#%:8__SEW!>KGW,N,Q>UY-'9A3Z[F:WU:GBMQ[JI%[) MWR^]J,O'8>0D7AB5"(KW;!/6S+0V8F#O.0*H;%R7XPEW4^%VPROV(0R._S@[ M^\0NT]G,YW*/L3"ZBT#>37V3/3M:^E/QY:/GFAHA&;QAAB1AJ6R&;\.()1/. M+KV?[$_QG4G,N/BSR_Z1!OQOOUD]\V7;-)AMVA9S E?^PX3-P>8.P.;VO1KQ MS N$*85I+.Q$A(C\YYC/$C;C(N^:.!%GSC1,@R3>_^A&JG93^RHN[(8"+,_2 MP$E=H88N3(.H:=2)Q)I#MYMM#P2+35J;0MWBW_IL/=@$;*+9XE]SPA[T'_JO MC?BW/G,/)@&3:+;XUQRX#?V'_NLC?J0)!$&!32!-T!@ Z#_2!& "D]"ZL% 6 MZ=T-1>[;-I&"7> M?XH)"F]^O_CR^JQT0?6S.@)#SF XO\ TA;JU!=5RLNX4AJ!U>(UE,(*@P":P M#*8Q -!_+(,!$Y@$'?&C6@[]UUK\2!,(@@*;0)J@,0#0?Z0)P 0F<2AEA49+ MOER*M>NMQ%IM%:QJY(;DD.MIN!AR#8=$R"P0H\(O*3 &NH'Q5%P[H6,,\$74 MUE";+FXJG@<1$1TS@!="1%0W %3\$B(B^"(L%V&Y",'17M&HW+M_^ZPT--+3 M,R2$4_!D>H93E1U9Q*]YD/(8[HN>]6!-2DMGA;"K>MB%DVD)&A+"+G@RA%T( MNPX L(7E0WB MT6'0S"">$)+\UELK(GFK1A%*M]TQ+*M+"!2]S&'+\/;1Q;\FO(6XH>T-%7^U MC11 ;04/%KN H+;4>LKV>LWQZVC6&O1P@4OIB5(RC;O$C/SBU>UVC/1@0 @4V0:S5!>*&MC=4 M_,@/ZD8 !H".;'W$#6U'P%]WP-\UC9YI$P(%-H& 7QMQ0]L1\&N-@.X&@+T M=10$BE,.&?\YXT',#7E>(:ID5(RB;O$C+SCMM V[BSXAF 32 FB[;N)'6E W M C [ G01]S0=L3[-6/2LXR!W2&$"4P"\;XVXH:V(][7&@'=#6#O^P+*:_YL M%$8NCPK1QJ'ON2S['%/O,W,B(<.FPY'7!CY%X;47RYT"XGO%^*#$^2D':1&J MFMT%6B%2K4VJ;HBRI&(7,#4Z\;#DC@-[N'?@*AE2V?O!F/:$299[@)2H.31P M#G6(^O=:#E "P6B/25;= ,$0\UX@&/H0(:FIEM387:/3[X-S*(&"I$9;#, Y MAPL1DAI"*(%@2&_N0%6G!,>;WR^^O#Z3.SM8>,4^G%^0*G<6\$C!KO5F\'C4 M)\GN!<)FYTF&:0X,Q9:U2>F M@+'V@,C3FN! *8FDHP-9(;\"41V=#MJ6,>A5;ZX#5S7762*[JA\#$%:#,41V MM:/LJMLRP5B4$'E:YTZEC?:FQ< R.G7X*A2EDU&0PZ=BT@2,,.U24_%CJ@$8 M _ALF[ (A"&IN+''#00!O!!BG%(&($QD&)H(VXP!FU\D&*0ATAWPL#HM3KA M^)A,>,2>96/6GC_L/!;L$B5@1G5#A,D$E7![-C#L8?4YS]@WN@=,GF,F 5P9 MV.: (,), D(H@5NH8H+=,22]%PB&/D1(9ZH=6V-T>M6;A<$XS34EI#3U8P#& M.5R(D-(00@D$@S%KAP+'F?NO-$ZXRS!OK5&X8AY \]*EX7!H]+P,ZFK5E@+$J(8-H:'!W("MD5B&IEVMI@JZ-,P57-=9;( MKNK' (358 R17>ULVAJR*U*(8-H:??>&C:VZXX-1"/0QTGQG*T8AZ"1N, 9M M?# *@3Q$( Q,6]-'W" ,XO@@Q:"/$1@#*88VX@9CT,8'*09YB'0G#$I[==PP M'?F,(B?LV#E,=T2KFWZX!+R.CHMNBVA_T*0HTNI/<,VS*-0:]/ MIIJ^T;_I9$GT^K_THYU:,8!=T,-D[; !P%(W+# 5>IBLW?,""JD]*D;.@ISE MX"'K&MWNT.C8=#J 03AU$PYREOHQ@%W0PP0Y"TE88"H[+KQ@)TGC*H[EBK#V M:0HY?&ZW>0$C:AAI7K5'FY=.XH:V$^CB @(P $W%CWT@2!" #Q*$0$(C($$ M01MQ0]N1(&B-@.X&L%Q,$,\IY""@L+I'M<(R'*Z00*EY8RS$RJ-&=6^\DK]? M>E67C\/(2;PP.$G%$T>^)[Y]='KN^./45[^71[/,3VR1VT$N@G$XY>PL22)O ME":.C"N3D'U]=_GJA;S^*:R.IM41*^$]BJF513H*??<7P0']-,,0ZA9_EI!O MT3G80/(A!PIL@E@&#OV'_FLC_FHY.4P")J&-^->4\:#_T']]Q(\T@2 HL FD M"1H# /U'F@!,8!(H*] L*\QKJ;UZ2ZEVMZ57\G;I_613\:=)S+AX/A?^B8I_ MPC)&_0# +<$MP2W5&S;=,N;+MFDP MV]QB!M%N#4IW/[9/6:\=9E>C\R*-"MP78%0Y0IAFM8Y:*9S^,0 M&^+X[.C8LV;S#SG4$$777U>_UV8T-Y!Y1&W7&U$/@-8*6I]X1,>8X,M0<-$9 M $3(Q/%!A'R(J(%5$"%31P@1,E6T$"$3LA34_JFO,%-Q9%9[W4E$NCNSLVF8 M!@D*_@T.Q.XX3 @%?Q(^:UVD!83F"%6>KO7:\U,Y3>MR(F14U] L- -0=8'H M>:+K A&V'538!M]&S+=A.W>]89M&DD30-NU8(>MYQLU MS_?W6K9-!Q#-3(&:)$1AL@;P S(&RKBU1ZVC6&O1P@UT ?R!FW$K9FV$V(' MY VGG59W0 <0S4RA_@Y?74L2G_PT?C'U@C1FSE4B(T/G)W/4"853\;3Q";K> MJ=A$W>*O=IX"(( %-%3\2 >@[?J('\>5/$CO*\= H@? MX;TVXH:V([S7&@'=#0#;#O8D^:]!Q(5T_\-=YH=QS,* .=>.YZN]!^+;+';$ M/\0+?>?9?H28C]/(2SP>HR)&Q5KJ%O_6IRDWKT3<;5<_90#VT&Q[0+( ;==' M_.@/.C5;9O4CLF /S;8'E :@[1J)'['_:=>P[#XA2& 1B/ZU$3>T'=%_[=$_ MMH61L8?#F__=)#@NID+K$A9>L;/+K\PVK=ZQ.2155JLR-U)K ZH;(KOR>$^M M6>>9;5C#_9L6IN?=@.TP364(*F+ M:WYA9GZ3Q$_-D8%KZ$.$S*82;I9A]ZO/9P79-->4D-W4CP$8YW A0G:S^_8M M\ WIJLZNZFNHZI3@N$Q'29@X?GGX$ZF*Y[VC2\%4M-L(JHZ@!9?=MU)G&;U> M];+0;MTEV.P7E^IV"P<2)YJ^#GQU\!@N9U:@JU\I+.W_2 ZP%4&V0F&)I*<# M6S4 0V17.SI RNB KFA!4I.M(<.J'P-P5H,Q1(:UL^+6_O>F@K$.=\VP$>%L-',UFW;1J=3 M?>OM8W=N;'2=.AD:O4Y!_1B-6AL:".N@">MAF1CX:LWI\]5GA(*LFNLH[ZAW M@:SJ]G8@JX,F*V17.\*T8YI&NU?]V&,05G.=);*K^C$ 8363L)!=[8BO6CTZ MFX9)DE7=?C(K<[U0117Q.]>[WNK-EU[TZ:JJE>_7U*O69EWEU[&ZK6[OZ3WO M()_8LF?K/,PZT=SU$NO%]M>_O)I$"_/]QH]'$7>^'SM7"8].'/^'I>-[(]\2WY5E?WC6/8L=G[[CC)Q-V MR:-K;\QC@UT$X]:K%_)"IW1"H_V,LB6"XCU=(9J9UD8,[#U',96-ZSP,5.#N MR%:2RT3\C]HF+4?AGH?36<0G/(B%_4E3"Z=<4V,C@RO,C606]\P+6#()T]@) MW'C_(^ZH6D?M:URP#@JP/$L#)W6%&KHP#:*F42<2W4%KN'KT3,V)3R5T&K,2 MW^H\PLEO$#;<#CWQ]UK]P5;G_C20CJEA I.@YOZA_]!_;<0/2J"'"4R"&B5 MW-#VAHH?!$ /$Y@$-0* _D/_M1$_*($>)KJ;! HVJ"'LEYT)BW]>RJ^YDF\- M6F9'JTCIRR3BG$W%'R?5#], .32&^JJ*N).S(#2B*=NT<:PY*40(^;T' M&=%^'2-IV. :#QE1X1KIC&*&:Z3E&NOW? @)X?<0$L+O(20\)-C@&@\9482$ MU!!Y^"KNHQ].NJYQMTFB_S _"I'.@;#82[GO,Y1UWP_5KX?KO;,[IFAPXFFED#.6<$WP]MA^_7PO=W MVQVCO<61[K"&ACLC^'YH.WR_%KY?'C@[["'N)^.,:,]):9+H/R83'K'QTC%! M6?F%/?/#.'Y^0FA#-B@9^]^U$7\U7@8",("FBA_N'MJNC?CA[NM& 8 =Z^1 MN*'M#?MFKK22I!'LYP3R(,V/B"/79?&P!W-MA@0" @$^(! 'K'4!0I!^G&8DJ;F MG< >M/$!>^R^= 7V(%"E.M ]8<2AN,C*5(GSD_&?,Q[$G#T;\8!?>O&CK9M&U:O^KYRF$2S30($ &W71_P@@%.[9QOVP*:# M"4P"!*"1N*'M((!Z=\^*#*#=108 DP !0-MU$S\(X+3=&QJ]SI .)KJ;!([V MJA6/]SR.3]BZ.@USDB3R1FGBC'PN3_<2EQF+BT2A[PN1BD\E/.)Q$F,(,2F# MJK^XC'W"M"'"$.)JBX7=Z@N%F$#<7#L"W=2/ >CF<"$"W52"K6-T^]5G3H!P MFFM)()SZ,0#A'"Y$()QJ^4T;1Q63 @1THRT&H)O#A0AT4PFVGC'$B<6T(*E_ M9]1=Q3@W3&7ER6YI0SZ5RG!?WUU2&MVK'TK4NCH>,+IW"30=8X@G=.![V-3> M!R'8Z/BB;5O&T*1S-,I&QZB3G=$[&@5\5;?# U^!K\!7IW:W;_3-/OB*$BC@ M*VTQ %^!K\!7=V^=LZS][YP 7]'SE>"K^C$ 7X&OP%=W[?2SC5ZW>HN+EGQ5 MMZO,"HXO5'%+_,[UKK=Z\Z47?;JJ;>7[W;ZJO(9ES]8I_;K+WB6A];?\ZU]> M3:*%.GWCQZ.(.]^/G:N$1R>._\.YB0MM, M&)RDXGDCWQ/?/CK]&GC7/(H=G[WCCI],V"6/KKTQCPUV$8Q;KU[("YW2(>O] M[-XF@N(][2)Z6=9&".P]/'W&7B7RJF=!+QP^^.[P1CSBXGG,O- MW%I:&!DT86,4G#YH(I5N M4=3>0,GX 9@<'(M4&4^E$=/8IEUC9[C6=**SNR*-"AP68<"$P]K_J85P6+6< M4+75>FV31'\6Q[R&\Z10):4A[BH;5[7V1'7CTVE5V9D*B&HU(8@?A*&)N$$8 MQ/$!89"'2'/"H-V,TR31GZ>17&5CCDKR3NC4]T#:**=J)/Y*W;! ;04/'# MW4/;-1(_W'W="&@N_@:5SZQVJT];^N=./&%.X+*Q_ ?_=^H)@8O'1%&-J/O! M L]NQ5]]D.N>5C^UGL%J#8>&:54_XP+6T&QG!-\/;8?OU\3W&[;=,3K#ZFV+ ML _]8G& 5-HP %0-LU$C\H0%" /3"&]O[/28=1H$!6O_0OT]G,]SCJ840Y M &M #1<_*-@:=@VK4ST'@TDTVR1 -!VC<0/ K"&IM%!5P0=DSC "7<-2\L^ M)A,>L?'2%K'#FQG5:".I?Y6HRD@HK?U8W1!UJ@[NTIO^!VW#MGID#J;?Z-M@ M2Z <#3 Y1PP1*"<2I33'AAFNP/*H01*_87 /:>A=K_5[M+&Y$N8./Y#\]#= MPH*@@.;Z986!5H@:B&-8;2X9PHK[AE(;[5[7:)O=FEPD @M*Y@;:JA\#T%:3 M,01M[037MF$/+&/0&X*V*,%2?UGV\1IC#TWTV):BD[@Q1YLX/IBC31XBS5NH M0!@ZB1N$01P?$ 9YB#0GC ;M>B0N^D]1..-1$@ZRUK@;C3[ M:R1^['^Q3*/=LXQ>#0NPL J:5@$.@+9K)'YPP- 8#+KB_ZO/H8%14,G(#G07 M)'$\WO,X/F'.>)Q.4]])N,M(1F'>(086=*%=B> M=8Q^VS+Z?1N;4RCA\AR$ V\&PCDDB$ X%0FG:]E&OX?=D*1P>5YG;1"9*('E M,@0 ]6. _2--QA#[1W:":]?HV4-C,-S_!#]$$/3,#;15/P:@K29C"-K:$6VU M^VW#LJLGOJ M+>JPVG;&9E-GLRD_)W16\M ,A4Y\C<1?J1D*", &BI^N'MH MNT;BA[NO&P'-Q=^@G8?T#_;X(PS='Y[OTUE. MVBJUXC\6.K2=L8FFW#[E4_ M<0-&T6RC 5 VS42/RB@;0P&MM&W]C^H&D;1_"H7_2SL-;_B4<1=Y@7C<,I9 MXOSD^S]?$7Q,0]RZNYZZQ0\^;G>,8:T'010,P&T>T;7:A/"1'.30*FLCE+9>"*>&U4R MJDR -:&&BQ]$W#$&/13)8!!P_]!V[<0/]]\QA@.X?S(&T?2AE/13,S6N _.] M2%E%_4M#&-]%'"+,I:XTG:O;-RQ[_WO4,)N+GBV!FNBQZT0G<:\$!MJ3/CE\;C$_(*(& MD>;]42 ,G<0-PB".#PB#/$2:$T:#MC42%_U[SQEYOI=XXBY.X+++)!Q_GX2^ M< WQ?[$W_TZ]Y(;.*A>8''W]&HD?YR'5C0#$#W>OC;BA[7#W>B.@N?A14]N7 MZ,_32)9PF;](OZJ?,HX%4ZSV0/S@W>8@ /'#W6LC;F@[W+W>"&@N_@95M^A/ MABDRK:F3I%%6YPJOF!\*<20\FC*7CQ(Z*Q"@8BSX:+1?0>^M!F;?:/=-0ICH M90W4G!%\/[0=OE\/W]]N6\9P.""$B5[6T.32%_V<[&P\#M,@B=G,N7%DY['L M/ SE",]R08S.@@68&>M#&HD?]&P9_5[7Z/=QTA&, A0 ;==._* R^CU!D:O MC]-.R1@%ZF9[E/Z?W/7&3B1RL_&8^_(((F$S:W. [O_.SSFTMV M-DY*>=PW<9,:IF*"OVF(6W=75;?XP=\BA>OV"2$"@X#[UT; M876K)V\P"2K)&PILOR[]CS.9L(FW9SYW8HZJ&@4+P.J1UN(')_=,HSNL?A0 M+*+9%@'_#VW72/SP_]VAT1_N_QA36 25>AJ.+5^!Y"T7$G!\53>+$R?A+'%^ M;I&C[>%D'IPJ2V#E"*?*$H<(I\I6V_5@M"TZ9\'A4-GZ3 F,4S\&8)P#A@B, M4P6V3L?HV-6[^,$XI//0W9XRO[<\U.ZWVEW:F&1'F8]O3Z7<^VH- @/*BYC; M'S&*R($:A@\Z*1:AQ>T&TV%O8 RLZ@-<=NLB$5U0,C?05OT8@+::C"%H:R>X MVD9G8!EFN_KYYJ MTDDQ_Y*ZI;_&#G_6^X@S'0- :X?FB[1N*'ZV_;MM&ST#9!QB10-=N7Z-^'XJT3 M'DV9RT>HCA$E :P$-5S\X."VT1GT#-NV":$"HP %:"-N:#LHH&X*Z-H=P^ZB M0D;&*% AVY?H7Q?'GGO!.)QN>V(#UD0;MBBGN=^I6_P@8Y3#8 QP_=!V[<0/ MU]\UNH/JRW P""HY&(IA#5L3 O-BL4T:B1_NOFX$ M-!<_BEO[$OUG[G(^=48^5WN]Q(>BT/>%*)@7)#SB,39^$75"6-UIN/BQW-DQ M>L/J+22VE8<:)Y+MNE0\W5"\T<.9F]N7A\^,6.Q-VBDA&R]J 07#VZ"Y-" M8EK[L;HA4N2^"Y0:'0 ,+6,XJ)X [M:[W6-&9=<&4P+C:( !&.> (0+C5(%M MT#$&M@7&H81)D\N#=K_5[M(6_YJ>&SQ*]/QBB M1G-[S^CV;;'A1EU>TML\3X12*/1Q"_<[WKK=Y\Z46?KBI<^7ZWKRJO8=FS M=7J_[K)W26C]+?_ZEU>3:*%.W_CQ*.+.]V/G*N'1B>/_<&[B0EM,<]NVH=T\ M8QUWS$!6D.]+(Q#F-/\Y-R_U"^,XOY M2?&/EVQ%LL7BB_B N(NX4/^HUM7,X?#I1G^,N''+9@$>A[V[V!)TJKN"A M=O]*_G[I15T^#B,G\<+@)!7/&_F>^/;1Z=? N^91[/CL'7?\9,(N>73MC7EL ML(M@W'KU0E[HE-":]%Y:98B@>,^RIEZ6M1$">\^<6MFVSL- !9-.PN7BI_B? MJ7B;F(57[-R))^RM'_Z(-;4P,FC"QBBF$\^\@"63,(V=P(V?PSBH++; . B@ M\BP-G-056NC",HA:1IU(]+NM]H!6KK,6'0&.PN;3Y>Y7A.>>J5>O9[+;K1X] MW[0J^1W:Q:7WDTW%GR8Q7%--$-3OFOY_]MZNN6TSR]H^GZKY#ZATW(]3!3/X M)NED6*5V[+%[TNU,G,Q3[]%3$'G+0C=%L %0MN?7OS=(299BRP)E"MC O@ZZ M.I8HDEAK[[7VOC]OZ-"]5EY*U*L'Z^K%Z563)7^*-,W8+[5P_KI9F3__R4^\ M'T+/[6[Y'TJ&DO6B\@JZ53+?&T7)_C.[VK4N\#@\218CW:XW'R5?FT3M*J-H MVM#&7E-JM9&C3$4QTOV^C[U&X88T /IQ!M,Y*?(SY_7:U%.@J[?.T;S*SK>[ M/IX*6N#16'D1ON<>L=V3"(,7.J?R%PZXIV MM%\2&Y'GN=,DDL.)LFP8\IS K:W -<2RRC[A_*!\[('^T>(?F[+:[7.JSMLU"MCU%P?ES>K;^P4G/\J+*_G?[(]II M*6G!"%/7E 1)[(:3B1Q.2 EF%Q3!3;1C -T:0.RYB1?(X41[2@QHBJ$'K<+C M_TRSU7?.,B]+QS8+9;HT]9EJ:5F::G?3Q/&FS%;&_KOY*12TT\,>S< V9H\C M=^*%86C@ _-M[YYX< MIZ6ICV X6YM5N9MF,._K_V;3@IB\8&BI:TK"L>N%[9\ 1$;(S @:!:)=#_SH M_RP,W6G,Y@4Q&<',0IOP_U+O1BCKUL"^=#>AX&1GZS0KZAT-],]2LH(!I:XI M&;O^M/W;B4D(F0E!FT"TZX$?^9\U/P>59)#2(;F_,3QYR^&TR;KSPB):1T M!O+G%?K1&10;LW"R^M9$4S9?:T2'/.P!"JQA]MAWHW@JAQ)E&=&\*V!V8%C: MHRS0I<&/],\>!ZX_93N:!.EGIJ"+?F"[5,B[^Q/2]QQLU!>78.RH M#9=(W''2O$,@)9@WZ"?2TL1'6:!+@Q_MG_F^U7YO+(<3[2G!O$&;\+^N3DWA MO,N+?UH(G'FZKO='..G%.B,:9RE9P5!2UY2$;IPTW[9&0@P[(>@3B'8]\"/_ MLR!QPSV.0"4CI+0)3"<< /Z_F44V3PM3=P9F65^S;!;..OVPNZCYQB3#LZ-? MG[]QCN;5]L?YMK]X:S]DCVZ"'IMAIX';R>-D.G8]GS.UF7.@ER#0%<&/^,^B ML=7^*?/-8E*".8?VYQRN7;=VU3O,3^V3[+$VB2Z;<:>!>\7C8.*.D^9[FDF) MKOH$YAR&)3[* ET:_&C_++9=0O-#LDD(*5T"4PZ'ZA)HD:4$/Z-&75-BW2 . MY#!"0C!IH ANHAWY[W8@:.PF>YQB048\W#@0TP5M(O_Q:*-R8_]@;B[O7;ZZ M*6&>GYV98IZE2V==F+-L1X$;=7 ==*,\NJZ&FG*I_0T2UQN3A_1 MZX7MWQ2!VTB=7FFY,XK\D2>\,_J[J9QY6IXZZR(_SQ9FX1Q_D M\RH[W]Y6+6H\X9*Z&O3/ZAX.UH=ANE9H'+3%^?[4C:))Z\1BPXP MK0%SB&D=R+3<*/;=<(]SV+$M%1-7#[?Z33CTS^H.[,4R?UIU9!46;Z2-1.C.B]$C$>I'DIZ'$T"-]CC=%URHJO%8VQT M&9;Z* MT:? C_K/'81RYB<]=31+$?T"3!?WH$>;&+$JG,'.3G9O%;MZ@3)?V M8_.3ZV?N'F_*;&7LOV7M:-&4)]+&,_".6>"[?M3\L%TR8M@90>] M.N!'_V? M)6X4-6\<2 AF& ;4/1S-_[7)RNUL0MTL?.P0M@W#^F+^@;9:2G8PU-0U)8PQ MD0QT"D2[-OB1_MGC:=+^_CKR@1F&;I%_M3K9[D=XG&^J[7]]MYMBL']H/V3E MF/?STW3UUCAS^_=%.J]*ISI-*^?4+.P/\TVQ/;/W]]%_C9QLNYNA7L1$P]T/ M7V$$JHW[_GPWFHSE<*(L);@77*OX* MT:?"C_;-X['H!5WR(R0BF']IM+>:% M24D W,3;<+_+"^KTO8&\TU1U%L?\L)9;XKY:=U3U"N8 MLK/U[G*/]'*)4[:JWW3WS\K,3U?V4=Y^<-+U>IG-T_VV5=.-,SXU<&=Y[+M! MU/P**3*"J8E^(BU->Y0%NC3XD?[9X\B-@N;G:9 1 A8\]?1ZC!YT&J^NEB[9 M%L+=-A?IXKR>D"B=*G>=?^29_=6Y_?VFV/4>>75J"E&-.<>*]V$DBU/#Q8UV M<5JXO"SBDHON.ZD^2VU^(W4QJBG-ZKWZ=[ 36D6]4*N[.K* MBGO<&=CFI;8UX%R_U-O!.:Y?^OH1ODGHCKWVQ_CP-U%S/K12@L4.P^H_AQC6 MH9JQ:>)._.8-&88EM2&3OW]&..I_O"GP1;9*5_/LGC<%LBY4PV@?#) 6N%G M^1K1K@9^Y+YK!K0G /M@VH3_5[/8S"^WN"QS"T-EBC-G88XY:4M,2H@8A%(^ M?C2>N.,])O3)B;[/;= 0"(%;5Z!+@Q_QGSV.XJD;AH$<4I3EQ$#G"7K0'APM M=C>&I\MZ_JK(WUDDN#V\)]X@9+!HT-Z0N/&8L]U)"%H#HET;_,C_+':CN/D5 ML"0$8.ND+^I^P\LU]K43KK-%O0)/?#%!@U M:J,C"-U)U-P32(FN&@)F#(8E/LH"71K\:/_LL3]V0[1?A/8S7= F\J_*J: MDL>QF_AC.90HRP@F%+1JC[) EP8_TC][/'$G'=PT048(F$_@MKU/FHAK.Q+R M=RM3E*?9^F//X!Q_<,XR^^JLLO]ASH[WN&BOS0.[/\;2EP1T3T'.$Y_*<)Q#GRU*V:C8BJ%^_;NO&_OY.KBAWO([KB[YZC"])?'VR9M5*F)5VG*#&G\-/0A*&)QM%;X6>>&8< /AM$;BK0;QM"G M@'K0ACP_.3'SJEX;9][/3]/56^,4:66F<7V]W)&;5C&T+.!-<;-;J$M21@R$T5(1WG$1$_W'& W_:4( MNVEX&)F;A%,<1Q(G YVD$8[ZXY_,O#!I:;YSLM7NO^HE<@_0#3%4)]N;^C)4 M-W1C\H+8C9)$#F_*QN^X-46K0&$@LOG!0.[F+!I/W,1K?BP"[L'LSY#'T)XU M;F1EWC6:&G?RJ'O?OM0[\7@H.TNB$,WF4S$' YTJY9JRC-Y)]'ILSAI0&X_:O ,*O1,]EJ5V6]V:S7B_-F?UBZ=+Y*2OGR[S<%/5.I1.G M[M*<%\O\G?-J5;]16M\8]%3.B)3V&5\1 X(P0 )HA9]50S,B6)$V92U'* V6 V MPS6;Q'>]"=,@HCCI?AJ$AN?3AF>>GQFG2M_;CZF;'M=9F>T!;X4YV:P6A+)R=_SU7;#T'I3S$_3IA<;^;)&=[_7D-Q[TT=V/\C$0KW^73S^Q?G\_6'\N'P[SD?_^;S^>%A]# M[:UYV_+[)Z;NJ%C5W;]GIF.HGE%\3ZMU#'D*IKV?W<;Y#\Q%.MG6U)%EME(A#F2B,.LJ&"VR/+#[+SX(_X,G9OO*'XS" M -P[V,F+QG03[>ULH%:-\@B,6XCDZ1]UN\T*_1KH0T:YI4A6C7$P\O[HA0-$ M679SB4 _= L)P@_?,()Q&^TA*#]\,PC&M'Z]1)G6C]9O&"C3^M'Z:6C].IY7 M_",GS"N"?9_G%T&_VWG&QOA/;C>#P8#>SB0CD'^YS03TUFMU(.^@"7TXT#^_ M!%L($NT$GYBUD^+P_TP3.6P&'CG/3M/56].;%G,X977SY>'IF7%>I/-LF54? MGGZZ$)Q&5&TK1"/:=8%.(THC.GC(:40'VPL >0>-J+CRW_GO35K8AZOOJS?- MKT892A*(X4-@1BAKB!/GS/[BM/PD$SHZSORB!_[#H1HWKD^^]; A8;U ?QWC MJM$= @U#:,FN=;]0(HF2BY:XAZ0,I[Z]UB?#0_<\[)IGF.B>B1$\R.TSIG?8 MQB4NFGJ1[T/O^\ +FA_F-^B$$<.+P.SQ[C![LN=+9V:-NSTR:QR.H@=8NRZD M'VD\SWTTWU3&>6;EY.J$.W&3W7\PJIJ,N_-L2%DE3OLZW5NC#NV;3D/XW\]1 M'OPL[0=R%#$T_&K.S6IC/^)Q^EWC['CX ^B_/'\XO*/&?7\T?B0(?[R@W6C_ MTMS@\*-=53,AAH5+Z7]BWL^7FX7]K+?YN2E6%\X>)VHXDF7 M/3P)1D%S>Z!5&&*KH#?:Z0RZ8.%H\8]-69F%<[0XR\HRRU?-'8 &X> Y89_8 MIT.0:0%T" \>[K0(G7K +VF5V:_G_)1^H _H,"V\?8:)Z /H _I,P!^CG3Z@ MPV$BYQ=3.)_V! 0M\? M3>@U9-H&O<9#1_O@SVX2@[RTT!^R+4O#NJW;8D"[W7MCP+O-&V1 N]V[9,"; M@EQ"^PG>1/= T.[XSIE^;';IZZCD=33[L'WR+^8T/<_L;Y;.2Y,NJ]-^;*74 MDSU=XXTWX UXP[!H^+@1\EA4[.N:=/)&4^:<$'J5P<[RMD'M@F0AVZ&I>N*S MD$VJ.["0[:&CG;:@;[L@:0\.GA,1_8%4!Z _>.AHIT'HWQY(NH"#9T6XS[ID MN@"Z@#X3\,=HIPL0LYWEX?9 TC@@9]PP,'.VV#&,MXR!V0=!J' MIG"OP28:#1J-/A/PQ;$F]C^*B7SV/PX(:_8_LO]QP'BS_Y']C\/%FWJ2S?\P;,PN/T.^?5ZHNCCNLB?UND9U>CCTY^XGSKQV/' M?L%EEJ_L+^;UC74+)ULYU:FQ_RN,<=+5PBFS]T_.[ >?.FM39/FB=,RJ?N%? M-ROCA)[K!%[@C8B!CF/@^'XQD/@/'P*,,NEQ/%5NUW5L,\K$*--P\6:4B5&F MX>)-'\XHTW#Q)KH996IKE*D%Z&_TDLYQW287E]B6^3);.+L7.ML'6J>%!5'] M<5N_OWSC/,M76WS2RBRZ.E_KJC&]%W'7%@?-[2]-<8C504*H[$C(KG6O4-* MDJLAU+#;$=0@&7F3+W-V"=?#\R7&G=Y8]5LMG/_>I(5]-.=Y/3+:44I]6G:1 M*IVE2GQ'J: Q5;+WSG8>X6("H=\EG;;?<9ZGCPS=!#7QSYJ[BS%E1-TW8=W2R/;/=@A4^6 M1P[Z8(5O0]>?CMW)I'GCTL)9(@A,NR'_A0FW 89\X(Z#J3N.(T$DL-2,LZ(> M,.03-_ ]=Y*,!9% R'-BU .&?.S&\=2-;@P:L:.O+?B?_^75;S\=.2M3U1LT M__[LE9Q!((I+-O<-$VU]W6L\\=U)V/ZD&[VK#+35]:[1Q':O2?/.E4U20PMX M99VK[WK>Q/4F$T$D$/(E;D3[T*)=5\_J MQR./"WHZO0":&=<^2 \SKH-"6UW+^FT\#MRQU_Y.++I6&6AKZUJ_C<93-V'& M57' ZVINWDW#BA@'SK1+:5R9>^R!"3+P."FUU7:P_ MOGF?>-?XT\(R\?J@T9Z(BO8A%S0"HUU7_^HG(Y]HUQOMNII7/[X9[4R\"@U] M)ED'A#7M:=>3K.!-.SH0M+FSDMFDX:+-G95$]W#1YLY*)D8?!OIG:7GJO%CF M[YP717[FO%Z;W>64' ,L46F8$!T4VG2<3( .&&TZ3J: AHNVM@G/;WU_ZD91 M\P.2"/BA!;RN.<]O?3>*?3>\WQ%)3'Q^)?P_I1]*YTVZM!_R>E.55;JJ<9 S M*$,IR43H,-%6MTY7' 'TJ>PU540 =3P[31^.@#@0!#ZASA[3AR,@&C.)VLDD MZCJKTJ7S_/W:V"ZUVA14AN:5F=%AHDWSVO7,Z*"=51S\-*],)@T7;77- M:^)&$\_U/4\0"32OTB94!TW M[&;3"9NPK[2SF99G>^=W_)Z<^G%)M/L?[?G M\\H9T:%_9?)UF&AS#E+7!-#0=AW_U)NBYJI FP[W8 2$\6@L^@K30:,O,/QU M-;>V>PRYT[3#OO;Y7U[]]M.1LS*5DY\X?W_VRGGL?R=GM(?&EHG98:)-8]LU M 32V7<<_M::H>2S0IK$]& '^:)P(@I^^EDG;%@D(1OZ];JQANO8P;>W1XA^; MLC*+K^QOF;@=T. :_2T3MYH(H+_M.OZI.45-98$V_>TA^UO1U[ .&GR!T:^M MO_7NM1R9:=O#]+?/TO+4>5'D9\[KM2FVJY%+9FZ%R@\SMX-"F\ZV:P+H;+N. M?ZI-49-9H$UG>[@UF:-H*@A^.EMF;EL=UXF9N>T"^+^;ROG2HF3G<<#$K40- M8N)V4&C3WG9- .UMU_%/R2EJ+@NT:6\/.7'+4VM[:;UFN4TM% M\DVG@PYC^RV'W&!=:W6_O%!YKYZ7<>>AC;RI,^90$/P8,^/.W44_X\X=F/%M MJZH8>A8J0PP]#PIMAIZ[)H"AYZ[CGZI3U&@<:-/A'G)E5?.+#!AZ'GST:^MP MPP9#S^..AYYMCM[28-60)^LO<-('$NIN]N>T,F7E1,Z_-FE1F:(4->SSB24, M"7YQPVRW%3R@W9+D#QKO6S3>][H5>=_S!ESF/PZ^VPYHNI>3B>EZ7>3OLS,K M^\L/SK?3L6._QS++5_4OR].\L.]LBC-G7@]_9JMS:PYG]K%*)RWK5_QULS). MZ+E.X 6^DZX6SK?Q.+IZCT]?Y(T^"8'OJ_1X:>S/%MGY7KC?@/G1=5A;1O7' MX\+Y?E8_V.>3UP\^F[V?^_Y?^L8?0^9Z.OW[O_UX6GS,A[?FR7%ATG\^24\L M<4_3Y;OT0WG_V#[,=^ST$Z\5SG/[IJ:XNW+^W'>XB)?C?+FX_L%1DUB[=V#5 M/[_Q' LSSW>S#T\W]OL5R\S^]3>SWU?9N2W6TJ7STJ3+ZM1Y8XKS;&Y*UWFU MFO_X??T^-]_M-!VKC:%]&B^J8SS+"V,\S(OMW=[ M7:$Z0%Q>Y(53G1KGM]/"F*V2O\G>.W^S+SXM'6._X6)(3_NI;]7>])!/V+K3 M9RO+9[XI[<.5WSWTD]V4WIV1;VW=.-/W.BV MZG(JPIK>I&?&>6%97V;5!^_?#N-*O,DSIZ:[#>%>EZ MH+R*ZXO;G&5OA.R0!R%:"730O\4OMG8! 82_3O11>D)=!_K1* X@@/#7BCY* M3ZCK0)^:GO#7C#Y*3ZCK0)^:GO#O$GTYY^P'TY'?XD;$SI'O.N[Q6$1&!_IT M4X2_9O11>D)=!_IT4X2_9O11>D)=!_K4](2_9O11>D)=!_K4](2_9O11>D)= M!_K4](2_9O11>D)=!_K4](2_9O11>D)=!_K4](2_9O11>D)=!_K4](1_E^BS MDT%KW&OS6"F7JOKQER[W:7I$X-U<7,>TNR/.=D=!Y>HIGF#E+4F97IP1:*DLB6IBD*BQ$D4U192UA>V MJ+8$D\- HV0R\)7.\;_RE:!;7QEO-_=<\E,C^UE3P7@^TGETEF]6%:./BG3K M7GF!L%V2=98M%DO3KK#%V[TL"-L>=#YR\A/[7M77WQG?ER?^U9R;U::^>/QS M&O. 88N8,_Y*<8D&BRLN&X"DN>TLGQ67[Q25B+E;,&3"@6.T] MG5T7J^B6G"(48:-8'0R=%*N,A Y8S/7@2G'96SJ[+BYIGL7I%B.A%)?]IY/B MDI'0SBFY_P+=9R]>>"^>\4%PGA/$Z_:VRH#PZ\NJ-@.@6[@6LJ M.@OX6SG,),UZM;O(N>;G1?U5#F'G4MCRW;$?NI-I(H-FF_7Q#L."OXC0/#I.'3J$K8AFA[:CCLI"]QI%+I!0-M!SN ?^ ?TT';0=O0$_.MM1^LGWM_* MP< WU+Q>FR*M[),[\U/[I4WY5-#ELICWT&[R!?TO]7::K5<:(^0#TJ\%;$*] M0_1W;1G2+X<1\@'IUP(VH4[5#R/D@PSTD7Y"70?Z5/W2&"$?D'XM8!/J5/TP M0C[(0!_I)]1UH$_5+XT1\@'IUP(VH4[5#R/D@PSTD7Y"70?Z5/W2&%&>#P.Z MKL0/1V/1X+])E_9GIG2==^E;^TGI:N$C3B47>*)3#AZYLX%PMG:JC*\JEH4^]'T^F;C(>RZ&$ MA$#[M8!-J%/O=UOO3^3PH2L;J/=UJHZN*)>&/O6^[X;3L3L).42T.?>C^,(C><-!]U(R$& MG1!H/Z&N!'WJ_2#<8TL%V4"]WT.G_L3]VI'\NAA(1 ^[6 3:A3[W>[G@?A%U#O[B_ MV:S7R\Q^Q,4^"D';B;!>]F[I0)^V*YA,]]I&04(,.B'0?D)="?JT77XRXDHB M 6U7U\"C^42Y#O2I]X,P="-NHB,AT'Y"717ZU/NVWF>@AWH?S2?*E:!/O1]/ M8C>>4.^3$&@_H:X)?>I]?\R]%-3[:#Y1K@5]ZOUH.G:G$?4^"8'V$^J:T*?> M9SV/C'J?6RG:P_TGLR[,/$NK+%\YZ6KAI&=Y467_N_V!H#U%^# ;N'2@3P\V M"=QIW-R)R8=!YP/23Z@K09\6+.+@*@D=6-? (_E$N0[TJ?;'$S>*N(Z(?$#Z M"75-Z%/MQWO< DXR4.WW$&=IHJ,KRJ6A3[7O)Y'K1\V7U9(0@TX(M)]05X(^ MY3Z#^Y3[2#Y1K@9]RGT_3MPP0?9)"+2?4->$/N5^O,?N:9*A^]T4A]K1Q>Z&R?99T6%KXA;['XV:2EV>ZMJ)\T779V8\4U#WYX M6F0GB+3-=_Z7*;D$3)&$26-HU\L=@J0A>[X_<;THZ4K9FNL:B839#)T!S*:W M#.V:1\SF#K/IX#A>G$;2F5V8C%@)PV2D,T1'TVS!FALG[1\#B<^(2R3,IFL& M,)O>,D1'0T?3/S[H:) P3*8W#-'1-&$MG+A^W'Q)'CXSV$3";+IF +/I+4-T M-'0T_>.#C@8)PV1ZPQ =3:..)G#C"7,TDBBAHU'* &;36X;H:.AH^L='IS?' MM+S72383;S;'55ZERR?YVA1I9:&ZW.I4MKX1D$) [,[8:S)6@_E9@Z%2$$WA MS;;T05D<="GA1M/0#?;8,'5@>:2@D)-L.%;7#.!8PZ7P9F^+8]V3ULEXC^X7 MLY(TGX=/#5[D\*G>4TAG=:#.*D@"-]IC4A"S&FRRX5A=,X!C#9=".JM#=5:8 ME21"Z*P0.7QJ.!3261V$UL"=3GW7"]L_TQVS$I=L.%;7#.!8PZ60SNHPG=6$ MSDH4(716B!P^-1P*Z:P.U%DE<>Q& 0LL)+%"9Z64 1QKN!3261V$UJDW"C K M081T>N_7K=EVL3UNJ*"_6LWS,^.<%/F9<['S+5\UW_'V\!NON72SDUWNM]J* M(D&21D_#5E6SJ0>!9QM13PYGNJ[NE)8QN ?N 3U[M8V:W<,/1E,YA.FRCO;/ M=L0U1("-:TBFAYZCP;7!H9OX[=\;C'&(S!C< _> 'GJ.YCW'6 YANJR#GD.G M+.$:HNFAY[C[T/AIY";32 YGNHQ#6L;@'K@']-!S-.TY?'H.>@Y< ]> 'GJ. MQFNK)F-WXK5_?PC&(3)C< _< WKH.9INMQFU?VL[SG'_C34/OHUM\!MK*E.8 MLKJ\1GY,')(O FQ542X-?4K]>(^-*"3#H),!W2?4E:!/J4^I3ZF/ MY!/E:M"GU(_VV/]!,@PZ&=!]0ET)^I3ZE/J4^D@^4:X&?4I]W_5#BGW2 >4G MU#6A3[%/L2^BV&_]/I(;>R2T7Z+UNCHUA?,XV]Y5\MW]=E04,H#/])8A^AE\IF]LX#-* M&LL0_0P^TSG.3O!DN]@ M-U30I6D;UV<*JP44"9 T>AKVI3#$E9LZT< 5> 3WT M%;U@"*_ *[2 C1))IH>^0CI#> 5>H05LE$@R/?05TAG"*_ *+6"C1)+IH:^0 MSA!>@5=H 1LEDDP/?85TAO *O$(+V"B19'KH*Z0SI-PK;NYLL5_3PF"9\)-O MNJVQPFV1=6@:KL-YG"\77\?+?4GXL?[YC2UM"S//B[3*\M73C?VZQ3*S?_W- M[&BY=([FF\HXS]+"."_SC331'^FM%'Z0EU'>C331'^FM%'Z0EU'>A3TQ/^FM%' MZ0EU'>A3TQ/^FM%'Z0EU'>A3TQ/^FM%'Z0EU'>A3TQ/^FM%'Z0EU'>A3TQ/^ MFM%'Z0EU'>A3TQ/^7:+/3@:M<:_-8Z\.INOX7#H_'OTQS+=/MOU*3^<62U/\ M< NKF/:W1%GOYT6QCAG]I>GI6/LUUL(2@&.FD-^D!_D!_E!?I ?Y.?@8?\F M>X_X=,X"XH/X(#Z(CPSQ:7W$[<;PVN4]$A? WKA*8OM Z[2P"&HAHTT&MK(/ M_K+-X4O\7(*EQ4#^NEF9/__)3[P?0L]U B_PN\H.)?S;E9;>J+QS^G,0\8MH@YXZ\4EVBPN.*2D0QQNG5G M_N@!GN*RMW127+9?7"+F8L6< 0.*U=[3V76QBF[)*4(1-HK5P=!)L]I;/KXI+F69QN,1)*<=E_.BDN&0GMG)+[+]!]]N*%]^(99V_>%WF; M^4YQD1#.X_2[QH;ZX,"K.PJF4[ ;N*:BLX"_E<-,TJQ7NXN<:WY>U%_E$'8N MA2W?'<>1&X7-=P^VD4^*TD6 MLA6Z431QI^-0#FNZ7$.VXD[+ G4XF M;AS'=R"&%E$#]M8!-J%/Q=UOQ<\\K%3^:3Y0K09^* MWW>#:.*. U\.*:0$ZJ\%;$*=BK_+BM\?,=0CH.(?T*45XK=5O*Y.3>'D5[=7 MF/=KLRI-\RT5;'!LT038T#5H]&G HCATO:3Y;>9 M_8B+?12"MA-AO>S=TH$^;5UQ 2D*@_82Z)O2I]_WQJ/G^.;*!>K^'.$M3'5U1+@U] MZOUH.G:G$<,\) 3:3ZAK0I]ZWT]&S??/D0W=;Z-X\*TLP]]&\9-9%V:>I566 MKYQTM7#2L[RHLO_=_D#0GB)\F U<.M"G!YN$;NBQH9%\0/H)=4WHTX)%>W1@ M) ,'5_409VFBHRO*I:%/M3^>N%'$.;7D ])/J&M"GVH_'G'_*-4^DD^4*T&? M:M]/(C=)N'V4A$#["75-Z%/N1]PZ3;F/Y!/E6M"GW/?CQ TI]TD(M)]05X4^ MY3Z7T(DH]UN_E.+&U@GG."\6IKA$M"Z>1=&87)B-6PC 9Z0S1T31; ML.;&2?-EROC,8!,)L^F: #A&$RO6&(CJ911Q.X\80Y&DF4 MT-$H90"SZ2U#=#1T-/WCH].;8UK>ZR2;B3>;XRJOTN63?&V*M+)076YU*EO? M"$@A('9G[#49J\'\K,%0*8BF\&9;^J L#KJ4<.,P=N.@_=.O*2C$)1N.U34# M.-9P*;S9V^)8]Z1U,A[%F)4@0MH_V ^?$BMR^%3O*:2S.E!G%4Q"=SJ-,"M! MK-!9*64 QQHNA716=%9#S#,Z*T0.GQH.A716AUEKZ7IQXB;3]L]TQZS$)1N. MU34#.-9P*:2S.DQG-1DU/Y$6LZ*SPJ?P*2BDLVJ9UL =>YX[F=!926*%SDHI M SC6<"FDLSH(K5-OQ (+281T>N_7K=EVL3UNJ*"_6LWS,^.<%/F9<['S+5\U MW_'V\!NON72SDUWNM]J*(D&21D_#5E6SJ0?^Q)WZ[>]Q_U)*D3&XAPJP<0_) M]#1L&S6[AQ_LL8P1Z^CYV8ZXA@BP<0W)]-!S-+@V.'1C/Y##F2[CD)8QN ?N M 3WT'/0[>R#0-W&",<9 QN ?N 3WT''OU'/X>2]^P M#GJ.'N(L399P#='TT'/COFC+-NN^-VK^#/J6^[_HAQ3[I@/(3ZIK0I]BGV!=1[+=^'\F-/1+:+]%Z79V:PGF<;>\J M^>Y^.RH.2PQWFPG3D$#[3-0/X M3&\9NKD?'Y_!9^2S@<\H90"?Z2U#]#/X3-_8P&>4,H#/])8A^AE\IF]LX#-* M&LL0_0P^TS*=>V5J_/5 ]V Q?I4("TT].P+X4AI5=NJD?GA"&\ J=Z.,5> 7TT%?T@B&\ J_0 C9*))D>^@KI#.$5>(46L%$B MR?305TAG"*_ *[2 C1))IH>^0CI#> 5>H05LE$@R/?05TAG"*_ *+6"C1)+I MH:^0SI!RK[BYL\5^30N#92(,ONF4E>FT/0N9M,S!X_0[Y]5JOMPL[,=\Z\=C MQW[L,LM73G[B/#OZ]?D;YVA>.>EJX>35J2F]U5ZO#3V9XOL_#-/7C^G'WQ\T&M(W'C21W<_R_:I_?HOKW^9?_^W'T^+ MCQR_-4^."Y/^\TEZ4IGB:;I\EWXH+_GRO'W3\C#?L?U/_#%U5NF9_;S_=_3\ MU>O??T[+ZME7?\./WZ+-D/R_]1URR\PJBY61 MM'+617Z>U;GJY)O"*DZY65:E8Y4I=?[\ITD0>#^\L: X+])YMLRJ#]N?^;:\ M2OGOSGT=$OSIE)RTUAOG.=B]]>"E\M7;F5J;2J/^[R MH^PW=DYV[Y[9%]6J=KPILY4I2_O/W>NMH%D)M/">;M]DOBGJK:G.!Y,6VS]8 M6^DK=O^\D$&W_E*G9KD^V2R=*M\^7+8Z-V65%_9#ZB]\\3UK4:U_^_&;V?^H M84Q7%/9/ZN<97:6U5A5N5M_2U/8Y]WB6X=!OBGK[V"_A/V+ MTE35TIQ9$.T_EN:M_9Q_;!9OMS_8(KI,WY6;K/[M/"]K)UJFNW=V;*C9K[#) MRM/ZU?63+X3[:N6 M>>TSV;G]D/J5V:I*5V\S"^3UO]^98WJ6;^J_VD)XEGZP 6V_X,G2 KT+E.LQ M8I_^6G2<9"M+:\U"6=D'VGWZ]GUV3U@_X.[E%W'TN0#8Q?YE&)CWV_!V3HK\ MS(;#-=?^^(T_QI9YOS:K[?/O$L_^LDK?;Y^Q+'=?Q])OOOLK(>9F_ MLV]=; .K-+>_07H5*[LW:?REZKSX!,BM5SF;6@B=H^72%BH;B].S^D->YN4Z MJRR8;VRH97-CT?KM] M?[#1=V#C=,E_GQ.[]LULOMKSY=2Y>GA[GYQ=?RF: M?;G9_?@B)O*3$QLM]MVJ=\;L\>CVFUN1.*YL$%MIL-]AO335Q6/;4%GM%'*G M%!^#Z)I2[-+]\TI1GN:;Y:(.4_/>JOQJ!^X\7ZWLH]55X+O,*EO]UO7WO8# M/OS"?H7BZO7I?&Y[ROJS=J_?BFW]3/:5ZSK=5S5,]O%,_6+[\VT:Y+7IE*8N M]%?;1G2;QY_-@_IOK(SLE+HP-A7L.]L_JT'9?87Z*[ZP#^SXWI/_VBI+_1G; MS-J5G3^9N3D[M@B'_J[TW+[IY9_\]]6?_&N3%O;9+O[J;VEAP_SB3_S1(>Q_ M9Z[^@8N*;BR[SJF[,N\B3SF6[?6O_[[L]_\A/OAS^\[XV:HJP3Y.2& MDKIUF%F@K6_6H;E-\!_LNUV^W58D+B3CY'9QN2HV;)U6QWMSU:OM\Q-INEV6 MW/K=ME_P\AO.3;$5CIOV]-&N_T#%]6IG_J]-5FM]OOUF=9I=PWYI2U#'"MG2 M*MZNRQ.<&QZEE:[ZA<>% M\[VMVNO7SS[_M'1=G71=GS_J9UY+37'W63^]"\3?5[;$+6QM[+PTZ=*Z^*6 MN_4 T66 7G^WSQG/37/Y9C;Z?&0?"-#=APWTHT]\^;5U8/N03MEW@/=ZV6K9! MMP]7?O?03W93?7=#D+OJ<3=G]1_?>-\X<[.LYP7FMA2Y^O?%H.[VWQ=#R+MO M=#5>?#'I-<^7RW1=FJ>7__&#\P=?^V3VP4^ZG7U(PM$D./P$Q">&]%5'G3VX ME-YL7Y\XS:55T^R"#%+%S:J.@DE[,WC:3^#L=AY-._K)* 9_HE\K^B@]L:X$ M_6@432" \->*/E)/K"M!GZ*>Z%>,/DI/K"M!GZ*>\.\2?5%WRR0MWBW3.?)= MQSTFB\HH09]VBNA7C#Y*3ZPK09]VBO#7C#Y23ZPK09^BGNA7C#Y*3ZPK09^B MGO#7C#Y23ZPK09^BGNA7C#Y*3ZPK09^BGO#7C#Y23ZPK09^BGNA7C#Y*3ZPK M09^BGO#O$GUV,VB->W4F>W5<7<>GU?GQI]#?XYS N\FX#FIW1YWMSKF\N.?F MZGQ+(4G D7,($ *$ "% "! "A ]2.#7YWLC/UVS@/P@/\@/\B-%?EH?>;LQ MS'9YQ?4%L#=NN=X^T#JM;^#30D:;#.R$'P*$V\.7"+I$2XN%U+>X[&Y+N[S* MI:OP8B%3W!"!28NGZ1*2\[D2J:>(@9NV)F1Y@$2FQ=$FJI! I>2)%Q868 M]88N*B[!Y##@*)D,G*5[ JZ<)>C66<;U;I]+>FI@/VLJ&,]'-H_.\LVJ8@Q2 MDV[=*S$0MDNVSK+%8FG:%;9XN[D%9=N#SD=.?F+?J_KZ>^3[\L2_FG.SVM3W MD7].9!XP;%%S!F&I+M%@<=4E0QGR=.O.!-*#/-5E;^FDNFR_ND3-Y:HY0P94 MJWUGL^MJ%=T25(4B;%2K@Z&3:I6QT"&KN1Y@J2[[RF;7U27=LSS=8BR4ZK+_ M=%)=,A;:.27W7Z3[[,4+[\4SSN.\+_(V\YWB(B&9I%&S=AQ<"EF^&WE3-XX3.:0I/TZ[:_2Q#JP# M>JY?K8"!?,E /&_4?,\FYG%0\!\) A[?P#>@A[ZC:=\1A%-W&D_ED*;+.J2E M#/Z!?T /?0=]1P_ I^]0*DSX!E,=?24K<,>>[\;3B1S2=+F&.#'#.K .Z*'E MH.60#SXMAU)APC=$TT/?<7??$0>^Z_G-CVG'.@:=,O@'_@$]]!WT'3T _WK? MT?KQ][=R,/"=-:_7ID@K^^3._-1^:5,^%73C+.X]N/M]0?\+S9UFZY5&".F M]*M!FUCO$/U=7X;VRV&$?$#[U:!-K%/V0PCI( )]I)]85X(^9;\T1L@'M%\- MVL0Z93^$D XBT$?ZB74EZ%/V2V.$?$#[U:!-K%/V0PCI( )]I)]85X(^9;\T M1I3GPX#N+O'#T5@T^&_2I?V9*5WG7?K6?E*Z6CC'9F5.LNJ6^WW8+-FQ_+"W M:]#HJ^_$QKY7GPLLAQ'R >U7@S:QWOD^>,WB'WNC2 X?NK*!T[64RHZN,)>& MOOJ"/XDFKA\@^^0#VD^LJT*?@C\.1J$;2T%=?\/MNY/ON MQ..^<3("]2?65:%/R4_)3\F/Z!/FBM"GY'?#<.)&4Y;UD!&H/[&N"GU*_C@< M@T5??@05) MX$["YE,NY,.@\P'M)]:UH$__Y4]&*+^ _JMKX!%]PEP)^A3\@>]&4V2??$#[ MB755Z%/P^^-1\ZEVLH&"OX] 2Y,=76$N#7WU!7_L3=S 0_;)![2?6%>%/@6_ M/QE-Y/"A*QLH^)7*CJXPEX:^^H(_2D)WD@1R&"$?T'XU:!/K%/S=%OS-C\PC M&[K?4L%M%5^-^YO->KW,[$=<[*40M*4([V4#EQ+TZ;NF;A@W;[M(AT&G ])/ MK&M!G[8K',5RZ-"5#)Q=I51U=(6Y-/35E_NQYX93KJ<@'9!^8ET5^I3[$>=6 M4>ZC^82Y&O35E_N^Y[G>M/EB6O)AT/F ]A/K6M"GW@]'8SETZ$H&ZGVEJJ,K MS*6A3[WO^>XT9E:7?$#[B755Z%/O1R-/#AVZDH%[*;K!_2>S+LP\2ZLL7SGI M:N&D9WE19?^[_8&@'47X,/NWE*"OO@>+8G<2<%0MZ8#T$^NJT*<%"_>X#9QD MX."J/@(M375TA;DT]"GW0S>(4'W2 >DGUE6A3[F_SP9JDH%ROX] 2U,=76$N M#7WUY?[4=_V T\E)!Z2?6%>%/N5^R"FUE/MH/F&N!GWUY?XD=JZ&S?99U6ECXAKS)XF>3 MEF:[NZ)^TG39V8T5UTWXX7F1G2'2MM_Y7Z;D$C!%&B:-H6TO=PB.ANSY4W<< MMW\\;J,4NJYJI!%>,W@*\)K>,K1K'C&;+[/F=7! %U8CZ=0N7$:NAN$RTAFB MHVET))@;ALL0+0TM3?_XH*5!PW"9_C!$2].LI8EB M9FDD44)+HY4"S*:W#-'2-&MIIEB-(#XZO3ZFY>U.LIEXLSFN\BI=/LG7ID@K M"]7E;J>R];V 5 )R=\=>T[$:S,\Z#*6": IO]*4/2N*02PG?]<83U_.:KV0_ ML#Q24,C)-1RK+.YQ;+N2>LXZ>#8;MQ*TN%^&)5D\AK=5! MSJ(8AVXR;?]J(:Q*7*;A5YU3@%\-ET(:J\,T5A,:*U&$T%BAAAUD)8H762BL%.-9P*:2U.DQK-=WC@ _<2NANN ??67JQ06ZHH+]: MS?,SXYP4^9ESL?K.;C>ZW^HHB19)&3[->5;.IAZ'OQE'[ MN]R_E%$D#.ZA VW<0S(]#?M&S?81A'NL9,0[>GZ^([8A VUL0S(]-!UWND:2 MN/9_0=-AU)=PC9$TT/3<6?3X4W=8()QD#"X!^X!/30=^S4= MWBB00Y@N[^CTKJE;.1C\[IK*%*:L+B^33L),2_6]YZJTAOI*&_;>XT MFV\8M7\X [D@,A?0?6)="_J[MDRS\'LCA%] T]4U\&@^8:X$?6K]I/D<#;DP MZ%Q ]XEU+>A3ZU/K4^NC^82Y'O35U_K)N/UC+,D%D;F [A/K6M"GUJ?6I]9' M\PES/>BKK_7'0?L7+9,+(G,!W2?6M:!/K4^M+Z+6;_U:DAN[)+3?I?6Z.C6% M\SC;7EGRW?WV5!R6&.XXD[@3[X[KE=@KV3E#-W;:?PU'0_;\Q^V?"LGU9+?3 M\1T>@X+A,;UAZ.9^?$SF%I/9I[/$9EJPF?9/!\-GY*H8/B.=(7J9!J1-@_8/ M?L%EQ"413M,Y!3A-;QFBHVDV5=;^^918C:33CG$9N1J&RTAGB'ZF 6F1UWS3 M#28SV"3":3JG *?I+4/T,X=>^H?5T,_@,K@,#-'/[$6:[TY\ALTD,4)'HY4" MO*:W#-'1,$/3/SXZO1J&'4XW[HNIMS8YQ\:^TCB[C4Y.E;XW9>N[_R@$Y.Z' M;7(3')7"#0J_E<->LVM&*2+N..(Z]-W C[K210H).3J)575. 58U7 H;7FR* M8=UQ^6DX:O_P)MQ*TB%^&)52BL%6-5P*:2G M.HQA^2-& "410D^%RF%4]%18U"6A<3)Q@XB>2A(G]%1:*<"JADLA/=6A>JKV MSYK'K>BI9*(O3>4P*GHJ[185>XD[CEA-(8D3>BJM%&!5PZ60GNHP/=4^6]YP MJX%O>;LUVRYVP0T5=&GBQA6:TJH!10HDC9YFG2D$<>NF3O3Q"KP">O;J"F$( ML]")/F:!64 /C44O",(K\ HU:"-%DNFAL9#.$&:!6:A!&RF23 ^-A7""\ J\ M0@W:2)%D>F@LI#.$66 6:M!&BB330V,AG""\ J]0@S92))D>&@OI#"DWBYN[ M6^S7M#!8)OSDFVYKK' T"0[O(M?A/,Z7BZ_CY;XD_%C__,:^MH69YT5:9?GJ MZ<9^W6*9V;_^9G:T7#I_,:?I>69_NW1>FG19G3K/TL(X;TQQGLWKBY_J-YMI MRR<91(K3,DJOP44ZZ'^A"P=_HE\G^B@]L:X$_5T/#0&$OT[TD7IB70GZ%/5$ MOV+T47IB70GZ%/6$OYQY+TYUTQ/WF"PJHP1]VBFB7S'Z*#VQK@1]VBG"7S/Z M2#VQK@1]BGJB7S'Z*#VQK@1]BGK"7S/Z2#VQK@1]BGJB7S'Z*#VQK@1]BGK" M7S/Z2#VQK@1]BGJB7S'Z*#VQK@1]BGK"OTOTV[5F>S5$74=GU#GQY]" MOWVT[7=Z.K=@FN*' Y!Q'=3NCCK[[;0PQCFSOSPM'6._WD)0$G#D' *$ "% M"! "A A0 \2^&^R]\A/YRP@/\@/\H/\2)&?UD?>;@RS75XL<0'LC;LEM@^T M3@N+H!8RVF1@)_P0(-P>OD30)5I:+.2OFY7Y\Y_\Q/LA]%PG\ *_J]S1[!B( M5/<$(%)BZ?I$I+SN1*IIXB!F[8F9'F 1*;%T2:JD$"EY(D7%A9CUABXJ+L'D M,. HF0RL9X/K)Y=)9O5A5CD)ITZUZ)@;!=LG66 M+19+TZZPQ<"P1]I9/JLOWJ$C67J^8,&5"M]IW-KJM5=$M0%8JP M4:T.ADZJ5<9"AZSF>H"ENNPKFUU7EW3/\G2+L5"JR_[3277)6&CGE-Q_D>ZS M%R^\%\\XC_.^R-O,=XJ+A' >I]\U=M0'!U[?P3"=HMW -A4=$/RM'&:21LW: M7=Q<\_.B_B:'L',I9/EN%-K_3<=R2%-^G';7Z&,=6 ?T7+]: 0/YDH%XWJCY MGDW,XZ#@/Q($/+Z!;T /?4?3OB.(IZX?A')(TV4=TE(&_\ _H(>^@[ZC!^#3 M=R@5)GR#J8Z^DA6XXRAQ)V$DAS1=KB%.S+ .K -Z:#EH.>2#3\NA5)CP#='T MT'?P&82"'-%W6(2UE\ _\ WKH.^@[>@#^];ZC]>/O;^5@X#MK7J]- MD5;VR9WYJ?W2IGPJZ,99W'MP]_N"_A>:.\W6*XT0T@'I5X,VL=XA^KN^#.V7 MPPCY@/:K09M8I^R'$-)!!/I(/[&N!'W*?FF,D ]HOQJTB77*?@@A'42@C_03 MZTK0I^R7Q@CY@/:K09M8I^R'$-)!!/I(/[&N!'W*?FF,*,^' =U=XH>CL6CP MWZ1+^S-3NLZ[]*W]I'2U<([-RIQDU2WW^[!9LF/Y86_7H-%7WXF-_=!-.!.8 M?$#[B75=Z-.*1=/15 X?NK*!T[64RHZN,)>&OOJ"/XFF;CA.Y#!"/J#]:M F MUBGX.V0D]D'D5[=8F/=KLRI-\VT5[')LTP78U35H]-5W8,$D=I-)\\6UY,.@\P'M)]:U MH$__%>QS>2#9T-&4"Z(_*-G1%>;2T*?@CV+7BV(YC) /:+\:M(EU"OXNY]NG M(Y2?@A_1)\RUH*^^X(_CR)U.FB^M)1\&G0]H/[&N!7T*_L ;!7+XT)4-%/Q* M94=7F$M#GX+?]]T@&,MAA'Q ^]6@3:Q3\'<[PL]B3@$%/[=5M(?[F\UZOZQKHIDX.RJ M/@(M375TA;DT]-67^['GA@G'EY .2#^QK@I]ROUHCWW3) /E?A^!EJ8ZNL)< M&OKJRWW?\]PX\>4P0CZ@_6K0)M:I]SL=WF^^G)9DH-[O(]#25$=7F$M#GWK? M"US/8SD/^8#V$^NJT*?>9WQ?1+W/O13MX?Z361=FGJ55EJ^<=+5PTK.\J++_ MW?Y T(XB?)C]6TK05]^#16/7GS1?8D4Z##H=D'YB70OZM&#A'E<#D@P<7-5' MH*6ICJXPEX8^Y7[L>F'SJ\!)AT&G ])/K&M!GW(_''%".>4^FD^8:T%??;D_ M#=TDX3HBT@'I)]95H4^Y'XXB.73H2@;*?:6JHRO,I:&OOMR?3-PIMU*0#D@_ ML:X+?Z*^DG396B-4NBZJI%&>,W@*LO0KGG$;+[,FM?! 5U8C:13NW 9N1J& MRTAGB(ZFR9%@OAO$S6_7Q6<&FT>83><48#:]98B6IEE+@]5(XH.6!@W#9?K# M$"U- ]("WPV3YEON\9G!YA%FTSD%F$UO&:*E:=;28#62^*"E0<-PF?XP1$O3 MI*4)WGU\>TO-U)-A-O-L=57J7+)_G: M%&EEH;K<[52VOA>02D#N[MAK.E:#^5F'H5003>&-OO1!21QR*>&[OA>[X[#Y MG:,'ED<*"CFYAF-U3@&.-5P*;S:W6-8]:1V/1[B5)$+:/]P/HY*K4TAK=9C6RDLF;A P:R6)%5HKK13@6,.ED-;J(+1.O%&"6PDBI-/KOV[- MMHLM7,HJ$P3UTH(U[2*:G8=^HV3Z"H(-C'_&./6?6L(U!Z1*V M(9H>FHX[72.>N%[4?'EH;!_>'MNG\ Z:CCX"+4V7L W1 M]-!TW,58;)N.)&Z^@@'C&'3"X!ZX!_30=.S1=(1R"-/E'30=2G4)VQ!-#TW' M78Q%T['K^B,-_6USI]I\77_:?,B/;!AT-J#\Q+H6]'>- MF6;I]T;MG\M#,NPYUX/F#TIU=(6Y-/355_MAW'RDC5P8="Z@^\2Z%O2I];V1 M)X<.7%/K4^(_LB:OW6KR:YL5-"^WU:KZM34SB/L^VU)=_= M;U_%88GAGC.)N_'NN&*)_9*=,W1CM_W7<#1DSW_<_LF07%%V.QW?X3$H&![3 M&X9N[LG'9&XQF7TZ2VRF!9MI_X0P?$:NBN$STAFBEVE VC1H_XH47$9<$N$T MG5. T_26(3J:0R^+PVHDK97#98:O8;B,=(;H9YH!J%VQ&7!KA-9U3@-?TEB$Z&F9H M^L='I]?#L,/IQITQ]=8FY]C85QIGM]')J=+WIFQ]]Q^%@-S]L$UN@Z-2N$'A MMW+8:W;5*$7$'8=X%3V53/2EJ1Q&14^EW:+B.':G7O/3+W"IP>HD5M4Y!5C5<"FDISI43X5; M22*$G@J5PZCHJ;"H2T*C:>1&T127$L0)/956"K"JX5)(3W406OWI*,2M!!'2 MZ9:W6[/M8A=<6Z#[H7)U:_<.3>!NX"0=:I!Z?IHUIS"D]>9-X,>G]:OMK^W_"F.V MKRZS]T_.[$>>EL[:%%F^*!UC'W_A_'6S,D[HN4[@!=Z(W.N&]EM2[_LJ/5X: M^[-%=OZ9)Z^?TP\^/N@U)&X\Z:.[GV6G./5?7O\R__YO/YX6'SE^:YX<%R;] MYY/TI#+%TW3Y+OU07O+E>?MFY6&^8_N?^&/JK-(S^WG_[^CYJ]>__YR6U:]U M,A5F\8O%Z"\U1-O?!-]8ZM*O_H8?OT6;(?E_Z\OFEIE5%BLC:>6LB_P\JW/5 MR3>%59QRLZQ*QRI3ZOSY3Y,@\'YX8T%Q7J3S;)E5'[8_\VU]DY99Z3RVN6QE MR?Z7Q2Y?/?G/HZ-?G#.3EIO"?.=#R8MMG^PMM)7[/YY(8-N M_:5.S7)]LEDZ5;Y]N&QU;LHJ+^R'U%_XXGO6HEK_]N,WL_]1PYBNYF;DO+:_ MNH' U1=/EV7NK,S&XKZT5#J/LQ,G7:^7V;S.;OOX]5X%:9^HBT'Q1;'B^^2K^J7KVQ85IO=[8 6R/IEN[7OX@?5=NLFI'QM4;6>SL@V7EZ8Z->;Y:V4>K3>Q==D',V_S< M%*OZ7?Y/>0%W]G;[()#:-RYKZUNFNT=Q M;&S;9][8#Z[?N'ZCA3FN7.=MFJW*[Y?Y+DY63IDNZ_^P)-B?5'^,)!L09^LT M*[:/6+]JF=?&EIW;#ZE?F:VJ=/4VL\Q=__N=&Z=G^:;^JRUG9^D'^Q3V"YXL M[>/OL+@>E!;N:^%XDJUL'-6T6_2J'>*[]]D]8?V NY=?!.[G(FZ7;)=Q9]YO M\\DY*?(S&W_7RH2/W_AC,)OW:[/:/O\NT^TOJ_3]]AG+9F_LV]=;".Y-+>_07H5G+LW:?REZD3\!,BM.3J;6GF=H^72^^L5&9S8T%[+?3+WRWTW1AIR?7WPO MFW7VY6;WXXNPR$].;,#8=ZO>&;/'T]MO;H7IN+)Q;.7(?H?UTE073VZC9;53 MY5W>?(RC:^JTDYC/JU-YFF^6BSI2S7OK+*O/)VW]UO7WO8# /OS"?H7BZO7I M?&X;V?JS=J_?"GS]3/:5ZUH95C5,]O%,_>+5QV3(:Z\K3=U>K+8-\#:;/YL- M]9]9]=H91&%L0M@WMW]6X[+[%O6W?&&?V?&])_^U%;3Z,[;YM:MV?S)S$UZWCT<)O M?;V.X:T8_&#?]/)=MX)R(2\GMPO153%DZ\@Z,9J+9&WOG\C8[1+FUN^V_8*7 MWW!NBJW(W'2SC^7$']BY7HW-_[7):FO(M]^LSL=K%"QMB>Q8T5M:=;SH0BU4 M]M_+^O__\*Z77^+:NV]]\)W->6=N;7SW*?8OJF(SKPN>&Y^UKC^K3OE;\I2F M:0O+KJ/ OZU&>N47SZM\7/?KVWQXK"AZ_)ZG"\7MX_Y14V$^KZJ M_&/]\QL/NC#6MK<"^W1;32RMD]H7_KZRY6Y1?E3M2\%VZ\$IFUCU&\VT#18) M8;'I,*V.U+J5@Z#EDJ=QVQLULC3?3&]>*#>B8C#+249MKG_K/,J[1ENYR'0-OS>* B@@ _3"/XK1 M>Z)="?R3D1?! F@%W[DGFA7 S]RWS4#)$"W(V>CZ0.,G $WT2X1?N2^:P9( M ,W5_5&](63X(,N*<1V@RY-V';@3[,CX0$$FLI%Q+;CK#/:AKV"B#V(-DP2T M98F+.OA9P]0Y!<"ON%]2!S?13@^EF0$2 +E7!#?1CMQK9H $8 V3'KB)=N1> M-0,D@.;JGOE 0%__O;\IZ>"0IYU3'H%1AW\K&/JG +@5]PSJ8.;:*>/TLP "8#<*X*;:$?N M-3- K".20_<1#MRKYH!$H#J7A'<1#MRKYD!$@"Y5P0WT8[<:V9 >P*TOB[J M^B*HB[O(+Z$M\V6V<':O<[;/LTX+BZ$B.MKD8+LJ"@H^0\'5?::^U^U]IF$T M&G^9HTL$)5UKWXC">Z\P?/;[;\^[RAAA-\\_*-"=:M-ND+\K<1+,@!QI"D;A M'12ITZ:_/']Y]#^O7O]Z]+/S\OG1S[^][$ZGFJ:.8CVC])56=U'Z=D[!E;\$ MW=J+[V]7L5]R5*/[66_!?ZX1ZB7?A][W@4]Y/-CR^(Z!<_)E* (XW0X-P^<] M],]#_] _\@7]T\;GHQ_K7UP^Z?6/>6:?^+C(:L[_Y">>Y;S^[6Q^FJ[>FD'+ MI;2#"-H?155D0(A7?_GLOGEES%2(>E'DH9/P29/;.=;HWS Y1/_ZR^>C70>K MH'45 GCW$^>WY@_W@7*.WG#1;N ,D@;0U/'C-5NB $=L[] *?[-^!3ZP%/BY MV@\(18(IPE%P%/C 47K"#XXBGB(= >Z)="_S-#K1'^\D&#=F ]A/M>N!'^V?>J/FV?-+AL-@_DH,\2\H( M=#WPH_NS,(SD\$$Z4/0K@IMH1_P[%G^*?M(!\2?:M<&/^,_\42"'#V7I\.@^ MZZTXD^SK0#\Z-T7ZUCC+;&Y6I5DXQV91"EIWR%(K5GFJ@9^E5K/$C?WVSXPG M(X1F!/T7T:X&?OHO*_]1C/R3$,@_T:X-?N1_YHVFPA$=9 MH$N#']V?!9'K)]3]9 1U/]&N#7[T?Q:$;CP.Y5!"1J#_BN FVM'_;O5_%,OA M0UDZW&O9%<=<'6;957J>9LOT>&GV6W?%$5=M.@ +/0<./^NN9HD;ALWG7LB( M@6<$#1C1K@9^&C K_\$8^2-O70^ZL>Z*0%<#/[I? MK[OR8@ZX)2.H^XEV;?"C__6ZJVA,Z4]&H/]$NS;XT?^]UEV1#@+677'! M_DM:9?9;.8OT Z=NEEQQU-6PE$=9H$N#'^&?^6Z<1.[40_U) M"FI_HET;_%B M8#(6D#B<> A28$%$.W:X,<"9LEH(HG @5<='GBU2.VG M.?5=@QN.NY*I_RST'#C\+,":A>YTXH_8^4A.T( 1[=K@IP&S!A!-QJ-(#B>D M! :@"&ZB'0/HSP(L\J&K!5B<>34LY5$6Z-+@1_AG_MCUO.D>\R_DQ+!S@M*? M:-<#/PXP\Q/7FT8@OY[/-^MT-?_P M9)G5BZ_,8K\+!SD"JTT+8,7GP.%G!=8L\=D +\*#NT:>WHM 5P,_O=^!'^>H$5^]D1?BI^ ET1_ A_O<"*.RP0?H2?0%<$/\*_UP(K MTD' BL.L/HZT(\69UE99OF*,ZMDJC[+. <./TNJ9N/$#0)6-I,2=%U$NS;X MZ;IF2>0&'A>WDQ'H/]&N#7[T?^9/]IAG)Q^ZFF[A!*MA*8^R0)<&/\(_\^M+ M WTJ?U*"RI]HUP8_!C#SO< =CSTYG) 2&( BN(EV#*#KO753.80HRP>.M.H M])_-ZFUUZN0G]N'2#X)6&[+JBK6=:N!GU=4LXAPK\H&^BVA7!S]]EQ7_YFT7 MZ3#L=$#\B78]\"/^LRN1]I8;T6@JX$?X:]G6YK?&$@^##L?*/N) M=CWPH_XS/]KCVD#R8=CY@/H3[7K@1_UG3Y)1\W6VY(. E5:<;=6J"'&NU;#0 MUJ4PXN!OML(*"LB H<)/AT6TJX&_68<% R3 4.%'[HEV-? SH":.$C*"PZOT MP$VT]T#_88 $&"K\E/M$NQKXD?NN&2 !D'M%T1TRHC7X.9^J)>1? MK=9IE=GOY13FW*PV1M"B0190L43SH>#_5A#RG$XUF[A)$KAA& NB15="B-,C M6C"B78/\TWW-$G<3($>I/M&N#'PN8^1Z# M/B(&?5H_I.KZVBKG."\6IKA$M1FTR:GX>,Z0PWFS"=[CG =/I+$:;3K-,9 M[W'I(GXC:I';@0CE@,LI[\4 M83G-+,=/7'_<_')A+&>XN83E=,\!EM-?BK"<9I83C@+\1A(C]UI R'EM7P?Z M;WF5+AW.;.N#=;2Q8OE2F&HTL79I_-Q<%GAOC@9M['[D>H'G!D$HB#A=6P'$ MY0T;P; 1^/E\AXB+?'XKF>N'OAO%G"%'VN BN C\X"+[+Q6?C)I/:N$?72W0 MXQ2Z84D3UB&;'ZRCR7%&XVGD^A[^0=;0?V B\(.)W,-$8L]WXY"I$+(&$\%$ MX <3V7\JQ!\Q"2)A$(M3];IDXG5U:@H.U!/ A+05URR*ET\1!^HU\_ID[$ZF MS8]09V'\<).)C5C=AN1'%"=Z.6 QRGOQ3A. W7:X3NV&^^ M9 /+&6XN83G=[=W9A%IMYE>6KD@/U^F,C+(R'(@[4:[CP(7"C,'23J<_R>$F\L!]++0?8 M3G\I8C]6(]HF[M2:SMAK/E")Z0PWFS"=[CG =/I+$:;3;'7>=-1\CQ!^(VK) M'H?J*= QK$8\15A-LU&U[:!:''+FA"A:Z&_4AZ81QXOH!)^N) MH@734]R]B]U(74)XJ'6<+"&\QL3?3=7]47LL(Y2[&KW) M;@'*A)LPZPK&%:5L/] M;SC6W?-[R=B-.S@M$,>2IY8X5O<RS?Q+&D+M]\\,70 [\66=K:F+D%W12#&BR41AH6TNV8 M()<<8R'P0\_1&XHP#'H.17"C1J+YP3#$4X1A8!B*X$:-1//#(%4/2=-N(4-? MPW8=P.-\N?A**NZ+^YNCOSUW7AP]>_7SJ]_^OZ>"PI^5;(B-&OAW"]6@@ S0 M"C\=&]&N!OY=0P8#)(!6^)%[HET-_,WDGN$U4D(-_*P!(]KUP$^]WS4#) #U MOB*XB7;D7C,#) !RKPANHAVYU\R ]@1H?:T4U[5VGPUE;^<4 M7/E+T*V]^/[A+KI7XS]>\GWH?1\TO].>\KBO^G7]FH][)<>M"C?D!)&L>-/# MW2^AAL\+P?,0/ 1/5> C9,/B\]&?_^0GW@_STW3UUC!J((<8 :.@BI!%POK+ M9_?-)^HE2KUH4A%&A)$FM>O<0?!Z2!J"UU\^A32SBE5OZ"?@B9Y"Y>P[-6CW M[/3:(POH(@R##D,1W*B1:'XP#/$481@8AB*X42/1 M_& 8XBG2;AB-UYT]>_'">_&,=6?W1?YE7JZS*EV63OYN919.NEHX2Y.69M$X M&1Z< M:BM8JV6_9=U!]UB%7?8C@)$D%\D [=:C^M&]&N!?Z] M;^E#^\F&P68#VD^TZX$?[9]YH^9[VTF'PV+_2 [R+ @CT/7 C^[/PA#=)QTH M^HEV;? C_H@_Z8#X$^T*X4?\&?$1,N+#.5\M@7YT;HKTK7&6V=RL2K-PCLVB M%+3ND*56K/)4 S]+K6:)&_OMG[1.1@C-"/HOHET-_/1?5OZC&/DG(9!_HET; M_,C_S!M-Y?"A+!V:+[CB!*YA"8^R0)<&/[H_"T)W'%+WDQ'4_42[-OC1_UK_ M([_]>P3)")D9@?X3[7K@1_]G_BB2PX>R=+C7LBN.N3K,LJOT/,V6Z?'2[+?N MBB.NVG0 %GH.''[67?U5:S M, G<,(@%D4).L.%%#]Q$.QM>NC4 ?^R&,8>=D!(8 -&N#7X,8.9'HT .(0 MI!AV4F !1+L>^+& 63)B\E?"Z \'7K5\X-4BM9_FU'<-;CCN2J;^L]!SX/"S M &L6NM.)/V+G(SE! T:T:X.?!LP:0#09L_N%E, B'9U\&, ^RW (A^Z6H#% MF5?#4AYE@2X-?H1_YH]=;^SM,?]"3@P[)RC]B78]\., ,S]QO2 9<>X5.8$# M$.W:X,)HY,LA1%D^(/Q:E4=9H$N#'^&? M^2'"C_"SXHI UP0_PC\;^R-.ND7XJ?@)=$7P(_RS9,(Q)P@_PD^@:X(?X9_% MC/2(T'V.MVI]?55ZGF;+]'AI]EM@Q1%7;7H :SH'#C\+K&9),)H(8D170@C: MX$[S1:#K@9_F:Q;'[&Y!^!%^ ET3_ C_?@NLR(?!"C\+K AT/? C_+-Q, KE M$*(L'P0)/Q4_@:X'?H2_7F#%&#_"C_ 3Z(K@1_CW6F!%.@A88,4!5E\'^M'B M+"O++%]Q9I5,U6<9Y\#A9TG5;)RX0<#*9E*"KHMHUP8_7=_';C)M?ELX*3'L ME*#R)]KUP(\!S'PO<(,@D<,)*8$!*(*;:,< NMY;QW5%$H9^.-*J)=!_-JNW MU:F3G]B'2S\(6FW(JBO6=JJ!GU57LX@]+N0#?1?1K@Y^^BXK_LVO#B$=AIT. MB#_1K@=^Q'_V)*3T%S'HUO5(&^NM"'0U\"/\]6Q+\\56Y,.P\X&RGVC7 S_J M/_,CCC,D'U!_HET=_*C_[$G,D+^(09_=2JOOJ_HR._NS17:^UU/?>,A'?WRH MZZG'N_;[7>OW\(/UYV3H%I\S/&WYLEQ8=)_/DE/*E,\ M39?OT@_EU8(9;]]JX3#?L8M/W*5DM;MM,B\6IOB/;[QOG+E9+FNYLH)V]>\+ M@=O^^T).Y_;C37&EG;LW>&*E:)FN2_/T\C]^K>:C'[^OWVBF;4VS$!8_ MJ3MO+FM6EEJWY_9X+\D3*V =Y(H&6OVY6YL]_\A/OA]!S MG< +?"==+>K_\$@5F:DRO'._FY?)C:@8RD98]IXA,GK@;[;W# K(@*'"S]PS MT:X&_F9SSS! @P5?N2>:%<#/W+?-0,D *=XZX&;:$?N53- FBN[H\L/LOA M@RPKQG6 +D_:=>!.L"/C P69R$;&M>"N,]B'OH*)/H@U3!+0EB4NZN!G#5/G M% "_XGY)'=Q$.SV49@9( .1>$=Q$.W*OF0$2@#5,>N FVI%[U0R0 )JK>^8# M 5V-M.O G6!'Q@<*,I&-C&O!76>P#WT-TW4 .SR%Z>B-\^OS7U[_^MOSGYX* M"GG6,>D5&'7PLXZIT5P$^W(O68&2 #D7A'<1#MRKYD![0G0^KJHZXN@+FXBOX2V MS)?9PMF]SMD^SSHM+(:*Z&B3@^VJ*"CX# 57]YGZ7K?WF8;1:/QECBX1E'2I M?2,*[[W"\-GOOSWO*F.$W3O_H$!WJDV[0?ZNQ$DP W*D*1B%=U"D3IO^\OSE MT?^\>OWKT<_.R^='/__VLCN=:IHZBO6,TE=:W47IVSD%5_X2=&LOOK]=Q7[) M48WN9[T%_[E&J)=\'WK?!S[E\6#+XSL&SLF7H0C@=#LT#)_WT#\/_4/_R!?T M3QN?CWZL?W'YI-<_YIE]XN,BJSG_DY]XEO/ZM[/Y:;IZ:P8ME](.(FA_%%61 M 2%>_>6S^^:5,5,AZD61AT[")TUNYUBC?\/D$/WK+Y^/=AVL@M95".#=3YS? MFC_L-%NX$S2!I 4\>/UVR) ARQO4,K_,WZ%?C 4N#G:C\@% FF"$?! M4> #1^D)/SB*>(IP%,X3U ,WAB&;'PQ#/$48!BT(?. H/>$'1Q%/$8Z"H\ ' MCM(3?G 4\11I=Y3&:^2>O7CAO7C&&KG[(O\R+]=9E2Y+)W^W,@LG72VOF6D5;N?1T#7^S^V>O+5$OZH\ZQ IU,9P$B2 ^2(=NM9\#[8EV M+? W.] >[2<;-&0#VD^TZX$?[9]YH^;;\DF'PV+_2 [R+"DCT/7 C^[/PO#_ M;^_<>N.VLBS\/D#_!\(3#QR *O-2UTR&@-J7V!AWG(F=!OJ1JCJRF%!D-O.%'$K(",;]BN F MVM'_;O4_=*=>^YI;,F+8&8'^$^UZX$?_HV#$HK^$=1_:7.VY["H^BY,T/DK- M;G57M+C:IP-0Z#EP^*F[BJ9N.&[OP63$P#.""1C1K@9^)F!6_H-9^_T7$F+8 M"8'\$^UZX$?^=ZJ[(AVZJKNBT=6PA$=9H$N#']VO]]T7\YD<2L@(QOV*X";: MT?^N]7_BL>Q/1J#_1+LV^-'_G>JN2 TN_HVT'^)J\3>E;.*/]+E2J;N M4]\YR4P "(=CWP M8P#18M1^VYUTZ*KBBDY7PQ(>98$N#7YT/PI=;[%PO2G-3D@*AOY$NS;XL8#: M B8S-_!9_2$IL "B71O\6$#DCQC_2UC]H=_5GOM=K6+[;4[]JL$-W:YDZC]U MG@.'G_JK:.SZTUUV8,B)@><$$S"B70W\3,"BT)W-%J.)'$Y("0Q $=Q$.P;0 M[0J<-VK_FG'RH:L"+%I>#4MYE 6Z-/@1_LB?N7[@CVAV2TXP]"?:M<&/ T3^ MU)TM9C@ .8$#$.WJX,;=9PM/QZD25U\95:[O6^0 M#EC[M J/@<./Q58T72\PRM'2(BN]E\X^C(PZ=$5Z-+@9^X53>:CJ1Q"E.4# MPJ]5>90%NC3X$?YHL4/!%>DP6-VGX(I UP,_NA_-_!U>,D(^#%;X&? 3Z'K@ M1_AKX:?%%<*/\!/HBN!'^*,#CQ&_".&GO=7>ZZOBLSA)XZ/4[%9@18NK?9H M-9T#AY\"JV@Z&53)EGS+.@<-/257DCQ>N/VX_ MY2(G!IX3S+N(=C7P,^^R!N"[BQGMJT@)#(!HUP8_!A!-:%HK8MVMZ\4V2JP( M=#7PH_M1$ ;N.&#@3THP\"?:M<&/ 41!$+JS^4P.)Z0$!J (;J(= ^B4DG"' M5P:2#@(JKFAI]6V@OS+9N^K$R8_MP\4?!54;4G5%;:<:^*FZBB;4.I,/3+N( M=G7P,^V*QC0Q)!T0?Z)='?R(OQ5_^II(6'/K>J&-:BL"70W\Z'[DASN\*I9\ M&'8^,.HGVO7 C_K7ZM^^SHI\&'8^H/Y$NQ[X4?_H(\2B#ZVM9(H0;:V& MA;8NA1$'?[L"*R@@ X8*/S,LHET-_.UF6#! @P5?N2>:%<#/PMJXB@A(VA= MI0=NHKT'^@\#),!0X6>X3[2K@1^Y[YH!$@"Y5P0WT2Y?[EG=(2/V!C_MJ?:$ M_,ML'5>)O2^G,&5_P?R<(>9I31?[,GT:])_I5^2/WG7OLIWQT+7'MY(YWV9CH3 M7$>@I.$ZTBG:3B QG:_0-G>]V=0=!^UWF3"=X683IM,]!YA.?RG"=-J5LX4[ ME+/A-Z)JW.YXD;,I:,-JA.D85B.>(JRF716='[K>(L!M))'"[$8M!UA.?RG" MXN83E=,\!EM-?BK"<5K3-1A0-B"+D5O6#]&O[-M#? MYE6<.O1LZX-S[*-@^4*8:C1Q=FG\7*\*O#5'@_;U8.;. L_U@YD@XG2=!!"7 M-QP#PT;@Y^8)(BYR<_<@=QJ.W>F,\V2D#2Z"B\ /+G(+%QE-Y#"FS#_H0:=5 MFK .V?Q@'6U:V4W\L3L.V]=$X!_#SAKF'Y@(_& B.YE(,)^Z RRGOQ1A.:UH._ 7 M(^8XHBBAEQY"AM?TB2*\IA5M?ABZ?LCT1A0I3&_4=YP M'%&D8#EJ.5DZ)WFY3NJV>K33DVP> M%/]KYX=V>BU:6,Q=+_3=8,$9,O*&,V38"/QPAFQW%PE=+_#8,U(>/]Q\XCQ6]QQ@._VEB/-8[5S'<[TP M.835]H@BK:6(6)GTW5?:\]Z@CEEJ.W.2[ ,.$ZA]\)HJ]E?S[&$%\[?.Y.)OL_*H=CR5-+ M'*M[#G"L 7.(;=W1J[J>4 Q\*Q<*PO.=9D.G&#L/V!9AQKN&J)8W7/ 8XU8 ZQK;OA=3;: M_VL3,2RI'2 _FVX#?RVRM-)S7H/.7H,,1_1I'BK\M/G',>#G MCMO\0Q&&,53X,0P, W[N[[TP2PNZ*0:U5BB--"RDVS5!7G*,A< /4(1A M,.=0!#=J))H?#$,\11@&AJ$(;M1(-#\L4O60-.T6,O0:MJL 'N7IZANIN"WN M;P[_]LQY?OCDY:N7;__Q@Z#PIY(-L5$#_[90#0K( *WP,V,CVM7 OYV0P0 ) MH!5^Y)YH5P-_.[EG>8V44 ,_-6!$NQ[X&>]WS0 )P'A?$=Q$.W*OF0$2 +E7 M!#?1CMQK9D![ NR]5HJWM7:?#;R?]&3W]X^Z^[MWWLP"R% =ZI-W;XJ1C #OA*^?%L\-7;U]TIU."^MP*(8>AK_AQ%T/?SBFX])>@6WOQ_;M[S[T: M__&FCT/O<="^O3K#X[[JU]6W?-PJ.3ZK<$-.$,F*M[B[UTNHX?-<\#P$#\%3 M%?@(V;#X?/A?_^E/O?]>GL39.\.J@1QB!*R"*D(6">LOG]U//E$O4>K%)!5A M1!B9I':=.PA>#TE#\/K+IY#)K&+5&WH'/-%;J/2^4X-VS[K7'EI T^&STL-W MMRIA1M9A"R6@=WNB3@G(/=,;;4[-BR_$4R3,'-3!S\%K# -^,(S>4(1AT(=/ M#]P8AFQ^, SQ%&$8S# 4P8T:B>8'PQ!/$8:!82B"&S42S0^&(9XB[8;1NN[L MR?/GWO,GU)W=%OD7>;E.JC@MG?Q]9E9.G*VUBOE'T7]5?=1=6W&$Z"J2 ^2(=NM9^I&]&N!?Z=W]*']I,-@\T&M)]H MUP,_VA]YH_9GVTF'N\7^H1SD*0@CT/7 C^Y'88CNDPX,^HEV;? C_H@_Z8#X M$^T*X4?\6?$1LN)#GZ\]@7YX9HKXG7'29&FRTJR<([,J!=4=4FI%E:<:^"FU MBJ;NQ \%44)&<%!&#]Q$>_?G8)3+_WBR_Q=MD! R$P+Y)]KUP(_\1_X.RV^D M0U<%5W3@&I;P* MT:?"C^U$0NC,?Z2=Y]Z$73^DN.S#DQ,!S@@D8 MT:X&?B9@4>C.9HO11 XGI 0&H ANHAT#Z'8%SN/HHX@EN*[7W2C (M#5P(_P M1_[,]7Q_1-,K M[0GTU\OE9AUGRX\':5(77YG5;N\;I /6/BV BL^!PT\%5C0=[_#*$1*BJ_T7 MCKX,3'IT!;HT^)E[19/YB+/O"#_"3Z K@A_ACQ:<>43W*;@BT#7!C^Y',Y]6 MAP@_ WX"71/\"'\M_+2X0O@1?@)=$?P(?^3M<+":=!!07D5WJ[LJKXK/XB2- MCU*S6WT5':[VZ0&4= XJ/UK!09':MDJCY5G .' MGXJJR!\O7'],93,YP;2+:-<&/],N:P"^NYC1O(J4P "(=FWP8P#1A):U(M;= MNEYLH\**0%<#/[H?!:'G^@':3THP\"?:M<&/ 41!$+BAU_X\-2DQ[)3 (AV M/?!C %%(1RL1*S]TM-H3Z*],]JXZ[5K_S+?_QX M4GP*V'?FX*@P\1\'\7%EBA_B]'W\L;PL_O!VM;Z[N<;8V_S[7AJ7]>E-<"L'V @=&66>1%729[]L+'W6Z2)_>L'T6]9=E MMAS]^+B^4/39,E%M]'Z6S>F>#:4UP6\VZW5J3NT36(Y_SK.#GPX/?W&>)N4R MSA'2>94)_FFC+.5U5WS86G6E6-Y=,J3N#!.?)IOLJK\7F9[U,EH/F4A88\G MAB:@O3\I"DX)=#_P,[CNG /B1>RUH$^P,[E4S0 )TG "3L2:Y9T]0:Z2S)\B>X(#QQD99 M-M!- ?"S;* %;8*=90/5#) J+T:M EV!O?**0!^Y%X+V@0[@WO5#) [ D. M>4_PV@;@>;^!"VS+/$U6SO:#3O- Z[BP((HZEM^*LIZEPY5=0BC9@1+[,/?( MQ_D^(HRT8.33V?1QMV?3Q]-1^!72+O!20]A%@X&ZTX#S]L0X_S!QX3S+:@2= MIV9I3H],X82^VW0HZ$C]]C/P$L)(ISZS'6,A:^+&9M1K"9F%4*]%O=: \?XD M_C6:-XZ-6 /I?,\'CB1SQ#)AYYM"7TT0571\,-@6#Y'. J.(HH.!L-2V6(P+"U7*/>AW.<+6WZ# MYJ,?Y3U0(*"B9^@D2!DR^<&U"1\%//8Q7^7OJ%7.M5D<13ERE.JFF5SW M_(CQDM9O02K,FPI"F M_8S"&%TQNNH5BWT][C%H#EJOQ3]Y_MQ[_H2U^+OEXV=3.9]$JV5FW"T5K,C? M0ISNE@)6Y#LEX9O*XMK,!C6Y_'>"Z&M9-7<7%%X9@!?U_0YJ_.T';CCQ77L7 M70DD(VI!>LEZI1 *>I(6@29.QCMMD>U@*WM8UU%%%,DCCQ,\A6G0,#AD&C3( M:=#$8QHDCAO_C(:9E)(!F^%%[1<'.2%_U2-^.\T//'<_G M@FC1E1#2] CU5Q3LVHO"+).F ;,3 M9RLG/LV+*OE7\PLY2<"I,4Z-#1AOYE,"JCY5KS),PM -@O9K#.3$L'."-09% MP =[B*^K$U,XC[:](+^_V$ETZP:1Q"Z!HNWQQ M%S0->HDC]#PWF(R[$KCVXD8R[6M0-MK+D P*AF8YPB>->RJ^AB41+/7*7U1Q M@K](%*\>^(MZBIC2M)O2^'-W/MW_"=!>68Z29,)R.J>@SY:C9&#&E*8/+/7* M7X1SWBS&8+V\KV_NT$%@^P@=[I&8^\ME">Q =KG[?E)59.<_^^O+M MT\/ZR*J3'SL_/WGI/#H25&=W1=YJE&_T&NE^M&]NOQ-$W_4YZKU2..A)K._. MYZ$;C-OOS-VM;BJK-.YT^$!M,0X#A[>?E^(RMW:9R6C_IUM4&LQ#O$6!+N$M MS%[PE7KVLICZS%X&+H,X# X#A\Q>.IR]S#"8(<]>.(?9X3G,5;XY2HT3C-1L MDG6ZL7_3>4LH$'#>$A*Z+D.ZQ:#W&FD,>@5P>+NU%7B456SV63&$DPZ+F;&H MKM+B5CHF)6^$%VG>+6FW6W6!MZYYZXD'J>($#Q(YQ&9XW7\.F2;UB<=>691P M3NYA6QJ+ZI*"H4R35)$VH&F2*M[P('FRY4'S>7YT+K Z'G78?C MJBJ2HTT5UUA4N?/;BS>NLS:%LTK23?W9\L2BXCR*Y9X;O7$^Q)RI3Y77]T;A ML&OB_-%X2E'G#V4U^#5'%G/Z% P-E/2.B\ M(';W63<-3Z1Q>+O5$WB45=0L\D4#JCCA13:=4T!:R./DZZ^I@192!4YP$*D# M9 ;'_>>024Z?>,2BI&X08%&=4T!:R..$28Y(6D@5>9SP/LZ>G;O4Q\V;^@AE MZ6Q*LW*2S')QNMY4%K'+,Y8F+C+[[[(Y>-DQ_MGI_%U -]QW@WQRY!>U]SN>T)2_ 6 MM/Z!^SC[GG%/"\ 5/P*/[>:?E"Q,=_ M?A]B_3][]8.?#@]_<8Z3+,Z629PZIR8N-X4I1UN"M___]L0X@1?X3F'.DOH, MH+TWLXR;+XY/\TU6E8[YL$PW*_N%]K/)J96--9:_F6!DZ+5TG.7;B M]3I-EO6MN?:C<75Q'_9ZFZ*P+#IYT=Q7;F\YKI(\LS>59$X6;R^4U=]2?ZRY MI%-NEB=.7#KKPAQ4\0=G8R]DH^U?]L;>Q4E6/D[SLK0LV"?:I,V)Q>,B/ZTO M8S]G_\/CE3G_J?Z2^MYM /QAL;0QNS'U$Y3;HX_VIZ4I*GO-\T\TZ);U72=5 M8C]P8M(&%WN=,U-6IS9>G#BSF9#&99D<)S54I1.?Q4G:_&G]T3*N8<@WA1.O M\G7]L/7W'+[YS:+M3P^\A=M<(K?W53CKO++7;#B**U/4/VPQN,3$=2SK%KS* M29/3I":GRMWZT4UA;ZGYQCJ*\DU97\)>X\K?VD>IJM34MVV)2LT[>_G?-ZMW MS2^:NTCC]^4FJ?_KISO9$MV@TW!6V$O%Q4>;_INBM#&V_.R?K9(: MF*3FT?[K]SRQ")W9"VT:?(OSQRQM\%?F7;+IF75]_DF#M;V%E3FJW.N\6T1KD)L[M#R8\VX^Q=4A.V_7/W_#8OPKZ)X=/XHW-D[,T=IV99;<_(UK%4AW1]W4_I M55;V]K>8-G^Y?9[Z<=:6F*(^/IODJW++^_54VJ9M8=:;8GG21&QSA55R?&SO MYR*LZQRL(ZWAW>X?U]UU$\S+/5EN&K@1#=9+7 M])5U5-1Q4YW8YTOS]_6#_5C+T86>7A&PI+*)M[2Z])/);.JFSLNLEK FAUWG M>5Z\CXO5P:L\_Z/^AC>?@*@?]=>D_,-Y;I\T+[:_^/E"FIY?8O>WO__[RZ8%?)VQI*2F7F[+621LI)LE&7RW? MV;LS:J[=V3O8>@MW]C_B4URULW^PF6%VA_UVO1W\B7UUV.M=2"?,%6'/$CJA MKQ1[%)XPUX ]@WAB7RGV2#QAK@![!O&$OE+LJ8"A N:>*V".KE3 //OKR[=/ M#YM"F/S8^?G)RV;7^PLU+M=+7'(G/VHVQ..FO75J*N-L[$,7915GS2:SO6JS MJ7QYG;4IFAWN;&G<+]U'>9)OTE6]JVP^6&"RBR;:66::Z@;G?5*=7*W@6=DO M+RX_&"^7>;&JOV7[P>9IMC4OI>7D2KE!GC4U]\VF](TU!_7V=Y973>V *4R5 M;_\TJ?>RUWE1.4W]ROECIDG=T+OYROKJ;S[5NM27>?9A>1)G[XSS)#\]3\\BTW7?9+27/S5_[X^"A??8S^8I_OI#I-[0__#U!+ M 0(4 Q0 ( &! ^U(_K4%'-D4$L! A0#% @ 8$#[4C458%PV!P @TP !0 M ( !W 0 '5H&UL4$L! A0#% M @ 8$#[4B.ABCT1!0 H2T !0 ( !1 P '5H&UL4$L! A0#% @ 8$#[4G+DU823$ 1(P !, M ( !AQ$ '5H